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i. ABBREVIATIONS 
 
4E-BP1 eIF4E binding protein 1  
IR Insulin receptor 
IRS Insulin receptor substrate 
GAP GTPase-activating protein 
mRNA messenger RNA 
mTOR Mammalian target of rapamycin 
N-terminal amino-terminal 
p70S6K S6 kinase 1 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PDK1 PtdIns(3,4,5)P3-dependent protein kinase-1 
PI(3)K phosphatidylinositol-3 kinase 
PIP3 PtdIns(3,4,5)P3
PKA protein kinase A 
PKB protein kinase B 
PKC protein kinase C 
P-Ser phosphoserine 
P-Thr phosphothreonine 
RNAi RNA mediated interference 
Rb retinoblastoma tumor suppressor protein 
S6 40S ribosomal subunit protein 6 
S6K1 S6 kinase 1 
S6K2 S6 kinase 2 
TOR Target of rapamycin 
5’TOP Five prime terminal oligopyrimidine tract 
TSC Tuberous sclerosis complex 
UTR Untranslated region 
 
Less frequently used abbreviations are defined upon their first use in the text. 
   
ii. SUMMARY  
Insulin signaling at the target tissue results in a large array of biological 
functions. These events are essential for normal growth and development and for 
normal nutrient homeostasis. Studying the signaling pathways involved in insulin 
and nutrient action could lead to better understanding of pathophysiology of 
insulin resistance associated with obesity and type 2 diabetes and identifying key 
molecules and processes could lead to the development of therapeutic strategies 
for the treatment of these common disorders.  
 Previously mice deficient for S6 Kinase 1 (S6K1), an effector of the 
mammalian target of rapamycin (mTOR) that acts to integrate nutrient and insulin 
signals, were shown to be hypoinsulinaemic, glucose intolerant and have 
reduced β-cell mass. However, S6K1-deficient mice maintain normal glucose 
levels during fasting, suggesting hypersensitivity to insulin, raising the question of 
their metabolic fate as a function of age and diet. The present study shows that  
S6K1-deficient mice are protected against obesity owing to enhanced β-oxidation 
and sensitive to insulin owing to the apparent loss of a negative feedback loop 
from S6K1 to insulin receptor substrate 1 (IRS1), which blunts S307 and 
S636/S639 phosphorylation; sites involved in insulin resistance, Thus under 
conditions of nutrient satiation S6K1 negatively regulates insulin signaling.  
 The actual cause of diminished β-cell size in adult S6K1-deficient mice 
has not been fully understood. The present study shows that loss of S6K1 leads 
to reduced β-cell size during development, intrauterine growth retardation, and 
impaired placental development. S6K1 deficient embryos supplied with a wild 
type normal placenta by tetraploid aggregation, developed normally and only β-
cell size was still smaller than wild type, suggesting the defect in β-cell growth is 
independent of placental dysfunction. Furthermore, β-cell specific transgenic 
expression of S6K1 restores β-cell growth and development in S6K1 deficient 
embryos.  
The present study indicates the impact of S6KI signaling in age- and diet- 
induced obesity and insulin resistance, and also gives insight into the interaction 
   
between insulin induced IRS-PI3K pathway and nutrient induced mTOR-S6K 
pathway in pancreatic β-cell growth and nutrient homeostasis. 
 
 
 I. INTRODUCTION   
 
When nutrient homeostasis is normal 
 
1.1. Energy homeostasis in adipose tissue, muscle and liver.  
   
Adipose tissue, which is the main energy storage site, is responsive to 
both central and peripheral metabolic signals by regulating lipid storage and 
mobilization. Dietary fat is absorbed through the gastrointestinal tract in the form 
of circulating chylomicrons and very-low-density lipoprotein (VLDL), part of which 
is metabolized to provide energy and the rest of which enters the liver and 
adipose tissues for short- and long-term storage, respectively. As a gauge of 
energy reserve levels, adipose tissue secretes several adipokines, such as leptin, 
which regulate energy homeostasis by signaling to the brain and peripheral 
tissues. Adipose tissues, through the lipolysis and re-esterification process, are 
also the main sites for fatty-acid cycling, thereby providing an energy supply to 
oxidative tissues such as skeletal muscle and the heart.  
The liver also has an important role as a homeostat for transient energy 
fluctuation; it protects other tissues from postprandial triglyceridaemia by 
temporarily storing fatty-acids from the circulation as triacylglycerol (TAG), and 
secreting them as VLDL when the period of maximum lipid load has passed. The 
liver is also an important site for energy conversion, exchanging energy sources 
from one form to another, such as glycogen to glucose, fatty acid to TAG and 
saturated fatty acid to unsaturated fatty acid (Saltiel and Kahn, 2001). 
 
 
1.2. How is dietary fat digested and absorbed?  
 
One of the main energy sources, dietary fats are present mainly as mixed TAGs, 
which comprise one molecule of glycerol and three molecules of fatty acid. Many 
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fats of animal origin are composed of saturated fatty acids — predominantly 
palmitic (C16:0) and stearic (C18:0) acids at the sn-1 and sn-3 positions — 
whereas vegetable oils contain mainly unsaturated fatty acids (70% linoleic acid 
(C18:2) at the sn-2 position). Dietary TAG undergoes a series of complex 
biochemical processes before entering intestinal cells and being transported into 
the circulation (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Adapted from (Shi and Burn, 2004) 
 
Fig. 1. The process of dietary lipid digestion and absorption.   
a | Dietary lipid digestion begins in the stomach, where lipids are subjected to partial digestion by 
gastric lipase and form large fat globules with hydrophobic triacylglycerol (TAG) cores 
surrounded by polar molecules, including phospholipids (PLs), cholesterol (CL), fatty acids (FAs) 
and ionized proteins. The digestive processes are completed in the intestinal lumen, where large 
emulsions of fat globules are mixed with bile salts (BS) and pancreatic juice containing lipid 
digestive enzymes to form an aqueous suspension of small fatty droplets to maximize exposure to 
the pancreatic lipases for lipid hydrolysis. Monoacylglycerol (MAG), diacylglycerol (DAG) and 
free FAs that are released by lipid hydrolysis join BS, CL, lysophosphatidic acid (LPA) and fat-
soluble vitamins to form mixed micelles that provide a continuous source of digested dietary 
products for absorption at the brush-border membranes of the enterocytes. b | FAs and MAG 
enter the enterocytes by passive diffusion and are facilitated by transporters, such as intestinal 
FA-binding protein (IFABP), CD36 and FA-transport protein-4 (FATP4). They are then re-
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esterified sequentially inside the endoplasmic reticulum by MAG acyltransferase (MGAT) and 
diacylglycerol acyltransferase (DGAT) to form TAG. Phospholipids from the diet as well as bile 
— mainly LPA — are acylated by 1-acyl-glycerol-3-phosphate acyltransferase (AGPAT) to form 
phosphatidic acid (PA), which is also converted into TAG. Dietary CL is acylated by acyl-CoA: 
cholesterol acyltransferase (ACAT) to cholesterol esters (CE). Facilitated by microsomal 
triglyceride transfer protein (MTP), TAG joins CE and apolipoprotein B (ApoB) to form 
chylomicrons (CM) that enter circulation through the lymph. 
 
 
1.2.1. What mediates fat transport inside cells? 
 
Fatty-acid transport and binding proteins. 
After digestion, lipolytic products — mainly fatty acids and MAG — are 
dispersed as vesicles and bile salt-mixed micelles, and are absorbed across the 
apical brush-border membrane of enterocytes of the small intestine. Both passive 
(diffusion) and active transport (facilitated by binding protein and/or transporters) 
diffusion process across adipocyte membranes is rapid and efficient at high or 
low concentrations of fatty acids (Kamp et al., 2003). In these sense, the 
transporter-mediated process may only serve to facilitate an appropriate 
subcellular distribution of lipids. 
At least three distinct membrane proteins might participate in long-chain 
fatty-acid transport across the intestinal epithelial cells: intestinal fatty-acid-
binding protein (IFABP), CD36 and fatty-acid-transport protein-4 (FATP4). 
Inactivation of IFABP does not attenuate lipid absorption in knockout mice 
(Vassileva et al., 2000), which indicates the presence of several compensating 
types of FABP in the small intestine. CD36, which is also known as fatty-acid 
translocase (FAT), is highly expressed in the intestine in a pattern that is 
consistent with a role in lipid absorption (Chen et al., 2001). Although CD36-
deficent mice showed defective fatty-acid uptake by various tissues — including 
the heart, oxidative skeletal muscle and adipose tissues — no notable 
impairment of lipid absorption was observed in knockout mice (Goudriaan et al., 
2002).  
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FATP4 is the principal FATP in the small intestine and is thought to have a role in 
facilitating fatty-acid uptake by intestinal epithelial cells (Schaffer and Lodish, 
1994). Targeted deletion of Fatp4 in mice results in embryonic lethality, which 
prevents the detailed study of its physiological role in dietary fat absorption. 
Although enterocytes that are isolated from heterozygous mice show a 40% 
reduction of fatty-acid uptake, this is insufficient to cause detectable effects on fat 
absorption in heterozygous knockout mice that are fed either a normal or a high-
fat diet (Gimeno et al., 2003).  
 
1.3. How is fat stored and mobilized? 
 
 
In mammals, the main metabolic functions of adipose tissue are the 
accumulation of surplus energy through triacylglycerol (TAG) synthesis and 
deposition (lipogenesis), and lipid mobilization by releasing free fatty acids 
(FFAs) under conditions of negative energy balance (lipolysis). Adipose tissue is 
the main storage site for TAG. Dysregulation of adipocyte lipogenesis and 
lipolysis is part of the pathogenesis that is associated with obesity, as well as the 
development of insulin resistance and type 2 diabetes (Kahn and Flier, 2000). 
For example, excessive accumulation of fat in adipose tissue causes obesity, 
whereas a deficiency of adipose tissue is associated with a severe form of insulin 
resistance and development of a fatty liver (Kahn and Flier, 2000). Acute 
regulation of lipolysis in adipocytes is important in supplying energy to the 
peripheral tissues in response to fasting and exercise (Fig. 2). The lipolysis re-
esterification process also participates in the 'futile cycle' that is believed to 
preserve fatty acids that are not used to supply energy (Hanson and Reshef, 
2003).  General processes of fat storage and mobilization are shown in Fig. 2. 
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storage and mobilization in adipocytes.   
 released from lipoprotein — chylomicrons and very-low-density lipoprotein 
talysed by lipoprotein lipase (LPL) enters the adipocytes through both passive 
active transport. Intracellular FFA is first converted to acyl-CoA by acyl-CoA 
), and is then used as a substrate by two parallel TAG-synthetic pathways in the 
eticulum (ER). Glycerol-3-phosphate (G3P) that is generated by glucose 
acylated sequentially by glycerol-3-phosphate acyltransferase (GPAT) and sn-1-
phosphate acyltransferase (AGPAT), and converted to diacylglycerol (DAG) by 
id phosphohydrolase (PAP); by contrast, the alternative pathway involves the 
onoacylglycerol (MAG) by MAG acyltransferase (MGAT). The two pathways 
 acylation of DAG to TAG by diacylglycerol acyltransferase (DGAT). Nascent 
at are generated from the ER are coated by at least one of the PAT family proteins 
es perilipin (PER), adipose differentiation-related protein (ADRP) and tail-
tein of 47 kDa (TIP47)) and S3-12, whereas mature lipid drops are mainly coated 
The relative rate of lipogenesis and lipolysis is determined by nutritional states and 
 endocrine factors, such as catecholamines and insulin, which impose their effect 
rylation of perilipin and hormone-sensitive lipase (HSL). The phosphorylation of 
 HSL to access lipid droplets, which results in the hydrolysis of TAG to FFAs that 
ed from the adipocytes. PA, phosphatidic acid; PKA, protein kinase A; LPA, 
ic acid. 
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How is fat mobilized? 
  
Adipocyte lipolysis is acutely regulated by hormones, neurotransmitters 
and other effector molecules, where hormone-sensitive lipase (HSL) is one of the 
major targets of this regulation. Catecholamines are important stimulators of 
lipolysis, whereas insulin is believed to be the most important anti-lipolytic 
hormone (Fig. 3). Binding of agonists to the β-adrenergic receptors, coupled to 
adenylate cyclase via the stimulatory G-protein, leads to an increased production 
of cAMP and activation of PKA (protein kinase A). The two main targets for PKA 
phosphorylation are HSL and the perilipins, which are proteins covering the lipid 
droplets of adipocytes (Londos et al., 1999). As a result, PKA phosphorylation of 
HSL and the perilipins causes a dramatic increase in lipolysis. The ability of 
insulin to antagonize hormone-induced lipolysis is accounted for by its ability to 
lower cAMP levels and therefore PKA activity. The decrease in cAMP is mainly 
the result of an insulin-mediated activation of phosphodiesterase 3B (Shakur et 
al., 2001). The mechanism of  hormonal control of adipocyte lipolysis is shown in 
Fig. 3. 
 
Mechanisms behind PKA-mediated activation of lipolysis 
PKA phosphorylates HSL (Holm, 2003). In vivo, PKA phosphorylation is 
known to result in translocation of HSL from the cytosole to the lipid droplets 
(Londos et al., 1999). Similarly, The perilipin proteins are, besides HSL, major 
targets for PKA phosphorylation upon β-adrenergic stimulation of adipocytes. 
They are located on the surface of the lipid droplet, where they seem to serve a 
dual role as suppressor of basal lipolysis and as necessary components for full 
lipolytic stimulation to occur (Londos et al., 1999). It has been shown that ERK 
(extracellular-signal-regulated kinase) 1/2,  MAP (mitogen-activated protein) 
kinases are activated through β3-adrenergic receptor coupling to Gi, raising the 
possibility that dual Gs/Gi-protein coupling to this receptor allows PKA and 
ERK1/2 to work in concert to stimulate lipolysis (Soeder et al., 1999). 
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Transgenic expression of human HSL in mice leads to an increase in 
hydrolytic activities against TAG, a reduction in fat mass and a decrease in body 
weight on calorie restriction (Lucas et al., 2003). By contrast, mice that are 
deficient in HSL manifest adipocyte hypertrophy, reduced fatty-acid release, and 
decreased hepatic TAG storage (Osuga et al., 2000). 
Ectopic overexpression of perilipin A, but not phosphorylation-defective 
mutants, results in the inhibition of TAG hydrolysis and enhanced lipolytic 
responses to protein kinase A (PKA) activation (Tansey et al., 2003). Ablation of 
perilipin leads to animals that are lean, hypermetabolic and resistant to diet-
induced obesity.  Perilipin-knockout mice show elevated basal lipolysis and 
resistance to stimulation by β-adrenoceptor agonists (Martinez-Botas et al., 
2000). The regulatory mechanism of fat mobilization, lipolysis is shown in Fig. 3. 
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 Hormonal control of adipocyte lipolysis 
g of agonists to β-adrenergic receptors (β-AR), coupled to the adenylate cyclase (AC) via 
ulatory G-protein (Gs), increases the levels of cAMP. This in turn leads to activation of 
hich phosphorylates HSL at three serine residues and also perilipin A on multiple sites. 
hosphorylation of HSL causes translocation from the cytosol to lipid droplets, whereas 
orylation of perilipin by PKA alleviates the barrier function of this protein and prompts its 
participation in the lipolytic process. β3-Adrenergic agonists have been suggested to 
te lipolysis via a concerted activation of PKA and ERK1/2 MAP kinase, accomplished 
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through dual coupling of the β3-adrenergic receptor to Gs and Gi. In hormonally quiescent 
adipocytes, HSL appears to be phosphorylated at a fourth serine residue, presumably by the 5´-
AMP-activated protein kinase (5´AMPK). The anti-lipolytic action of insulin can to a large extent 
be accounted for by its ability to lower cAMP levels. This in turn is mainly the result of an 
insulin-mediated activation of phosphodiesterase 3B. TG, triglycerides; DG, diglycerides; MG, 
monoglycerides; MGL, monoglyceride lipase. 
 
 
1.4. How is fat synthesized and oxidized? 
 
The synthesis and metabolism of fatty acids and TAG is a coordinated 
process, which is mediated by metabolic enzymes that are regulated by 
nutritional and hormonal stimuli in response to starvation, exercise and surplus 
energy (Fig. 4). For example, fasting reduces fat synthesis by decreasing mRNA 
levels of both fatty-acid synthase (FAS) and glycerol-3-phosphate 
acyltransferase (GPAT) (Sul and Wang, 1998). In the fed state, the body aims to 
convert the amino acids, hexoses and triglycerides produced by the digestive 
tract into forms which can be stored. In the fasted state, the body aims to 
mobilize stored reserves to provide the necessary metabolic fuels. 
Fatty-acid synthase (FAS) mediates synthesis of saturated fatty acids. 
   Mammalian FAS catalyses the de novo synthesis of saturated fatty acids, 
such as myristate, palmitate and stearate, using acetyl- and malonyl-CoA. It 
functions as a homodimer of a multifunctional protein that contains seven 
catalytic domains and a site for the prosthetic group 4'-phosphopantetheine 
(Smith et al., 2003). FAS is believed to be important in addition to carnitine 
palmitoyl transferase (CPT) and acetyl-CoA carboxylase (ACC) in maintaining 
energy homeostasis by converting excess food intake into lipids for storage and 
providing energy by upregulating the rate of β-oxidation. In addition to a role for 
FAS in fat metabolism, the enzyme also has a pivotal role in embryonic 
development. Targeted deletion of the Fas gene results in mice that die in utero 
(Chirala et al., 2003), while 50% of heterozygous Fas-knockout mice also fail to 
survive embryonic development (Chirala et al., 2003). The development of mice 
with a targeted deletion or inducible knockout of the Fas gene in liver and 
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adipose tissues will provide a better tool to examine the role of the FAS enzyme 
in fat synthesis and obesity. 
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Fig. 4. |  Interconnection of metabolic pathways involved in lipid synthesis in 
doplasmic reticulum and lipid oxidation in mitochondria of liver and skeletal 
e.  Among the lipid metabolic enzymes, acetyl-CoA carboxylase (ACC), fatty-acid 
e (FAS) and carnitine palmitoyl transferase (CPT) are the three main enzymes that 
e the synthesis of malonyl-CoA, which is the principal inhibitor of fatty-acid entry into 
ondria for β-oxidation. Stearoyl-CoA desaturase-1 (SCD1) regulates lipid oxidation by 
ting stearic acid (18:0) to oleic acid (18:1). The saturated fatty acyl-CoAs are known to 
ically inhibit ACC1, whereas monounsaturated fatty acyl-CoAs are the preferred 
tes for the lipid synthesis of triacylglycerol (TAG) in the endoplasmic reticulum (ER). 
l-CoA and stearic acid reciprocally regulate the entry of acyl-CoA into mitochondria by 
ting the activity of CPTA. Lysophosphatidic acid (LPA) and phosphatidic acid (PA) are 
ized in the ER; they are also produced in mitochondria and transported to the ER where 
minal enzymes for TAG synthesis are located. Mitochondrial FAS (FAS II) and acyl-
protein (ACP) are involved in fatty-acid synthesis. ACS, acyl-CoA synthase; AGPAT, 
cerol-3-phosphate acyltransferase; CLS, cardiolipin (CL) synthase; DGAT, diacylglycerol 
 acyltransferase; GPAT, glycerol-3-phosphate (G-3-P) acyltransferase; MCD, malonyl-
ecarboxylase; MGAT, monoacylglycerol (MAG) acyltransferase; PAP, phosphatidic-acid 
ohydrolase; PGPS, phosphatidylglycerophosphate (PGP) synthase; TAG, triacylglycerol; 
ricarboxylic-acid cycle. 
9
Carnitine palmitoyl transferase (CPT) mediates fat oxidation. 
CPT catalyses the conversion of palmitoyl-CoA to palmitoylcarnitine, 
which is a rate-limiting step in the transfer of long-chain fatty acyl-CoAs from the 
cytosol to the mitochondria for β-oxidation.  Its activity is inhibited by malonyl-
CoA, which acts as an allosteric inhibitor (Fig. 4). In mammals, three CPT 
enzymes have been identified so far: liver CPT1, muscle CPT1 and CPT2. These 
enzymes are encoded by three different genes (van der Leij et al., 2000). Muscle 
CPT1 has a crucial role in controlling the rate of β-oxidation in heart and skeletal 
muscle; it also has a much higher Michaelis–Menten constant (Km) for carnitine 
than the liver isoform and is more sensitive to malonyl-CoA inhibition (van der 
Leij et al., 2000). Several investigations have provided evidence that the malonyl-
CoA/CPT1 axis is crucial in controlling the influx of fatty acids into mitochondria 
for β-oxidation in the heart and skeletal muscle. In addition, abnormal CPT1 
activity might also contribute to the cause of obesity in human and rodent models. 
For example, impairment in CPT1-mediated lipid oxidation in skeletal muscle  is 
observed in obese patients (Kim et al., 2000).  Recent studies show that CPT1 
inhibition causes insulin resistance, whereas activation of CPT1 through the 
inhibition of ACC improves insulin sensitivity and lowers blood glucose levels 
(Abu-Elheiga et al., 2001).   
 
Acetyl-CoA carboxylases (ACC1 and ACC2) regulate fat synthesis and lipid 
oxidation. 
ACC enzymes catalyse the carboxylation of acetyl-CoA to malonyl-CoA, 
which is a crucial regulator of mitochondrial fatty-acid β-oxidation through its 
inhibition of CPT1 (Fig. 4). In mammals, ACC exists in two isoforms, ACC1 and 
ACC2, which are encoded by two different genes. ACC1 is the principal isoform 
in lipogenic tissues, whereas ACC2 is predominantly expressed in oxidative 
tissues, such as the heart and skeletal muscle. Both isoforms are expressed in 
the liver, where fatty-acid synthesis and oxidation coexist (Abu-Elheiga et al., 
1997). ACC1 is a cytosolic enzyme, whereas ACC2 is associated with the 
mitochondrial membrane through its extended amino terminus (Abu-Elheiga et al., 
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2000). This difference in compartmentalization might contribute to the diverse 
roles of the two isoforms in fat metabolism; ACC1 is believed to regulate fat 
synthesis in lipogenic tissues, whereas ACC2 controls the rate of lipid oxidation 
(Abu-Elheiga et al., 2000) in oxidative tissues.  
ACC activity is mainly regulated by citrate and AMP kinase (AMPK) 
(Hardie and Pan, 2002). Citrate is believed to be an allosteric activator of ACC, 
as suggested by a strong positive correlation between levels of malonyl-CoA and 
citrate concentrations. Phosphorylation of ACC by AMPK inhibits its activity, 
which is accompanied by a reduction in malonyl-CoA levels. This is seen in 
skeletal muscle following treadmill exercise (Winder and Hardie, 1996), The 
incubation of isolated rat soleus muscles with the AMPK activator AICAR 
decreases ACC2 activity and simultaneously increases the rate of fatty-acid 
oxidation (Kaushik et al., 2001). Acc2-null mice are hyperphagic and show an 
elevated rate of fatty-acid oxidation concomitant with decreased malonyl-CoA 
levels in the skeletal muscle and heart. These knockout mice are resistant to 
diet-induced obesity and related diabetes, with improved insulin sensitivity and 
decreased fatty-acid levels (Abu-Elheiga et al., 2003). The mRNA levels of 
uncoupling proteins (UCPs) are markedly higher in the adipose, heart (UCP2) 
and muscle (UCP3) tissues of mutant mice, which together with increased β-
oxidation might account for an upregulation of energy expenditure (Abu-Elheiga 
et al., 2003).  
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What controls energy expenditure? 
 
 Most energy is used for the basic maintenance of cells but smaller, 
variable amounts are expended in physical activity or adaptive thermogenesis 
(the process of heat production in response to diet or environmental temperature). 
Adaptive thermogenesis may be an important defense system against obesity. 
Energy excess or exposure to cold temperatures activates the sympathetic 
nervous system to enhance energy dissipation. Mice lacking all three isoforms of 
the β-adrenergic receptor have impaired thermoregulation and increased 
susceptibility to diet-induced obesity, demonstrating the importance of a central 
control to adaptive thermogenesis (Bachman et al., 2002).  
In brown fat and skeletal muscle, adrenergic signals stimulate the 
formation of mitochondria and the uncoupling of ATP synthesis from oxidative 
metabolism. A key effector in this process is the PPAR-γ coactivator-1 (PGC-1), 
which is induced by adrenergic signals and enhances the transcription of genes 
involved in mitochondrial biogenesis and uncoupling (Wu et al., 1999a). In 
skeletal muscle, PGC-1 is preferentially expressed in mitochondria-rich, oxidative 
type 1 (slow twitch) muscle fibers, and transgenic expression of PGC-1 in muscle 
induces the conversion of type 2 fibers to type 1 (Lin et al., 2002). Effect of PGC1 
expression on thermogenesis is shown in Fig. 5. 
Uncoupling protein-1 (UCP-1) is also upregulated by β-adrenergic 
signals and, in some tissues, by PGC-1 (Lowell and Spiegelman, 2000). As their 
names imply, UCPs promote leakage of protons and exhaust the electrochemical 
gradient across the inner mitochondrial membrane. Consistent with this, UCP-1-
null mice have impaired cold-induced thermogenesis (Enerback et al., 1997). 
Overexpression of UCPs induces energy expenditure in mice (Clapham et al., 
2000) (Li et al., 2000), while mice deficient in UCP-1 are not susceptible to 
obesity, suggesting that alternative or additional factors may be important in diet-
induced energy dissipation (Enerback et al., 1997). 
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PPAR-δ as an important mediator of fat burning 
Genetic studies and recently developed synthetic PPAR-δ agonists have 
helped uncover the role of  PPAR-δ as a powerful regulator of fatty acid 
catabolism and energy homeostasis (Dressel et al., 2003; Tanaka et al., 2003). 
The PPAR- agonist GW501516 was shown to lower plasma triglyceride levels in 
obese monkeys while raising high-density lipoprotein levels, prompting the 
initiation of clinical trials to assess its efficacy in hyper-lipidemic patients (Oliver 
et al., 2001). 
Studies in adipose tissue and muscle have begun to uncover the 
metabolic functions of PPAR-δ. Transgenic expression of an activated form of 
PPAR-δ in adipose tissue produces lean mice that are resistant to obesity, 
hyperlipidemia and tissue steatosis induced genetically or by a high-fat diet 
(Wang et al., 2003). The reason for this is that the activated receptor induces 
genes required for fatty acid catabolism and adaptive thermogenesis. Taken 
together, these data identify PPAR-δ as a key regulator of fat-burning. The 
thermogenic function of PPAR-δ is markedly similar to that of the nuclear cofactor 
PGC-1(Wu et al., 1999a), Indeed, PPAR-δ strongly associates with PGC-1 both 
in cultured cells and in tissues (Wang et al., 2003), so it is possible that many 
metabolic effects of PGC-1 may be mediated through PPAR-δ. Treatment with 
GW501516 ligand significantly retards weight gain, but does not affect food 
consumption in animals fed a high-fat diet. Treatment with a PPAR-δ agonist also 
improves insulin resistance induced by a high-fat diet, probably as a 
consequence of increased fat-burning by muscle and overall improvement in 
systemic lipid metabolism (Dressel et al., 2003; Tanaka et al., 2003) (Fig. 6). 
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1.5. Adipose tissue 
 
In humans, the fat-depot consist of white adipose tissue which, at a cellular level, 
is composed of the lipid-filled adipocytes surrounded by a matrix of collagen 
fibers, blood vessels, fibroblasts and immune cells (Cinti, 2000; Hirsch et al., 
1989; Tiraby and Langin, 2003). The adipocyte is a specialized cell, whose 
primary function is to store energy in the form of triglycerides when an excess of 
nutrients are available and, when nutrients are being scarce or absent, release 
energy again in form of free fatty acids (FFA). The size of the adipose tissue 
depots are mainly determined by the balance between energy intake and energy 
expenditure (Hirsch et al., 1989), where the adipose tissue seems to provide a 
virtually limitless storage site for triglycerides based on its life-long ability to 
increase fat cell size (hypertrophy) as well as to increase the number of fat cells 
(hyperplasia)(Couillard et al., 2000; Hirsch and Batchelor, 1976; Hirsch et al., 
1989) Obese people tend to have larger adipocytes and more of them than 
normal weight subjects (Couillard et al., 2000).   
 
1.6. What are the characteristics of white adipose tissue and 
brown adipose tissue? 
 
The mammalian adipose organ is composed of subcutaneous and visceral fat 
depots, themselves composed of two tissue types that have critical and 
interrelated roles in energy balance (Cinti, 2000; Tiraby and Langin, 2003). The 
main characteristics of these adipose tissue types are briefly listed in Table. 1. 
White adipose tissue (WAT) is populated mainly by white adipocytes and yet can 
contain a variable amount of brown adipocytes (Guerra et al., 1998). Conversely, 
brown adipose tissue (BAT) is composed almost exclusively of brown adipocytes. 
Cells in certain fat depots appear to be able to "change" between the white and 
brown adipocyte phenotype in an age- or environment-dependent manner (Cinti, 
2000; Tiraby and Langin, 2003). Now under debate in the field is the possibility of 
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transdifferentiation between WAT and BAT states. Both adipose tissue types are 
able to store NEFAs as triacylglycerol (TG), but whereas WAT TG hydrolysis 
satisfies the energy needs of the whole organism, fatty acids released from BAT 
are used within the tissue to promote non-shivering thermogenesis (Foster and 
Frydman, 1979; Tiraby and Langin, 2003).  
 
 
Table 1.  Some basic characteristics of WAT and BAT 
Characteristics White fat cell Brown fat cell 
Unilocular appearance 
 
Multilocular appearance 
(numerous small lipid 
droplets) 
(Single large lipid droplet) Numerous mitochondria with 
many cristae 
Morphology 
Large cells (up to 200µm)  
Storage of energy as 
triglycerides and 
mobilization as fatty acids 
Fat oxidation and 
thermogenesis 
Function 
Secretion of adipocytokines 
(+++)a
Secretion of adipocytokines 
(+) 
Uncoupling protein 1 (0) Uncoupling protein 1 (+++) 
Uncoupling protein 2 (++) Uncoupling protein 2 (+) 
Uncoupling protein 3 (+/-) Uncoupling protein 3(+) 
Subunit c of F0-ATPase (+) Subunit c of F0-ATPase (+/-) 
Respiratory chain genes (+) Respiratory chain genes 
(+++) 
Fatty acid oxidation 
enzymes (+) 
Fatty acid oxidation enzymes 
(+++) 
Expression of genes 
involved in metabolism 
Glycerol kinase (+/-) Glycerol kinase (+++) 
ano (0), very low or uncertain (+/-), moderate (++) and high (+++) expression. 
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 WAT is the predominant type of adipose tissue in adult mammals; its amount 
usually increases with age, and in obese individuals it can account for more than 
half of total body weight. In healthy adult humans, it accounts for 15%-20% of 
body weight in men and 20%-25% in women. The principal cell type of WAT 
contains a single (unilocular) and large (20-200 µm) lipid droplet, resulting in the 
near disappearance of the cytoplasm and compression of the nucleus 
underneath the plasma membrane (Cushman, 1970). These cells are grouped 
into small lobules surrounded by connective tissue. WAT is considered to be less 
well vascularized than BAT (Cushman, 1970).  
 
1.7. How are adipocytes differentiated? 
 
At the cellular level, a positive energy balance induces changes in the 
microenvironment, which stimulate mature adipocytes to accommodate excess 
energy through enhanced triacylglycerol storage. When adipocytes reach a 
critical size threshold, it is postulated that signals are transmitted from adipocytes 
to preadipocytes to stimulate the formation of new adipocytes to store the excess 
energy (Fruhbeck et al., 2001). Early in life, adipose tissue expansion occurs 
primarily through new fat cell formation or hyperplasia (Lemonnier, 1972). 
However, humans and rodents have the capacity to form new fat cells from 
preadipocytes throughout life (Lemonnier, 1972). Compared with lean animals, 
obese animals have a greater number of, and larger, adipocytes (Hirsch and 
Batchelor, 1976). Some studies have suggested that preadipocytes from 
severely obese individuals display inherent proliferation defects that lead to an 
excessive number of adipocytes (Ravussin and Smith, 2002). 
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Fig. 7. Adipogenesis is a multistep process. 
Mesenchymal cells proliferate (clonal expansion). At some point, some of these cells differentiate 
into preadipocytes. Preadipocytes proliferate at the site of adipogenesis (clonal expansion). 
Preadipocytes undergo a second differentiation step and begin to fill with lipids. At first, lipids 
accumulate within the cell in small droplets (multilocular cells) and eventually the droplets fuse 
into one large droplet (unilocular cells). The adipocyte can continue to enlarge by accumulating 
additional lipids. The average mesenchymal cells is 10-20µm in diameter, whereas adipocytes 
easily reach 100µm (and in some cases 200µm) in diameter. Thus volume of the cell increases as 
much as a thousand fold largely because of lipid accumulation. 
 
 
 
The signal for differentiation of new adipocytes is related to nutritional state. 
Important stimuli for differentiation include insulin and fatty acids. Fatty acids act 
through members of the peroxisome proliferator-activated receptor (PPAR) family, 
PPAR (also known as fatty acid-activated receptor, FAAR (Amri et al., 1995). The 
natural ligand for PPAR is probably a fatty acid derivative (Forman et al., 1995). 
In addition, differentiation is regulated by a pathway involving the sterol 
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regulatory element binding protein-1c (SREBP-1c, also known as adipocyte 
determination and differentiation factor-1, ADD-1), a pathway that in adipocytes 
is regulated by insulin (Kim et al., 1998). Given that individual adipocytes can 
also expand over a very large range as they store more TG, the net effect is that 
the capacity to store fat can increase seemingly without limit. 
        Expansion of fat stores, especially if differentiation of new adipocytes is 
involved, requires new blood vessels. Angiogenesis in adipose tissue appears 
also to be regulated in part by factors produced within the tissue. Leptin 
produced by adipocytes has angiogenic properties (Sierra-Honigmann et al., 
1998). In addition, expression of genes involved in angiogenesis is upregulated 
during weight gain in animals (Morimura et al., 2001) and inhibition of 
angiogenesis reduces fat deposition in various obesity models in mice (Rupnick 
et al., 2002).  
        The number of adipocytes present in an organism is determined to a large 
degree by the adipocyte differentiation process, which generates mature 
adipocytes from fibroblast-like preadipocytes. One of the first steps in the 
process of adipogenesis is the re-entry of growth-arrested preadipocytes into the 
cell cycle and the completion of several rounds of clonal expansion. Hansen et al. 
demonstrated that mouse lung embryonic fibroblasts (MEFs) with targeted 
disruption of the gene encoding Rb completely failed to undergo adipocyte 
differentiation (Hansen et al., 1999). Generally, Rb phosphorylation status 
correlates well with cell-cycle progression: hypophosphorylated Rb in growth-
arrested preadipocytes and hyperphosphorylated Rb in proliferating cells. 
Hypophosphorylated Rb is complexed with transcription factor E2F, and upon 
addition of adipogenic hormones, Rb rapidly undergoes hyperphosphorylation by 
cyclin-dependent kinases (CDKs). This results in the dissociation of Rb and E2F, 
allowing E2F to promote cell-cycle progression into S phase (Fig. 8). Just before 
entering the terminal differentiation state, Rb returns to a hypophosphorylated 
state, sequestering E2F and causing cells to permanently exit from the cell cycle 
(Hiebert et al., 1992). Many cell-cycle-associated proteins (CDKs and their 
inhibitors, p18, p21 and p27) play crucial roles during cell-cycle progression that 
 20
precedes entry into the terminally differentiated state (Morrison and Farmer, 
1999).  
Two transcription factor families have emerged as the key determinants of 
terminal adipocyte differentiation: the CCAAT/enhancer-binding proteins C/EBPα, 
-β, -δ, and peroxisome proliferator-activated receptor γ (PPARγ , encoded by 
PPARG) (Yeh et al., 1995b). As cells undergo the differentiation process in 
response to adipogenic signals, the initial event is the rapid induction of C/EBP-β 
and -δ expression (Yeh et al., 1995b). A potential role for C/EBP-β and -δ is to 
increase p21 levels, leading to an inhibition of CDK-mediated Rb phosphorylation. 
A role for C/EBP  -β and -δ and PPARγ2, a key regulator of adipogenesis, has 
also been reported (Elberg et al., 2000).  Overexpression of C/EBP -β and -δ in 
preadipocytes enhanced adipogenesis (Yeh et al., 1995b), whereas embryonic 
fibroblast cells (MEFs) derived from mice lacking either C/EBP -β or  -δ had 
reduced levels of adipogenesis compared with the wild type (Tanaka et al., 1997).  
The induction of C/EBP-β and -δ is immediately followed by an increase in 
PPARγ and C/EBPα expression. PPARγ is itself a ligand-dependent nuclear 
receptor transcription factor. In mice there are two isoforms, PPARγ1 and 
PPARγ2. Interestingly, levels of PPARγ2 expression, but not PPAR1, correlate 
with the degree of lipid accumulation. Cells with a 95% reduction in PPARγ2 
expression completely failed to undergo adipogenesis, whereas cells with a 50% 
reduction in PPARγ2 expression produced a corresponding 50% loss in 
adipogenic capacity. These results strongly suggest that PPARγ2, but not 
PPARγ1, plays a key role in adipogenesis (Ren et al., 2002). During the later 
stage of differentiation, C/EBPα expression rises immediately after PPARγ2 
expression. In summary, PPARγ and C/EBPα are key transcription factors in 
adipogenesis, acting synergistically to generate fully differentiated, insulin-
responsive adipocytes (Rosen et al., 2002)(Fig. 8).  
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                                            Adapted from (Camp et al., 2002) 
 
Fig. 8. In vitro model of adipogenesis.  
Conversion of preadipocytes into lipid-containing adipocytes can be achieved by adding 
appropriate adipogenic hormones, such as dexamethasone (DEX), isobutylmethylxanthine 
(IBMX) and insulin (INS). Lipid accumulation is visualized by staining adipocytes with Oil-Red-
O stain. The adipogenic process is divided into three distinct stages: growth arrest, clonal 
expansion and differentiation. A set of distinct genes are induced and activated in each stage 
during the adipogenic process. Solid arrows represent direct modulation, whereas the dotted 
arrow represents potential modulatory activity. The bar represents inhibitory action. 
Abbreviations: CDK, cyclin-dependent kinase; C/EBP, CCAAT/enhancer-binding protein; Glut4, 
glucose transporter 4; pRb, phosphorylated retinoblastoma protein; Rb, retinoblastoma protein.  
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2. When nutrient homeostasis is out of order 
 
2.1. Obesity 
 
Obesity can be defined as a condition of abnormal or excessive body fat 
accumulation, to the extent that health may be impaired (Vega, 2004). A useful 
(and inexpensive) way of classifying or estimating the prevalence of obesity in a 
population is done by calculating the Body Mass Index (BMI = the weight in 
kilograms divided by the square of the height in metres (kg/m2). However, BMI is 
a crude estimate of individual adiposity since it does not account for the 
differences in the amount of body-fat and muscle tissue (Segal et al., 1987) 
Furthermore, it is well-known that abdominal fat accumulation is an even greater 
risk factor for disease as is excess body-fat per se (Despres et al., 2001). 
 
Table. 2.: Classification of body weight in adults according to BMI (Frankenfield et 
al., 2001) 
-------------------------------------------------------------------------------- 
Classification BMI (kg/m2)   Risk of co-morbidities  
-------------------------------------------------------------------------------- 
Underweight < 18.5   Low  
Normal weight 18.5 - 24.9   Average 
Overweight 
Pre-obese 25 - 29.9   Increased 
Obese class I 30 - 34.9   Moderate 
Obese class II 35 - 39.9   Severe 
Obese class III 40                         Very severe 
-------------------------------------------------------------------------------- 
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To obtain more precise and detailed data on the obese phenotype, body 
composition can be estimated using dual-energy X-ray absorptiometri (DEXA) 
scans or bioelectrical impedance.  
 
 
 
Epidemiology of obesity 
 
During the last twenty years the prevalence of obesity has increased by 50 - 
100 %, making it the most common metabolic disorder in the developed parts of 
the world (Must et al., 1999) . A similar increase in the prevalence of obesity has 
been observed in United States where 60% of the adult population are 
considered to be overweight or obese (Must et al., 1999). Obesity is known to be 
associated with numerous diseases, and consequently with increased morbidity 
and mortality. Of special interest are the disease states such as insulin 
resistance, type 2 diabetes, hypertension and cardiovascular disease, which are 
associated with obesity and often referred to as metabolic syndromes (Despres 
et al., 2001; Vega, 2004) 
 
Obesity related diseases are  
(Must et al., 1999; Vega, 2004) 
---------------------------------------------------------------------------------------------------- 
Certain cancer types (breast, Coronary heart disease Non-insulin dependent  
colon and endometrial cancer) Hypertension, diabetes mellitus  
Polycystic ovary syndrome, Osteoarthritis, Dyslipidaemia 
Impaired fertility, Hyperuricaemia, Insulin resistance 
Lower back pain, Gout, Sleep apnoea  
Increased anaesthetic risk, Gallbladder disease  
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2.2. Insulin resistance  
 
 
The term ‘insulin resistance of obesity’, as used currently, refers mainly to 
resistance to insulin-stimulated glucose disposal (Kahn and Flier, 2000). Under 
normal homeostasis, binding of insulin to its receptors in skeletal muscle and 
adipose cells initiates a phosphorylation cascade culminating with the 
translocation of the glucose transporter, GLUT-4, from intracytoplasmic vesicles 
to the plasma membrane, thereby facilitating glucose entry into the cell (Wang et 
al., 1999) (Fig. 9). After phosphorylation to form glucose-6-phosphate, glucose is 
either stored as glycogen or enters the glycolytic pathway to form pyruvate. 
Pyruvate is irreversibly decarboxylated to acetyl Co A and enters the 
mitochondria for oxidation in the citric acid cycle forming CO2 and H2O. Any 
unoxidized surplus is returned to the cytosol via the acetyl-group shuttle and 
carboxylated to malonyl CoA, the first intermediate in the pathway of fatty acid 
(FA) synthesis. In addition to being a lipogenic substrate, malonyl CoA inhibits 
the mitochondrial enzyme, CPT1. This reduction of FA oxidation by malonyl CoA 
is referred to as the McGarry effect.  
In addition to stimulating the uptake of glucose, insulin induces expression 
of the enzymes of lipogenesis through upregulation of the lipogenic transcription 
factor, SREBP-1c (Fig. 10)(Shimomura et al., 1999), thereby providing the 
enzymatic machinery for de novo synthesis of fat. Ironically, insulin-responsive 
SREBP-1c and its lipogenic target enzymes are expressed at higher levels in 
tissues of so-called ‘insulin-resistant’ obese rats with defective leptin receptors 
than in tissues of the ‘insulin-sensitive’ control animals(Kakuma et al., 2000). This 
implies that the tissues of insulin-resistant animals are not resistant to insulin-
stimulated lipogenesis and fits with the idea that glucometabolic insulin 
resistance is secondary to the overaccumulation of lipids (Boden and Shulman, 
2002). 
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(4)Newly synthesized fatty acids (FA) and FA from dietary fat are transported as 
very low-density lipoproteins and stored as triacylglycerol (TG) in adipocytes, 
resulting in obesity. 
(5)Leptin secretion by adipocytes increases in proportion to the increase in fat 
accumulation. 
(6)The hyperleptinemia downregulates SREBP-1c in liver and activates AMP-
kinase. This increases FA oxidation in peripheral tissues, thus limiting ectopic 
deposition of fat. 
(7)Despite this, insulin resistance and glucose intolerance result from the small 
increase in unoxidized FA accumulating in skeletal muscle, although serious 
lipotoxicity is prevented. 
(8)Later in the course of the disorder, leptin-mediated protection against the 
lipotoxic metabolic syndrome diminishes, in part because of leptin resistance 
factors that prevent leptin inhibition of SREBP-1c expression and block the 
compensatory increase in FA oxidation induced by hyperleptinemia. Unoxidized 
FA increases and lipid derivatives such as TG and ceramide accumulate in 
nonadipose tissues, compromising their functions and promoting apoptosis (Fig. 
10). 
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2.3. What causes insulin resistance? 
 
Insulin resistance observed in and type 2 diabetes is characterized by 
defects at many levels, with decreases in receptor concentration and kinase 
activity, in the concentration and phosphorylation of IRS-1 and -2, in PI (3) K 
activity, in glucose transporter translocation, and in the activity of intracellular 
enzymes (Kahn and Flier, 2000). Genetic and acquired factors can also 
profoundly influence insulin sensitivity. Genetic defects in the insulin receptor 
represent the most severe forms of insulin resistance, and are exemplified by 
leprechaunism, the Rabson Mendenhall Syndrome, and the type A syndrome of 
insulin resistance (Taylor and Arioglu, 1998). The high level of insulin resistance 
may be due to the severity of the genetic defect, the ability of the mutant 
receptors to form hybrids with IGF-I or other receptors, and other background 
genetic or acquired factors that modify the insulin-resistant state.  
Targeted deletions of the components of insulin signalling in vivo have 
provided some insight into the complexity of insulin resistance. The IRS1 
knockout mice have peripheral insulin resistance (Tamemoto et al., 1994), while 
deletion of IRS2 results in impaired pancreatic β-cell proliferation and diabetes 
(Withers et al., 1998). In addition, defects in the insulin-signalling pathway, such 
as knockout of PKBβ, can result in insulin resistance and diabetes (Cho et al., 
2001a).  
Combinatorial knockouts have been produced that mimic polygenic type 2 
diabetes with heterozygous deletion of the insulin receptor and IRS-1 (Bruning et 
al., 1997a), or of the insulin receptor, IRS-1 and IRS-2 (Kido et al., 2000). In 
some of these combinations there has been clear evidence of genetic epistasis. 
For example, although heterozygous knockout of either the insulin receptor or 
IRS-1 alone does not produce diabetes, the double-heterozygous knockout 
produces diabetes in up to 50% of mice (Bruning et al., 1997a). This finding gives 
insight into insulin resistance where insulin-induced downregulation, or genetic 
polymorphisms in the receptor or IRS-1 alone, might produce modest changes in 
signalling capacity, but when combined can lead to severe insulin resistance.  
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  The role of specific tissues in the pathogenesis of insulin resistance has 
been explored using tissue-specific knockouts of the insulin receptor (Michael et 
al., 2000) (Bruning et al., 1997b). Mice with a knockout of the fat-specific or 
muscle specific insulin receptor have normal glucose tolerance, whereas the 
liver-specific insulin-receptor knockout shows both impaired glucose tolerance 
and decreased insulin clearance with marked hyperinsulinaemia (Bruning et al., 
1997b; Michael et al., 2000). Taken together, these findings suggest that 
impaired insulin-induced signaling results in insulin resistance in insulin target 
tissues, such as liver and muscle.  
 Notably, one genetic model with a surprising phenotype regarding glucose 
homeostasis was the knockout of the p85 regulatory subunit of PI (3) K. Although, 
PI(3)K is central to the metabolic actions of insulin, p85 heterozygous knockout 
mice counter-intuitively exhibit improved insulin sensitivity (Fruman et al., 2000). 
This protection seems to be due to a unique feature of the insulin-signalling 
pathway in which the stoichiometric balance between p85, the catalytic subunit 
p110 and IRS proteins is critical for optimal signal transduction. 
 
What is the relationship between fat cells and insulin sensitivity? 
 
Adipose tissue plays a special role in insulin resistance. Circulating FFAs 
derived from adipocytes are elevated in many insulin-resistant states and have 
been suggested to contribute to the insulin resistance of diabetes and obesity by 
inhibiting glucose uptake, glycogen synthesis and glucose oxidation, and by 
increasing hepatic glucose output (Bergman and Ader, 2000). Elevated FFAs are 
also associated with a reduction in insulin-stimulated IRS-1 phosphorylation and 
IRS-1-associated PI(3)K activity (Shulman, 2000). The link between increased 
circulating FFAs and insulin resistance might involve accumulation of 
triglycerides and fatty acid-derived metabolites (diacylglycerol, fatty acyl-CoA and 
ceramides) in muscle and liver. Nuclear magnetic resonance imaging has 
revealed a close correlation between intramyocellular triglyceride content and 
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whole-body insulin resistance in patients with obesity and type 2 diabetes 
(Hwang et al., 2001). 
Randle proposed that free fatty acids competing with glucose for substrate 
oxidation, along with increased fat oxidation, may result in insulin resistance seen 
in obesity and type 2 diabetes (Randle, 1998). According to this hypothesis, 
increased free fatty acids levels lead to elevated mitochondrial acetyl-CoA/CoA 
and NADH/NAD ratios which, in turn, inhibit pyruvate dehydrogenase activity and 
lead to an increase in citrate levels that inhibits phosphofructokinase activity. This 
process induces an increase in glucose 6-phosphate concentration, which 
inhibits hexokinase and reduces glucose transport/phosphorylation activity. 
(Randle, 1998).  
 
Does IRS-1 serine phosphorylation relate to cellular insulin resistance? 
 
Prolonged stimulation of cells with insulin also induces Ser 
phosphorylation of IRS-1, suggesting there may exist a negative-feedback 
mechanism that uncouples the IRS-1 proteins from their upstream and 
downstream partners and blocks insulin signal transduction under physiological 
conditions.  For example, TNFα increases serine phosphorylation of IRS-1, 
resulting in inhibition of insulin-stimulated tyrosine phosphorylation and impaired 
insulin signaling (Rui et al., 2001). Recently, phosphopeptide mapping, 
mutational analysis and phosphospecific antibodies allowed the identification of 
the serine residues phosphorylated in response to insulin and TNFα. Interestingly, 
insulin and TNFα signaling lead to phosphorylation of the same residues in IRS-1, 
namely Ser307, Ser612 and Ser632 (Ozes et al., 2001) (Gual et al., 
2003b)(Fig.11). (see below.) 
Ser307 is located at the end of the phosphotyrosine-binding domain 
involved in the interaction of IRS-1 with IR, where its phosphorylation blocks this 
interaction (Fig. 11) (Aguirre et al., 2002). However, its mutation prevents the 
inhibitory effect of TNFα on insulin-induced IRS-1 tyrosine phosphorylation. 
Ser307 phosphorylation induces a conformational change of the 
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phosphotyrosine-binding domain, reducing its affinity for the IR (Aguirre et al., 
2002).  The mTOR (mammalian target of rapamycin) signalling pathway was 
shown to be involved in insulin-induced phosphorylation of Ser307 in adipocytes, 
and muscles (Gual et al., 2003b), (Carlson et al., 2004). Hyperosmotic stress, 
which also induces insulin resistance, increases the phosphorylation of IRS-1 on 
Ser307 by an mTOR-dependent pathway (Gual et al., 2003a), indicating the 
importance of this site in insulin resistance.  JNK is also known to be involved in 
Ser307 phosphorylation of IRS-1 in fat-induced insulin resistance. JNK is 
activated by fatty acids and JNK activity is abnormally elevated in obesity 
(Hirosumi et al., 2002). Interestingly, JNK1-knockout mice have a decreased 
adiposity, resistance to a high-fat diet, an improved insulin sensitivity and an 
enhanced insulin receptor signalling capacity. Moreover, genetically obese 
(ob/ob) mice with a targeted mutation in Jnk1 put on less weight than their 
relative control (ob/ob) mice and they are partly protected against 
hyperinsulinaemia and hyperglycaemia (Hirosumi et al., 2002).  
Phosphorylation of Ser307 could have a more general role in the 
regulation of insulin signalling. Its phosphorylation, by inhibiting the interaction 
between the IR and IRS-1, could favour the dephosphorylation of all IRS-1 
tyrosine phosphorylation sites, leading to termination of the insulin signal. 
Moreover, the regulation of serine versus tyrosine phosphorylation of IRS-1 may 
regulate IRS-1 degradation, since IRS-1 with a point mutation of Ser307 is more 
resistant to degradation following long-term exposure to insulin (Greene et al., 
2003). 
Ser612 and Ser632 are located close to tyrosine residues which are 
major phosphorylation sites involved in the binding of PI 3-kinase and are 
required for insulin-stimulated glucose uptake (Fig.11). The role of the 
phosphorylation of these two serine residues could modulate the interaction 
between IRS-1 and PI 3-kinase and/or its activation (Mothe and Van Obberghen, 
1996). Phosphorylation of these sites is mediated by MAPK and/or mTOR 
signaling pathways in response to both insulin (Gual et al., 2003b) and TNFα 
(Ozes et al., 2001).  Interestingly, the basal level of IRS-1 phosphorylation on 
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Ser632 was abnormally high in primary cultures of skeletal muscle cells obtained 
from type 2 diabetic patients (Bouzakri et al., 2003), suggesting this site may be 
involved in predisposition of insulin resistance. Phosphorylation of 
Ser612/Ser632, in addition to the closely located tyrosine residues, could thereby 
regulate PI 3-kinase activity (Fig. 11). 
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3. How does nutrient signaling coordinate with insulin 
signaling? 
 
Binding of insulin to insulin receptor induces trans-autophosphorylation of 
receptor on tyrosine residues (Kasuga et al., 1982).  The phosphorylated 
Tyrosine residues serve as docking sites for insulin receptor substrate (IRS) 
proteins, which themselves become phosphorylated on Tyr residues by the 
receptor (Whitehead et al., 2000). This leads to recruitment of the heterodimeric 
PI (3) K to the membrane, which leads to the generation of PIP3 at the 
membrane. PIP3 production is counteracted by the tumor suppressor PTEN or by 
PI (3) K inhibitors such as wortmanin. PKB translocates to the membrane by 
virtue of its pleckstrin homology (PH) domain, which also mediates binding to 
PIP3. (Burgering and Coffer, 1995; Franke et al., 1997). The interaction of PKB 
with PIP3 is thought to cause a change in conformation, which facilitates 
phosphorylation of the activation loop site (T308) by PDK1 (Alessi et al., 1997) 
and of the conserved regulatory site in the carboxy terminus (S473) by DNA-
dependent protein kinase (Feng et al., 2004). Phosphorylation of the T308 and 
S473 sites is required for full PKB activation (Bos, 1995). Following activation at 
the membrane, PKB targets substrates in the cytosol and translocates to the 
nucleus  where it phosphorylates as yet unclear substrates (Brazil et al., 2004). 
Together this kinase cascades mediate the metabolic and growth functions of 
insulin, such as the translocation of GLUT4 glucose transporter containing 
vesicles from intracellular pools to the plasma membrane, stimulation of glycogen 
and protein synthesis, uptake of amino acids, and the inhibition of specific gene 
transcription programs (Fig. 12) (Ueki et al., 1998; Yang et al., 2004). 
Tuberous sclerosis complex 1/2 heterodimer protein (TSC1/2) and Rheb 
(Ras homolog enriched in brain) are upstream components of the mTOR 
(mammalian target of rapamycin) signaling pathway (Gao and Pan, 2001; Gao et 
al., 2002; Manning and Cantley, 2003). Tuberous sclerosis complex 2 (TSC2) is 
phosphorylated and inhibited by the pro-growth protein PKB, which is activated 
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by growth factors such as insulin (Inoki et al., 2002). TSC2 is a GTPase-
activating protein (GAP) for the small G protein Rheb (Inoki et al., 2003; Li et al., 
2004). Inactivation of Rheb by TSC2 is significant because GTP-bound, activated 
Rheb leads to an increase in the activation of mTOR, a central regulator of cell 
growth (Garami et al., 2003; Inoki et al., 2003; Li et al., 2004; Manning and 
Cantley, 2003) .  In response to amino acids and cellular energy levels, mTOR 
controls translation through activation of S6K1 (p70 ribosomal protein S6 kinase) 
and inhibition of eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1) 
(Nojima et al., 2003; Proud, 2004a; Proud, 2004b). It is known that cellular 
nutrient levels (intracellular amino acids) can regulate the function of mTOR 
(Beugnet et al., 2003), but it remains to be seen what roles TSC1/2 and Rheb 
have in the intracellular amino acid and energy-sensing network. (Fig. 12). 
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(Novak-Hofer and Thomas, 1984). This phosphorylation of S6 was also observed 
in the liver following partial hepatectomy and during refeeding after starvation, 
both of which which induce the activation of protein synthesis required for cell 
growth (Gressner and Wool, 1974; Kozma et al., 1989). S6 phosphorylation by 
S6K and other unknown kinases occurs in an ordered fashion: Ser 236 > Ser 235 
> Ser 240 > Ser 244 (Krieg et al., 1988).  Translational upregulation of 5' 
Terminal Oligopyrimidine tract (5'TOP) mRNA following mitogen stimulation 
closely follow the multiple phosphorylation events of S6 and activation of S6K, 
indicating the role of S6K in translational control as a mediator of cell growth 
(Jefferies and Thomas, 1996). The 5'TOP transcripts represent mRNA encode 
ribosomal proteins, translational initiation and elongationl factors (Meyuhas et al., 
1996).  
Deletion of S6K1 gene in mice did not impair either S6 phosphorylation or 
5'TOP mRNA translation, leading to the discovery of S6 kinase 2 (Shima et al., 
1998), which shows 82% homology in the catalytic domain and in the linker and 
autoinhibitory domains. S6K1 and S6K2 belong to the AGC family of 
serine/threonine protein kinases including PKA, PKB, and PKCs where they 
share high degree of homology in the catalytic  domain (Brazil and Hemmings, 
2001; Shima et al., 1998).  
S6K1 has five distinct domains. The first domain is represented by a short 
segment at the amino terminus, which confer rapamycin sensitivity. The catalytic 
domain of S6K1 contains a key site of phosphorylation in the activation loop, 
T229.  The catalytic domain is coupled to the carboxyterminal autoinhibitory 
domain through a linker domain. The linker domain contains two essential 
phosphorylation sites, S371, and S/TP site and T389 (Dennis et al., 1998; 
Pearson et al., 1995). In contrast to most member of the AGC family which end 
with the linker domain, S6K1 and S6K2 have two additional carboxy-terminal 
domains which contains four S/T-P phosphorylation sites: S411, S418, T421, and 
S424 which are critical for T229 phosphorylation (Dennis et al., 1998), and a 
PDZ-binding domain. The order of S6K1 sequential activation mechanism is 
described in the legend of Fig. 13. TOS (TOR signaling motif) motif in the amino 
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terminus of S6K1 binds to Raptor (regulatory associated protein of TOR) which 
mediates interaction with mTOR (Schalm and Blenis, 2002). The S/TP sites in 
autoinhibitory domain must be first phosphorylated to facilitate TOR-mediated 
phosphorylation of T389 (Dennis et al., 1998). Once phosphorylated, T389 in the 
hydrophobic domain becomes a docking site for PDK1 via its PIF-binding pocket. 
PDK1 then mediate the first step of S6K1 activation, the phosphorylation of the T 
-loop site T229 (Alessi et al., 1998; Pullen et al., 1998)(Fig.13). 
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a reduction in S6 phosphorylation, as this response proved to be intact in S6K1-
deficient animals (Shima et al., 1998). S6 phosphorylation in such animals was 
still sensitive to rapamycin (Shima et al., 1998). Rapamycin inhibits the 
mammalian target of rapamycin (mTOR) (Dennis and Thomas, 2002), the 
upstream S6K1 kinase (Dennis and Thomas, 2002), suggesting there exists a 
second S6K which may compensate for loss of S6K1.  Moreover, proliferation of 
S6K1 deficient MEFs as well as 5' TOP mRNA translation were intact (Shima et 
al., 1998), indicating the small body size phenotype may not stem from reduced 
translational capacity regulating cell cycle. On the other hand, measurements of 
the humoral environment, such as growth hormone and insulin-like growth 
factors levels which regulate body growth has not been studied in S6K1 knockout 
mice. Thus, it is not clear whether reduced body mass in S6K1 knockout mice is 
due to cell autonomous effects coming from deletion of S6K1 gene.   Given that 
body size differences were more pronounced during embryogenesis, growth 
retardation in S6K1 deficient mice could be due to defects in fetal development.  
As efficient nutrient uptake is essential to body growth and development and 
extraembryonic tissues such as placenta regulate nutrient transport to the 
embryo (Rossant and Cross, 2001), it remained to be determined whether any 
impairment of nutrient uptake or function of the placenta was responsible for the 
growth retardation in S6K1 deficient mice (see results). 
Given the differences of S6K2 gene expression level in various tissues of 
S6K1 deficient mice (Rossant and Cross, 2001), it would be interesting to see if 
the extents of S6K2 upregulation influence the physiological function of individual 
tissues operates. Despite the presence of S6K2, S6K1 deficient mice are mildly 
glucose intolerant and have reduced levels of circulating insulin. Reduced insulin 
levels result from a selective reduction in β-cell cytosolic endocrine mass 
indicating reduction in β-cell size (Pende et al., 2000). This would suggest that 
the function of S6K2 at least in pancreatic β- cell growth and insulin secretion, is 
different from S6K1.  Consistent with this, S6K2 deficient mice did not exhibit the 
reduced circulating insulin and diminished β-cell size seen in S6K1 deficient mice 
(S Um, S. Kozma, and G. Thomas, unpublished results).  
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Raptor 
 Raptor (regulatory associated protein of TOR) is a conserved 150-kDa 
protein that also binds the downstream effectors of mTOR, S6K1, and 4E-BP1 
(Hara et al., 2002; Kim et al., 2002). Knockdown experiments of Raptor by RNAi 
in mammalian cells also suggest its positive role in mTOR activity (Hara et al. 
2002; Kim et al. 2002). Although Raptor is normally a positive regulator of mTOR, 
one report indicates that, upon nutrient deprivation, Raptor-mTOR association is 
stabilized in a manner that inhibits mTOR kinase activity (Kim et al., 2002). 
Raptor binds S6K1 and 4E-BP1, both downstream effectors of mTOR, leading to 
efficient phosphorylation of S6K1 (Beugnet et al. 2003; Choi et al. 2003; Nojima 
et al. 2003; Schalm et al. 2003). The interaction of Raptor with S6K1 and 4E-BP1 
is mediated by a 5 amino acid motif termed TOS (TOR signaling) that is present 
in the N-terminus of S6K1. (Schalm and Blenis, 2002). Taken together, these 
findings support a model whereby a change in the configuration of the mTOR-
Raptor complex, which is mediated by nutrient conditions such as amino acid 
availability, affects the ability of mTOR to interact with and phosphorylate its 
substrates such as S6K1 and 4E-BP1 (Hall. M., 2004).  In the absence of amino 
acids, the mTOR-mLST8-Raptor complex precludes mTOR from binding to its 
substrates and/or prevents the access of mTOR (or mTOR-associated kinases) 
to the substrates (Chen and Kaiser, 2003; Kim and Sabatini, 2004). Conversely, 
in the presence of amino acids, a conformational change promotes efficient 
interaction between Raptor and mTOR substrates and/or increased accessibility 
of the substrates to mTOR and its associated kinases (Kim and Sabatini, 2004).  
 
mTOR 
The mammalian target of rapamycin (mTOR) was identified and cloned 
(Brown et al. 1994; Chiu et al. 1994; Sabatini et al. 1994) shortly after the 
discovery of the two yeast genes, TOR1 and TOR2, in the budding yeast 
Saccharomyces cerevisiae during a screening for resistance to the 
immunosuppressant drug rapamycin (Kunz and Hall, 1993). mTOR is a large 
protein with homology to members of the lipid kinase family. mTOR regulation of 
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S6K1 is inhibited by the drug rapamycin, which, in a gain of funtion complex with 
the small protein FKBP12, specifically binds and inhibits mTOR activity (Brown et 
al., 1995) . The function of mTOR has also been studied in yeast. Loss of TOR 
causes effects identical to nutrient starvation: reduction of protein synthesis, 
accumulation of glycogen, enlargement of vacuoles and specific gene expression 
reflecting starvation (Hardwick et al., 1999; Kunz and Hall, 1993; Kunz et al., 
1993; Noda and Ohsumi, 1998) indicating the critical role of mTOR to mediate 
nutrient-induced cell growth and protein synthesis. 
 
PKB  
Mammalian cells express three unique PKB proteins. A downstream 
effector of PI3K, PKB is Ser/Thr kinase phosphorylated by 3-phosphoinositide-
dependent kinase-1 (PDK1) and by DNA-dependent protein kinase (Feng et al., 
2004). Overexpression of a dominant-negative form of PKB impairs insulin-
mediated phosphorylation of 4E-BP1 (Gingras et al., 1998). This finding suggests 
that PKB is an upstream regulator of mTOR. PKB plays a role in directing GLUT4 
vesicles to the plasma membrane and thus promotes glucose transport in muscle 
(Hill et al., 1999). The physiological significance of this process is a net 10- to 40-
fold increase in glucose flux into the cells. Constitutively active PKB in quiescent 
3T3-L1 adipocytes promotes high levels of lipogenesis (Kohn et al., 1996). 
Overexpression of active PKBα in cells of transgenic mice leads to a significant 
expansion of β-cell mass, owing to an increase in both cell size and number 
indicating the importance of PKBα  in pancreatic cell growth (Tuttle et al., 2001).  
 
TSC1/TSC2 
Understanding how growth factors and PKB regulate mTOR activity was 
achieved by the discovery that the TSC1 and TSC2 proteins are upstream 
regulators of mTOR. TSC1 (also known as hamartin) and TSC2 (also known as 
tuberin) are encoded by the tuberous sclerosis complex 1 (TSC1) and tuberous 
sclerosis complex 2 (TSC2) genes, respectively, which are associated with the 
dominant genetic disorder, tuberous sclerosis complex (TSC), characterized by 
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hamartomas with large cells in many organs (Cheadle et al., 2000). The similarity 
between the phenotypes caused by TSC1/TSC2 and dPTEN deficiencies in 
Drosophila prompted genetic epistasis experiments, which showed that TSC1 
and TSC2 function between PKB and S6K in the insulin-signaling pathway 
(Potter et al., 2001). These observations and the fact that S6K1 is highly 
phosphorylated in mammalian cells lacking functional TSC1 or TSC2 provide 
potential links between PKB and TSC1/TSC2 and between mTOR and 
TSC1/TSC2 (Jaeschke et al., 2002). These links were established by the finding 
that TSC2 is directly phosphorylated by PKB in vitro and in vivo (Inoki et al., 
2002).  Further analyses of TSC2-deficient cells, as well as TSC1 and TSC2 
overexpression experiments, demonstrate that the TSC1/TSC2 heterodimer is an 
upstream negative regulator of mTOR (Inoki et al., 2002; Jaeschke et al., 2002).  
Overexpression of both TSC1 and TSC2 in HEK-293 cells impairs insulin-
stimulated phosphorylation of S6K1 and 4E-BP1. In summary, these 
observations provide strong evidence that PKB activates mTOR, at least in part, 
through the phosphorylation and inactivation of TSC2. An intriguing phenomenon 
of a negative regulatory loop was observed in TSC2- or TSC1-deficient cells, in 
which PKB activity mediated by insulin and other growth factors is significantly 
diminished (Jaeschke et al., 2002). This negative regulatory loop may serve to 
coordinate mTOR and PKB functions.  
 
Rheb 
Rheb was first identified in a differential screen of mRNAs induced in 
neurons by agents that provoke seizures. It is ubiquitously expressed, but is 
particularly abundant in muscle and brain (Yamagata et al., 1994). Recent 
genetic studies in Drosophila place Rheb in the insulin-signaling pathway, 
downstream of TSC1/2 and upstream of mTOR/S6K1 (Saucedo et al., 2003; 
Stocker et al., 2003; Zhang et al., 2003). Most significantly, it was recently 
demonstrated that Rheb is a physiological substrate of TSC2 GAP activity 
(Garami et al., 2003; Zhang et al., 2003).  TSC2 is the functional component of 
the TSC1/2 complex that inhibits Rheb and mTOR signaling, whereas the 
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physiological function of TSC1 is to stabilize TSC2 (Inoki et al., 2003; Li et al., 
2004; Manning and Cantley, 2003). Biochemical data has shown that Rheb 
stimulates phosphorylation of S6K1 and 4E-BP1 dramatically (Garami et al., 
2003). According to recent data, Rheb could activate mTOR via two proposed 
mechanisms. First, Rheb may be a direct component of the mTOR signaling 
complex, regulating either mTOR itself or its binding protein. Second, mTOR 
signaling has been shown to play a part in sensing intracellular amino acid levels 
(Rohde et al., 2001). Current data supports the model whereby TSC1/2 
antagonizes the mTOR/S6K1/4E-BP1 signaling pathway via stimulation of GTP 
hydrolysis of Rheb (Inoki et al., 2003). In addition, TSC1/2 and Rheb have pivotal 
roles in mediating growth factor, nutrient and energy-sensing signals to mTOR-
dependent targets.  
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 4. Pancreatic β-cell growth 
  
Previously, mice deficient for S6 Kinase 1  (S6K1) were shown to be 
hypoinsulinemic, and exhibited reduced β cell size suggesting β-cell growth can 
be regulated by S6K1 (Pende et al., 2000). Traditionally, genetic factors and 
nutritional alterations during fetal and postnatal periods have been implicated in 
β-cell dysfunction and impaired β-cell growth in adult, (Blondeau et al., 2002). We 
questioned whether diminished β-cell size in adult S6K1-/- mice arose from an 
altered nutritional environment during development in vivo or stem from impaired 
β-cell development due to absence of the S6K1 gene.  
As fetal and neonatal life are known to be crucial periods for pancreatic β-
cell growth and development, exhibiting the most active β-cell replication and 
neogenesis, the baseline for β-cell mass occurs is in early life (Rahier et al., 
1981), (Bonner-Weir, 2000), (Nielsen et al., 1999), (Finegood et al., 1995), 
(Kaung, 1994),  we next questioned whether diminished β-cell size in adult S6K1-
/- mice originates from impaired body growth during embryonic development. In 
addition, given that defects in placental development or dietary protein restriction 
during gestation lead to fetal growth retardation (Rossant and Cross, 2001), 
(Parimi et al., 2004), we also questioned whether growth retardation and 
developmental delay arise from low levels of nutrient availability due to impaired 
placenta development. A brief overview of placenta development and functions 
which regulate fetal growth and pancreatic β-cell growth are given below.  
 
4.1. What controls nutrient transport required for body growth 
during development in mammals?  
 
-Placental development.  
 The placenta is unique organ exclusive to mammals. It develops from a 
fertilized egg and is, therefore, an organ of the embryo (Rossant and Cross, 
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2001). During gestation, development and growth of the fetus depends on the 
placenta for exchange of gases, nutrients and waste products between mother 
and fetus (Rossant and Cross, 2001). The placenta also produces pregnancy-
associated hormones and growth factors for the fetus. Any genetic or 
environmental alterations which affects placental development or function may 
result in placental insufficiency and consequent impairment of fetal development 
and intra-uterine growth retardation (Tam and Rossant, 2003).  
Placental development is initiated from E3.5 and proceeds until E12.5. 
Functional establishment of the placenta improves the developmental conditions 
and growth of the fetus. Fetal mass accumulates at an increasing rate from 
E12.5 to E16.5 and the placenta undergoes remodeling and growth together with 
the fetus (Rossant and Cross, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
                           Adapted from (Rossant and Cross, 2001) 
Fig. 14. Placental development in the mouse.   
Early development of the mouse embryo from embryonic day (E) 3.5–E12.5, showing the origins 
of the extra-embryonic lineages and the components of the placenta. ICM, inner cell mass. 
 
In early embryo development, there are two populations of cells in early 
blastocysts, the inner cell mass (ICM) and the trophoblasts, a monolayer of 
epithelium.  The inner cell mass will contribute mainly to the embryo proper, while 
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the trophoblast develops into a great part of the placenta (Rossant and Cross, 
2001).  In late blastocysts, a third population of cells appears called the primitive 
endoderm, and the trophoblast differentiates into the polar trophoectoderm and 
mural trophoectoderm (Fig. 14) (Rossant and Cross, 2001). In development, the 
mural trophoectoderm forms the primary trophoblast giant cells from implantation 
and the polar trophoectoderm or the ectoplacental cone, a primitive placenta  
(Fig. 14). Later in gastrulation, some mesoderm cells give rise to the allantois 
and part of the chorion. Meanwhile in the ectoplacental cone, the secondary 
trophoblast giant cells develop and the choriononic ectoderm is also formed 
(Rossant and Cross, 2001) . Thus, the chorion has two different origins, namely 
the mesoderm of the epiblast and the ectoderm of the ectoplacental cone. By 
E8.5, the allantois makes contact with the chorion, an event termed 
chorioallantoic fusion. After several hours of allantoic attachment, folds appear in 
the chorion where a fetal vascular network will be constructed (Rossant and 
Cross, 2001) (Tam and Rossant, 2003). The trophoblast, together with its 
associated fetal blood vessels, subsequently undergoes extensive villous 
branching and remodeling to generate a densely packed structure, the labyrinth 
(Tam and Rossant, 2003) (Rossant and Cross, 2001). At the same time, 
chorionic trophoblast cells begin to differentiate into the various layers of the 
trophoblast in the labyrinth.  
 
Which components make up the Placenta?  
The mature placenta consists of three main layers: maternal decidua 
basalis (db), junction zone (jz) and labyrinth zone (lb).  Below is a schematic 
representation of a sagittal section of an E15.5 placenta with the maternal side at 
the top and fetal side at the bottom (Fig. 15) (Georgiades et al., 2001). The 
placenta is linked to the maternal uterine wall by deciduas basalis. The labyrinth 
is a vascular network in which the fetal vessel capillaries are immersed in the 
maternal blood space (mbs) for nutrient, gas, and waste product exchange. 
Some of the spongiotrophoblast (st) between the decidua basalis and the 
labyrinth synthesize glycogen (gc). The trophoblast giant cells (tg) line up 
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between the spongiotrophoblast and the decidua basalis (Georgiades et al., 
2001). 
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e major regions and cell types of the mouse placenta at E15.5. (a) 
presentation of a sagittal section of the mouse placenta. The placenta is oriented with 
side at the top and the fetal (flat) side at the bottom. The plane of sectioning is 
enter of the placenta and perpendicular to its flat surface. All sections shown in this 
ectioned in this way. The major placental zones (db, decidua basalis; jz, junctional 
rinth zone) are shown; their constituent cell types are depicted by different colors. 
y, placental abnormalities often underlie embryonic lethality or growth 
 accompanied by impaired β-cell cell growth. This is caused by the 
utation of genes and can arise from defects in embryonic trophoblast 
mpartments of the placenta.  
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 Pancreatic β-cell growth and development are exclusively sensitive to the 
level of nutrients provided by the placenta. Why then is pancreatic β-cell 
size diminished in S6K1 deficient mice?  To know the reason, A brief 
overview of regulation of pancreatic β-cell mass is given below.  
 
4.2. How is pancreatic β-cell mass regulated?  
 
 β-Cell mass is dynamically regulated. 
β-cell mass is the major factor in determining the amounts of insulin that can be 
secreted to maintain nutrient homeostasis (Bonner-Weir, 1994). Major 
contributing factors that regulate β-cell mass is β-cell replication, size of β-cells, 
incidence of β-cell neogenesis, and rate of β-cell apoptosis (Dor et al., 2004) 
(Bonner-Weir, 2000). 
 
Phase of pancreatic β-cell growth. 
Just after birth, there is a burst of islet cell replication, and then later, during 
weaning, there is a transient neogenesis that supplements the increased β-cell 
replication.  Postweaning, as the young animal grows up, the rates of β-cell 
replication, neogenesis, and apoptosis all markedly trail off. In adult life, there 
remains a very slow turnover of β-cells with the estimated life span of  β-cell 
being 60 days (Bonner-Weir, 2000). About 0.5% of the adult β-cell population is 
undergoing replication, which is balanced by 0.5% of β-cells entering into 
apoptosis (Bonner-Weir, 2000). Thus, the most active period of β-cell replication 
and neogenesis that occurs in early life will dictate the baseline for β-cell mass 
for the rest of the mammalian organism's life, which could have consequences 
for the susceptibility to acquiring type 2 diabetes. In humans, a low birth weight 
has been associated with an increased susceptibility for the onset of type 2 
diabetes later on in life (Hales and Barker, 2001).  It is possible that, by being 
born small, there is a correlatively undersized β-cell population (Hales and Barker, 
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2001). The neonatal β-cell replication and β-cell neogenesis rates appear to be 
constant, so that the final β-cell population in the adult that develops from a small 
neonate will remain relatively low irrespective of how large the adult grows. 
Therefore, a small β-cell mass in adulthood has less capacity to expand in 
response to increased insulin demand and/or metabolic homeostasis, which, in 
turn, contributes to an increased risk of acquiring type 2 diabetes. Thus, 
maintaining β-cell mass is a crucial factor for maintaining nutrient homeostasis 
and preventing type 2 diabetes.  
 
4.3. What kind of factors modulates β-cell growth? 
 
Nutrients and growth factors 
Certain nutrients and various growth factors stimulate mitogenesis of 
existing β-cells, and influence the proliferation and differentiation of pancreatic 
precursor cells into insulin-expressing cells. As a general trend, nutrients that 
stimulate insulin secretion and synthesis also increase β-cell mass (Bonner-Weir 
et al., 1989). Glucose is the most physiologically relevant and has been shown to 
increase rodent β-cell proliferation in vitro and in vivo in a manner that is 
dependent on glucose metabolism (Bonner-Weir et al., 1989; Schuppin et al., 
1993). The effect of nutrients on β-cell growth has focused primarily on existing 
adult β-cells, but it is unknown whether nutrients have a direct effect on inducing 
β-cell neogenesis. 
In addition to glucose, feeding normal rats with high fat diet for six weeks 
results in a modest increase in body weight and insulin resistance, but islet 
density and β-cell size significantly increases by 30-40%, suggesting the 
flexibility of β-cell growth to adapt to changes in nutritional status (Fig. 16) 
(Buettner et al., 2000). β-cell mass is enhanced 50% in glucose infused rats 
through inducing hyperplasia and hypertrophy (Bonner-Weir et al., 1989). In 
addition, nutrients, especially amino acids signaling in β-cells are known to 
promote insulin production, suggesting the importance of nutrients in β-cell 
 48
function and mass (McDaniel et al., 2002).  Consistent with this model, loss of 
S6K1, a downstream effector of the mTOR-signaling pathway which integrate 
nutrient and mitogen signaling results in reduced pancreatic β-cell size leading to 
hypoinsulinemia (Pende et al., 2000).  High fat diet-induced β-cell hypertrophy is 
shown in Fig. 16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                     Adapted from (Lingohr et al., 2002a) 
 
Fig. 16. Increased pancreatic β-cell area in normal rats fed a high-fat diet (HF; 42% 
calories from fat) for six weeks compared with rats fed standard chow (SC; 4% 
calories from fat). 
 (a) Serial sections of pancreata were fixed and stained with hematoxylin and eosin (H and E), or 
immunohistochemically for insulin to detect pancreatic β-cells, or for glucagon and somatostatin 
to give an indication of non β-cells in the islet. (b) There was a significant increase (p ≤ 0.05) in 
β-cell mass in rats fed a high-fat diet compared with controls fed standard chow. This is, 
presumably, a response to an increase in insulin demand caused by peripheral insulin resistance in 
these animals (Buettner et al., 2000) .  
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 Can genetic factors modulate β-cell growth? 
 
IRS 
IRS-1 knockout mice have peripheral insulin resistance and glucose intolerance, 
but this is compensated for by a marked increase in β-cell mass ensuring the 
animals do not develop diabetes (Fig. 17)  (Tamemoto et al., 1994). By contrast, 
IRS-2 knockout mice, which also have insulin resistance, do not have the ability 
to compensate by increasing β-cell mass and these animals are diabetic (Withers 
et al., 1998). Indeed, β-cell mass in IRS-2 null mice is markedly reduced, and 
even more so when crossed with mice deficient in one allele for the IGF-1R (Fig. 
17) (Withers et al., 1999). These IRS-2 knockout mice studies are 
complementary to observations that higher IRS-2, but not IRS-1, expression 
levels increase mitogenesis in rodent β-cell lines (Lingohr et al., 2002b). Thus, 
IRS-2 appears key in maintaining optimal β-cell mass to compensate for 
peripheral insulin resistance.  
 
PKB 
Overexpression of constitutively active PKBα in pancreatic β-cells of mice 
produces a significant increase in both β-cell size (Fig. 18) and total islet mass 
leading to improved glucose tolerance and resistance to streptozotocin-induced 
diabetes without increase of β-cell mitogenesis (Bernal-Mizrachi et al., 2001), 
(Tuttle et al., 2001).  However,  PKBα deficient mice display growth retardation 
but normal glucose homeostasis (Cho et al., 2001b). PKBβ deficient mice display 
insulin resistance accompanied by hyperinsulinemia and dramatic increase in the 
size and number of pancreatic islets although no report on individual β-cell size 
and number (Cho et al., 2001a). 
 
S6K1 
S6K1 deficient mice are hypoinsulinemic and mildly glucose intolerant due to 
reduction in β-cell mass and selective decrease in β-cell size (Fig. 19) (Pende et 
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al., 2000). Since S6K1 deficient mice are growth retarded (Shima et al., 1998), a 
similar  phenotype to that of  nutrient deprivation,  further experiments would 
have to be performed to address if reduction of β-cell mass is likely to be a cell 
autonomous effect  due to loss of S6K1 signaling or  secondary consequences 
from developmental  delay (see results). 
 
 
 a.   IRS2-/-                   b.  wild type        c. IRS1-/-
 
 
 
 
 
  
 
 
 
Adapted from (Withers et al., 1998) 
Fig. 17. Islet morphology and β-cell mass in IRS2-/- , IRS1-/-  and wild-type mice. 
 
 
 
 
 
 
 
 
 
 
      Adapted from (Tuttle et al., 2001) 
              wild type          β-cell expressing myr- PKBα 
 
 
Fig. 18. Fluorescent staining of GLUT2, glucose transporter.  Constitutive active 
PKBα expression augments β-cell size.  
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                                                   Adapted from (Pende et al., 2000) 
a. wild type 
b. S6K1-/-
 
Fig. 19. Haematoxyline and eosine stain (left) and immunostain for insulin- and 
glucagon-containing cells (right) in pancreas sections from wild type and S6K1-/-
mice.   
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How can we distinguish between effects of nutrients provided by the 
placenta versus genetic defects on reduced β-cell size in S6K1 deficient 
mice? 
 
-Distinguishing between primary (due to a genetic defect) versus 
secondary defects (due to a placental defect).  
Given pancreatic β-cell development is exclusively sensitive to the level of 
nutrients provided by the placenta (Godfrey, 2002) and general fetal 
development, the dimished β-cell size phenotype (Pende et al., 2000) in  S6K1 
deficient mice may be a culmination of the loss of  S6K1 gene function in the 
primary target cells, pancreatic β-cells (the primary effect), or additional effects 
that are elicited in other tissues such as the placenta (the secondary effect) 
which regulates nutrient transport required for  pancreatic β-cell growth.  
Since the main vascularization structure of the placenta originates from 
the trophoblast of  embryo  (Georgiades et al., 2001), S6K1 deficient embryos 
develop with S6K1 deficient  placenta. Under these circumstances, it is difficult to 
dissect S6K1 deficient β-cell phenotype solely because β-cell development and 
growth are controlled by S6K1 deficient placenta.  However, if we were able to 
provide a wild type placenta to the S6K1 deficient embryo using tetraploid 
aggregation techniques (Tam and Rossant, 2003),  we would be able to 
distinguish between primary (due to a genetic defect) versus secondary defects 
(due to a placental defect).  
Using ES cell tetraploid embryo chimeras, we could produce mouse 
fetuses by aggregating homozygous S6K1-/- embryonic stem (ES) cells with wild-
type tetraploid embryos (Fig. 20). (Rossant and Cross, 2001; Rossant and 
Spence, 1998; Tam and Rossant, 2003). In the resulting chimeras, the embryos 
are ES cell derived. The wild type tetraploid cells contribute exclusively to the 
trophoblast cells of the placenta and endoderm of the yolk sac, but owing to 
increased ploidity, they are rigorously excluded from the embryo proper. Diploid 
ES cells cannot make trophoblast tissues in vivo but make up the entire embryo 
proper (Fig. 20).  (Tam and Rossant, 2003). If chimeras produced by the 
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aggregation of S6K1-/-  ES cells with tetraploid wild type embryos are not growth 
retarded and have normal β-cell growth and development, it will indicate that 
these features of S6K1-/- phenotype are caused secondarily by extra-embryonic 
dysfunction, most likely of the placenta (Fig. 20). However, if S6K1-/-  ES cell 
derive fetus which are still small and have impaired pancreatic β-cell growth and 
development, it will imply that this phenotype occurs as a result of the loss of 
S6K1 in embryonic tissues, an effect that is unrelated to placental deficiency. 
Chimera analysis should thus be a useful tool to dissect cell autonomous versus 
non-cell autonomous roles of S6K1 in fetal growth and pancreatic β-cell 
development. The principle of tetraploid aggregation is shown in (Fig. 20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Adapted from (Rossant and Spence, 1998) 
 
Fig. 20. Tissue contribution in chimeras.  
The primitive endoderm gives rise to the entire endoderm layer of the yolk sac and the 
trophectoderm to the trophoblast layers of the placenta, while the epiblast gives rise to the entire 
 54
embryo as well as some extraembryonic cells. Orange-white combinations are embryo-embryo 
combinations; green-white combinations are ES cell-embryo combinations. Solid colours, non-
mosaic contribution; stripes, mosaic contribution. Tetraploid embryos are generated by 
electrofusion of the blastomeres of a two-cell embryo. 
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II MATERIALS AND METHODS 
 
Part 2: Absence of S6K1 protects against age- and diet-induced obesity 
while enhancing insulin sensitivity. 
 
Mice 
S6K1-/- mice were generated by homologous recombination and genotyped as 
previously described (Shima et al., 1998). S6K1-/-  and WT mice were on a hybrid 
background derived from the C57Bl/6 and 129Ola mouse strains. Animals were 
maintained on a 12-h light/dark cycle and six month old male mice were used for 
experiments. 
 
Diet studies and metabolic measurements 
At 10 weeks age male mice were placed on either a NCD (Diet #3807, KLIBA-
NAFAG, Switzerland) or HFD ad libitum (Diet D12492; Researchdiets, New 
Brunswick, NJ USA) and were followed for a period of 24 weeks. Body weight was 
recorded weekly and food intake was measured every second day for 15 
consecutive days. Insulin tolerance tests were performed by intraperitoneal injection 
of insulin (0.75 U/kg body weight) after a 3 h fast. Blood was collected before 
injection and 15, 30, 60 and 90 min after injection. Oxygen consumption and RER 
were measured every 15 min for 8 h by an indirect calorimetric method, employing 
an Oxymax (Columbus Instruments, Columbus, OH)(Picard et al., 2002). 
 
Metabolite assays 
Blood was collected from retroorbital sinus after an overnight fast or 1 hr after the 
beginning of the meal followed by an overnight fast. The amount of non-esterified 
fatty acids, ketone bodies and triglycerides were measured by enzymatic assays 
(Boehringer-Mannheim, Germany)(Picard et al., 2002). Plasma leptin and total 
triiodothyronine and thyroxine serum levels were measured using either the Rat 
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leptin kit (Linco Research, St Louis, MO.) or the radioimmunoassay kit (Immunotech 
SA, Marseille, France), respectively (Picard et al., 2002).  
 
Histology and morphometric analysis of tissues 
Adipose tissue was removed from each animal, fixed in 10% formaldehyde/PBS for 
24h, dehydrated and embedded in paraffin. 6µm sections were cut and stained with 
haematoxylin and eosin. Images were captured and morphometric analysis was 
performed with ImageJ software (NIH). Epididymal WAT from 500 or more cells from 
three different animals per genotype was analyzed. Adipose and plantaris muscle 
tissue were prepared as described for scanning and transmission electron 
microscopy (Picard et al., 2002). 
 
Magnetic resonance imaging analysis 
MRI experiments were carried out on a Biospec 47/30 spectrometer (Bruker Medical, 
Fällanden CH) at 4.7 T equipped with a self-shielded 12 cm bore gradient system, 
capable of switching 200 mT/m in 170 µs (Doty et al., 1999).  During experiments 
animals were anaesthetized with 1.5% Isoflurane (Abbott, Cham Switzerland) in a 
1:2 mixture of O2/N2O administered with a facemask. Adipose tissue was measured 
with an optimized turbo-RARE2 imaging sequence for body fat visualization 48. 
Acquisition parameters were: Repetition delay TR = 250 ms, echo delay TE = 8.6 ms, 
RARE factor = 32 (effective echo time 73.1 ms), number of averages NA = 8, slice 
orientation transverse, image matrix = 128x128 pixel, field-of-view FOV = 3.5x3.5 cm, 
slice thickness = 1.2 mm (contiguous). 50 to 64 transverse slices have been 
recorded. The volumes of fat pads were assessed with an in-house developed 
software algorithm based on IDL software package (Research Systems Inc., 
Boulder/CO U.S.A.). The images were filtered using a Gaussian-type filter and then 
classified in 16 classes followed by quantization, classes 7 to 16 being allocated to 
adipose tissue. Fat depot volumes were calculated based on the segmented area in 
each slice and the distance between slices. Body fat indices were calculated by 
dividing adipose tissue weight (i.e. adipose tissue volume multiplied with the specific 
weight of fatty tissue of 0.8 g/ml) by body weight.  
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 Lipolysis in isolated adipocytes 
Primary adipocytes were prepared from epididymal fat pads by collagenase 
digestion as described previously (Marette et al., 1991). Cells were incubated for 30 
min at 37°C with or without norepinephrine (Sigma-Aldrich SARL, St-Quentin 
Fallavier, France) at the indicated concentrations. 
 
Real-Time quantitative RT-PCR 
Total RNA was extracted from frozen tissue samples or cells using the RNeasy 
kit (Qiagen, Courtaboeuf, France). cDNA was synthesized from total RNA with 
the SuperScript First-Strand Synthesis System (Invitrogen) and random hexamer 
primers. The real-time PCR measurement of individual cDNAs was performed 
using SYBR green dye to measure duplex DNA formation with the Roche 
Lightcycler system and normalized to the expression of either β actin or 18S 
ribosomal rRNA.  The primers and probes used in the real time RT-PCR were the 
following: UCP1 sense, 5'-GGCCCTTGTAAACAACAAAATAC-3', and antisense, 
5'-GGCAACAAGAGCTGACAGTAAAT-3'; UCP3 sense, 5'-ACTCCAGCGTCGCC 
ATCAGGATTCT-3', and antisense, 5'-TAAACAGGTGAGACTCCA GCAACTT-3'; 
mCPT1 sense, 5'-TTGCCCTACAGCTCTGGCATTTCC-3', and antisense, 5'-
GCA CCCAGATGATTGGGATACTGT-3'; mPPAR δ sense, 5'-
CTCTTCATCGCGGCCA TCATTCT-3', and antisense, 5'-TCTGCCATCTTCTGC 
AGCAGCTT-3'; PGC-1 sense 5'-AAGTGTGGAACTCTCTGGAACTG-3', and 
antisense 5'-GGGTTATCT TGGTTGGCTTTATG-3'. 
  
Measurement of insulin receptor phosphorylation in vivo.  
After a 6 hour fast, mice were anesthetized and 0.75Ukg-1 insulin (Eli Lilly) or an 
equal volume of vehicle was administered by i.v. injection. Liver, adipose 
(Epididymal fat pads) and muscle (Gastrocnemius) were collected in liquid nitrogen 
5 minutes after injection. Insulin receptor tyrosine phosphorylation was measured in 
liver. Protein extracts (1mg) from tissue samples were prepared for 
immunoprecipitation and analyzed as described (Hirosumi et al., 2002). Antibodies 
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were purchased from Santa Cruz (anti-insulin receptor β, and anti-S6K1), Upstate 
Biotechnology (anti-phosphotyrosine) and Cell Signaling (anti-PKB, anti-IRS-1, anti-
phospho PKB-Ser473, anti-phospho IRS1-Ser 636/639, anti-phospho S6K-Thr 389, 
anti-phospho S6 240/244). Antibodies to S6 were provided by J. Mestan (Novartis 
Pharma AG, Basel, Switzerland). 
 
RNA interference 
Double stranded RNA duplexes corresponding to mouse and human S6K1 (5'- 
AAGGGGGCTATGGAAAGGTTT-3') were purified, annealed, and transfected into 
HeLa cells using oligofectamine (Invitrogen). The effect of RNAi on S6K1 expression 
and on insulin dependent PKB phosphorylation was measured after 72 hours. 
Following overnight serum deprivation, cells were either lysed directly or stimulated 
with 200 nM insulin for 30 minutes. Cell lysates were incubated for 4h with anti IRS1 
or anti insulin receptor β antibody pre-absorbed on protein A sepharose beads at 
4°C and washed.  Equal amounts of cleared lysates were analyzed by Western blot 
analyses with the indicated antibodies. All RNAi experiments were performed on at 
least three independent times with comparable results.   
 
Statistical Analysis 
Data are presented as mean ± s.e.m. The main and interactive effects were 
analyzed by ANOVA factorial or repeated measurements (growth curve and insulin 
tolerance tests) or one-way ANOVA followed by Bonferroni t-test (MRI analysis). 
Differences between individual group means were analyzed by the Fisher's PLSD 
test or Student's t test. Analyses were performed using Statview Software 
(Brainpower, Calabasas, CA). Differences were considered to be statistically 
significant at P<0.05. 
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Part 3: Regulation of pancreatic β-cell growth by S6K1 during development 
 
Mice 
Wild type (S6K1+/+) and S6K1-/- mice were generated by homologous recombination 
and genotyped as previously described (Pende et al., 2000).  Animals were 
maintained on a 12-h light/dark cycle. Embryos and placentas used in this study 
were derived from homozygous crosses or intercrosses between S6K1+/- mice. The 
genotypes of dissected embryos and placentas were determined by Southern blot 
analysis or PCR using DNA isolated from the yolk sac or placenta. The PCR primers 
corresponded to the S6K1 (S6K1 forward, 5'-GTAGGGCACTTAAATGACCAC-3'; 
S6K1 reverse, 5'-TGTCCCTATT AATGCTCAAGG-3') and the neo gene (neo 
reverse, 5'-GCCTTCTTGACGA GTTC TTCTGAG-3'). 
 
Histological analysis 
 
Embryos and placentas were freshly collected and fixed in 10% formalin overnight at 
4°C. Fixed samples were embedded in paraffin and 5µm-sections were cut and 
mounted on slides such that series of six slides with comparable sections were 
created. For general morphological analysis, one slide from each series was stained 
with haematoxylin and eosin. For immunofluorescence, sections of embryonic 
pancreas were stained with rabbit anti-glucagon (Zymed, 1:50), guinea pig anti-
insulin (Linco, 1:400), and rabbit anti-Glut2 (provided by B. Thorens, 1:200). 
Detection was performed using Alexa Fluor 488 and 594 (Molecular Probes). 
Morphometrical analysis and cell counting was done on pancreases from three 
individuals for each genotype using ImagePro Plus software (Media Cybernetics). α- 
and β-cell counting was performed on pancreas sections representing 1/6 of the 
organ. To calculate the mean size of the individual α and β cells, the cell area was 
divided by the number of cell nuclei in the covered area positive for either insulin or 
glucagon as previously described (Shima et al., 1998). Immunohistochemistry and in 
situ hybridization on placenta sections was performed using sections from the 
middle of each placenta from three embryos for each genotype. For anti-PECAM-1 
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staining, the sections were incubated with 0.1% Trypsin for 12 min at 37°C after 
rehydration, followed by 20 min incubation with 2N HCl. They were then incubated 
overnight at 4°C with rat monoclonal anti-PECAM-1 (Pharmingen, 1:50). Biotinylated 
horse anti-rat (Vector Lab) was used as a secondary antibody, followed by 
incubation with the ABC-reagent (Vector Lab), detection with DAB (Vector Lab), and 
nuclear counterstaining with haematoxylin. 
 
In situ hybridization analysis  
 
Dr. Janet Rossant provided the plasmid pKS 4311. The 4311 (Tpbp) gene is used as 
a molecular marker specific for spongiotrophoblast cells. Sections were rehydrated 
and tissue was permeabilized using 20µg/ml proteinase K in 10mM Tris pH8/20mM 
EDTA for 15 min at room temperature, refixed in 4% paraformaldehyde/0.2% 
glutaraldehyde, and dehydrated in a graded series of methanol. Antisense and 
sense riboprobes were generated by in vitro transcription using the DIG RNA 
Labeling Kit (Roche Diagnostics) (Wilkinson and Nieto, 1993). The DIG-labeled 
probe was denatured at 70°C for 7 min and used in hybridization buffer. 50µl 
hybridization solution were applied per section, and incubated in a hybridization 
oven at 60°C. The next day, slides were washed twice for 30 min in 25% 
formamide/2x SSC at 60°C, 30 min in 2x SSC at 60°C, 30 min in 0.2% SSC at 60°C, 
and 3x 10 min in PBS/0.1% Triton X-100 at room temperature. Blocking sections 
were incubated with 10% sheep serum in PBS/0.1% Triton X-100 for 30 min. 
Incubation with AP-conjugated anti-DIG antibody (Roche) occurred at 1:2000 in 
blocking buffer overnight at 4°C. Sections were washed and followed by a 10 min 
wash in NTMT buffer (100mM TrisHCl pH9.5, 50mM MgCl2, 100mM NaCl, 0.1% 
Triton X-100). NBT (nitroblue tetrazolium chloride) and BCIP (5-bromo-4-chloro-3-
indoyl-phosphate, 4-toluidine salt) (both from Roche) were used as a substrate.  
 
Measurement of insulin content in embryonic pancreas 
Isolated embryonic pancreases were placed into phosphate-buffered saline (PBS) 
and then sonicated three times for 10s. The insulin concentration was measured 
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using ELISA (Crystal Chem Inc., Illinois, USA) or radioimmunoassay (Linco, St. 
Louis, USA). 
   
Embryo growth analysis 
For the staging of embryos, we considered noon of the day of the vaginal plug 
appearance as E0.5. For developmental analysis of growth, embryos and placentas 
were dissected, patted dry with absorbent paper, and wet weights were determined 
using a microbalance.  
 
Preimplanation development in vitro  
Following superovulation and mating, E1.5 embryos or E3.5 embryos were collected 
and individually cultured as described. Each embryo was subsequently transferred 
to a drop of M16 medium overlaid with mineral oil and incubated at 37°C. The 
morphology of the embryos was recorded (Nagy, 2002) .  
 
Skeletal staining 
Embryos were eviscerated, skinned, fixed in ethanol and then stained with Alcian 
Blue 8GS (cartilaginous elements) and Alizarin Red S (mineralized elements) for 
3-5 days, as adapted from McLeod (McLeod, 1980). The tissues were cleared 
with 1% KOH and the skeletons stored in glycerol.  
 
Scanning electron microscopic analysis 
Embryos were fixed in 1.25% glutaraldehyde, 1% paraformaldehyde in 0.08M 
cacodylate buffer containing 0.02% CaCl2 for 1h at room temperature, and overnight 
at 4°C. They were postfixed in 1% OsO4 in water, washed, and dehydrated by 
alcohol.  Scanning electron microscopic analysis was performed as described 
(Picard et al., 2002). 
 
Establishment of embryonic stem (ES) cells  
Embryos were flushed at the morula stage and incubated overnight in M16 
medium. The next day, the blastocysts were transferred to 6cm dishes with 
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500,000 inactivated mouse fibroblasts and 500,000 inactivated 5637 cells (ATCC 
HTB9) known to facilitate ES cell development. A few days later, the ICM were 
picked with a glass pipette, treated with trypsin for 10 min at room temperature, 
and further propagated on inactivated fibroblasts. The medium was always KO-
DMEM supplemented with 15% FBS, pen/strep, glutamin, β-mercaptoethanol, 
gentamycin, and LIF (Nagy, 2002). 
 
Aggregation of tetraploid wild type embryos with diploid  S6K1-/- ES cells 
Wild type embryos derived from S6K1+/+ mice were recovered at the 2-cell stage 
(E1.5). The two blastomeres were fused by elecrofusion (Nagy, 2002), and the 
resulting tetraploid embryos (Nagy et al., 1993) cultured for 48 hours at 37°C, 5% 
CO2, and 100% humidity in M16 medium (Nagy, 2002). Following culture, the zona 
pellucida was removed from the 4-cell stage tetraploid embryos by Tyrod's Acid 
treatment (Nagy, 2002). Micro-drops of M16 media were placed in plastic tissue 
culture dishes, and covered with light mineral oil (Merck). Depression wells were 
created within the micro-drops using a blunt darning needle. Two tetraploid embryos 
were placed in each well. Three independent S6K1-/- ES cell clones were prepared 
by 5 min trypsin (Life Technologies) treatment to create a single cell suspension. 
Residual fibroblast feeder cells were removed by 15 min pre-plating at 37°C, and 
careful removal of the ES cell-containing suspension from the fibroblasts adhering to 
the culture dish. The ES cell suspension was allowed to re-aggregate into small 
clumps by incubation for approximately 1 hour at room temperature. One small 
clump of approximately 1-15 ES cells was placed in each well containing two 
tetraploid embryos. The aggregates were incubated overnight at 37°C, 5% CO2, and 
100% humidity. The following day, blastocyst stage embryos could be harvested 
from the wells, and were implanted into the uterus of E2.5 pseudopregnant recipient 
CD1 outbred female mice.  
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Generation of transgenic mice expressing S6K1 in pancreatic β-cells  
The transgene consisted of a 720-bp fragment of the rat insulin II promoter (rip) 
driving transcription of myc-S6K1. Injection of DNA containing rip-S6K1 into fertilized 
eggs was performed by the FMI transgenic and chimeric mouse facility. Founders 
were identified using PCR analysis, and germ line transmission was confirmed by 
Southern blotting.  Genotyping was executed by PCR using primers derived from rip 
and an internal S6K1 sequence.  To obtain mice with a homozygous knockout for 
S6K1 that were rip-S6K1 transgene positive (S6K1-/-ripS6K1), S6K1+/-ripS6K1 and 
S6K1+/-  were crossed.  S6K1+/- were maintained on a pure C57BL/6 background.  
 
Assessment of transgene expression 
Genotypes of embryos, placentas, and mice were determined by Southern blot 
analysis or PCR. Isolated islets were obtained by collagenase P digestion as 
previously described.  For western blot analysis, blots of islet lysates were 
probed with antibodies against S6K1 (Santa Cruz Biotechnology, Santa Cruz, 
California, USA) and myc (Upstate Biotechnology). The nested PCR primers 
corresponding to rip were foward 5'-CAGGCCACCCAGGAGCCCC-3', reverse 1: 
5'-GCATGATGTTCTCCGGCTTCAGG-3', reverse 2: 5'-GTAAATGCC 
CCAAAGCCATGGAG-3' 
 
Statistical analysis 
Data are presented as mean ± s.e.m. The main and interactive effects were 
analyzed using factorial, repeated measures, or one-way ANOVA. Differences 
between individual group means were analyzed using the Fisher's PLSD test or 
Student's t test. Analyses were performed using Statview Software (Brainpower, 
Calabasas, California, USA). Differences were considered to be statistically 
significant at P<0.05. 
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III. RESULTS 
 
Part 1: …………………………………………………………………………………. 
 
S6K1 (-/-)/S6K2 (-/-) mice exhibit perinatal lethality and rapamycin-sensitive 
5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-
activated protein kinase-dependent S6 kinase pathway. 
 
Pende M, Um SH, Mieulet V, Sticker M, Goss VL, Mestan J, Mueller M, Fumagalli S, Kozma 
SC, Thomas G. 
Mol Cell Biol. 2004, 24(8):3112-24 
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Activation of 40S ribosomal protein S6 kinases (S6Ks) is mediated by anabolic signals triggered by hor-
mones, growth factors, and nutrients. Stimulation by any of these agents is inhibited by the bacterial macrolide
rapamycin, which binds to and inactivates the mammalian target of rapamycin, an S6K kinase. In mammals,
two genes encoding homologous S6Ks, S6K1 and S6K2, have been identified. Here we show that mice deficient
for S6K1 or S6K2 are born at the expected Mendelian ratio. Compared to wild-type mice, S6K1/ mice are
significantly smaller, whereas S6K2/ mice tend to be slightly larger. However, mice lacking both genes
showed a sharp reduction in viability due to perinatal lethality. Analysis of S6 phosphorylation in the
cytoplasm and nucleoli of cells derived from the distinct S6K genotypes suggests that both kinases are required
for full S6 phosphorylation but that S6K2 may be more prevalent in contributing to this response. Despite the
impairment of S6 phosphorylation in cells from S6K1//S6K2/ mice, cell cycle progression and the trans-
lation of 5-terminal oligopyrimidine mRNAs were still modulated by mitogens in a rapamycin-dependent
manner. Thus, the absence of S6K1 and S6K2 profoundly impairs animal viability but does not seem to affect
the proliferative responses of these cell types. Unexpectedly, in S6K1//S6K2/ cells, S6 phosphorylation
persisted at serines 235 and 236, the first two sites phosphorylated in response to mitogens. In these cells, as
well as in rapamycin-treated wild-type, S6K1/, and S6K2/ cells, this step was catalyzed by a mitogen-
activated protein kinase (MAPK)-dependent kinase, most likely p90rsk. These data reveal a redundancy
between the S6K and the MAPK pathways in mediating early S6 phosphorylation in response to mitogens.
Recent studies showed that the 40S ribosomal protein S6
kinase (S6K) p70S6K/p85S6K, termed S6K1 (51), is a major
effector of cell growth. This conclusion stems from gene dele-
tion studies with Drosophila (39) and with mice (51) as well as
recent studies with cell cultures (11). The loss of the Drosophila
S6K (dS6K) gene is semilethal, with the few surviving adults
having a severely reduced body size. The larvae of such flies
exhibit a long developmental delay, consistent with a twofold
increase in cell cycle doubling times. The few surviving adults
are quite lethargic, living no longer than 2 weeks, and females
are sterile. Surprisingly, the reduction in mass is strictly due to
a decrease in cell size rather than to a decrease in cell number
(39).
In mice, removal of this kinase is not lethal, but the mice are
approximately 20% smaller at birth (51). Such mice exhibit
normal fasting glucose levels but are mildly glucose intolerant
due to markedly reduced levels of circulating insulin (42).
Reduced insulin levels are caused by a reduction in pancreatic
endocrine mass and an impairment of insulin secretion, which
can be traced to a selective reduction in -cell size. Unexpect-
edly, the effects on body mass and hypoinsulinemia do not
appear to be attributable to a reduction in S6 phosphorylation,
as this response proved to be largely intact in S6K1-deficient
animals (51). However, S6 phosphorylation in such animals
was still sensitive to the bacterial macrolide rapamycin (51),
which inhibits the mammalian target of rapamycin (mTOR) (1,
7, 16, 48), the upstream S6K1 kinase (4, 8, 18), suggesting the
existence of a second S6K. Subsequent searches of expressed
sequence tag databases and biochemical studies led to the
identification of S6K2, which exhibited overall homology of
over 80% with S6K1 in the highly conserved kinase and linker
domains (17, 47, 51). In all tissues examined from S6K1-defi-
cient mice, S6K2 transcripts were upregulated (51). From this
observation, it was reasoned that S6K1 and S6K2 functions
were redundant and that a deletion of the S6K1 gene led to a
compensatory increase in the expression of S6K2.
In parallel studies, it was demonstrated that rapamycin sup-
pressed the serum-induced translational upregulation of a fam-
ily of mRNAs which contain a polypyrimidine tract at their 5
end (5-terminal oligopyrimidine [5TOP] mRNAs) (20, 55).
These mRNAs largely code for components of the transla-
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tional apparatus, most notably, ribosomal proteins (37). Ear-
lier studies had shown that the translation of such transcripts is
under selective translational control (22) and requires an intact
5TOP tract (19, 49). In addition, a dominant interfering allele
of S6K1 inhibited the mitogen-induced translational upregula-
tion of 5TOP mRNAs to the same extent as rapamycin,
whereas an activated allele of S6K1, which exhibits a substan-
tial degree of rapamycin resistance, largely protected these
transcripts from the inhibitory effects of rapamycin (19, 49).
Seemingly consistent with these arguments, in embryonic
stem (ES) cells from which S6K1 had been homologously de-
leted by selection with high doses of G418, serum no longer
had an effect on the upregulation of 5TOP mRNAs, nor was
there a redistribution of 5TOP mRNAs from polysomes to
nonpolysomes in the presence of rapamycin (24). However, S6
phosphorylation was initially reported to be abolished in these
cells (24), despite the fact that it was largely intact in cells and
tissues derived from S6K1/ mice (51). This difference
seemed to be resolved in subsequent studies, where S6 phos-
phorylation was detected in these same S6K1/ ES cells and
S6K2 was present and active (31, 60). Despite these observa-
tions, it was again recently reported that S6 phosphorylation
was absent from these same cells (53). Furthermore, it was also
claimed in the latter study that S6K activation, S6 phosphory-
lation, and rapamycin had little impact on 5TOP mRNA
translation in PC12 cells (53), although others working with
these same cells had reported earlier that rapamycin treatment
abolished the selective recruitment of these transcripts from
small to large polysomes (44).
Obviously, cells lacking both S6K1 and S6K2 would facilitate
such studies. Therefore, we set out to delete the S6K2 gene
from mice and to determine whether we could generate
S6K1//S6K2/ mice. Here we report on the deletion of the
S6K2 gene and the effects of deleting both S6K1 and S6K2 on
animal growth and viability as well as on S6 phosphorylation,
cell proliferation, and 5TOP mRNA translation.
MATERIALS AND METHODS
Generation of an S6K2-targeted allele. A P1 129/Ola mouse ES cell library
(Genome Systems Inc., St. Louis, Mo.) was screened by PCR with the following
S6K2-specific primers: 5-CCTTTGAGGGGTTCCGG and 5-TTCTCACAGC
TGCCCTCTCTTCCTCTATTCTCCTAACG. A positive clone containing a
genomic DNA fragment larger than 70 kb encompassed all of the S6K2 coding
exons. The 1.3-kb EcoRI-PstI fragment of the S6K2 gene was ligated to the
ClaI-NotI sites of a targeting vector containing a neomycin resistance gene and
a thymidine kinase gene for negative selection and positive selection, respectively
(2). The 5.5-kb SmaI fragment of the S6K2 gene was ligated to the HpaI site of
the targeting vector (Fig. 1A). The S6K2 targeting vector was linearized at the
ClaI site and electroporated into E14 129/Ola ES cells as described previously
(51). Homologous recombination events were identified by Southern blot anal-
ysis of ES cell DNA after digestion with BamHI and hybridization with the probe
corresponding to the 1-kb BamHI-SpeI fragment of the S6K2 gene (Fig. 1A).
Three clones were found to be positive for the homologous recombination event.
Hybridization with a probe for the neomycin resistance gene revealed a single
integration site.
Animals and cell cultures. S6K2-targeted ES cells from clone 36 were aggre-
gated with morula-stage embryos as described previously (51). Chimeric mice
were crossed with C57BL/6 mice, and germ line transmission was assessed by
Southern blot analysis. S6K2/ mice were crossed with S6K1/ mice (51) to
generate mice carrying the combined deletions. Wild-type and mutant mice
initially were kept in a hybrid C56BL/6-129/Ola background and subsequently
were backcrossed in a pure C57BL/6 background for 10 generations. Animals
were maintained on a 12-h light-dark cycle and were allowed free access to food.
Mouse embryonic fibroblasts (MEFs) were prepared from embryos at embryonic
day 13.5 and analyzed for cell proliferation and mRNA translation as previously
described (51).
Primary hepatocytes from 12- to 14-week-old male mice were isolated by liver
perfusion by the method of Seglen (50) as modified by Klaunig et al. (25). After
cannulation in the subhepatic vena cava, the liver was perfused at a flow rate of
10 ml/min with calcium-free HEPES buffer (0.33 mM, pH 7.6) for 3 min and then
with HEPES buffer containing 7 g of collagenase (Liberase; Roche)/ml and 5
mM calcium chloride for 5 min. The solutions were allowed to run through a cut
made in the portal vein. After enzymatic digestion, cells were collected in L-15
medium (Invitrogen Corporation) supplemented with 1 mg of bovine serum
albumin (BSA)/ml, filtered, and centrifuged for 2 min at 100  g. Viable hepa-
tocytes were purified by centrifugation on a 45% Percoll gradient for 10 min at
100  g. The pellet was collected and washed twice in L-15 medium containing
1 mg of BSA/ml. Hepatocytes were plated at 12  104 cells/cm2 in Primaria
dishes (Falcon) or on coverslips coated with collagen I (Sigma) in M-199 medium
(Invitrogen) supplemented with 10% fetal calf serum (FCS), 1 mg of BSA/ml,
and 100 nM dexamethasone in a 37°C incubator with a 5% CO2 atmosphere.
After 3 h of adhesion, cells were incubated in serum-free M-199 medium con-
taining 1 mg of BSA/ml. On the next day, hepatocytes were treated as indicated
above. All of the media contained penicillin (100 U/ml), streptomycin (100
g/ml), and amphotericin B (Fungizone) (250 ng/ml).
Antibody production. S6K2 cDNA sequences coding for amino acids 1 to 43 or
440 to 484 were cloned into vector pMAL (New England Biolabs) to bacterially
express N-terminal or C-terminal S6K2 peptides fused to maltose binding pro-
tein. Fusion proteins were purified according to the manufacturer’s protocol.
Monoclonal antibodies (MAbs) were generated by immunization of BALB/c
mice with the following protocol. Two mice were immunized by intrasplenic
injection (52) of 13.5 g of purified antigen, 10 g of adjuvant peptide (N-
acetylmuramyl-L-alanyl-D-isoglutamine; Sigma A5919), and 10 mg of liposomes,
with encapsulated muramyl tripeptide phosphatidylethanolamine as an addi-
tional adjuvant (mixed in phosphate-buffered saline [PBS]; total volume, 70 l).
Booster injections with mixtures of 15 g of antigen, 10 g of adjuvant peptide,
550 U of interleukin 2, and 560 U of gamma interferon with 10 mg of liposomes
in PBS were administered at days 17 (subcutaneously [s.c.]), 33 (s.c. and intrperi-
toneally [i.p.]), 49 (s.c.), and 67 (s.c. and i.p.).
Serum samples were taken on days 40 and 73 and tested for the presence of
specific antibodies by using an enzyme-linked immunosorbent assay with full-
length S6K2 protein fused to glutathione S-transferase (GST) (N terminus free
and C terminus free, respectively). A final booster injection (same composition)
was administered i.p. at day 86, followed by fusion of the spleen cells (30) at day
89. The fusion partner cell line was mouse myeloma line SP2/0-AG-14. After
hypoxanthine-aminopterin-thymidine selection, hybridomas were grown in
HB101 hybridoma medium containing 10% CLEX serum supplement, and hy-
bridoma supernatants were screened for the presence of antibodies to the GST-
S6K2 fusion protein. Positive hybridoma cells were subcloned, and clones pro-
ducing specific MAbs were selected (enzyme-linked immunosorbent assay,
Western blotting, and immunocytochemical analysis). MAbs to the S6K2 N
terminus (140.9.11 and 140.8.1) and to the S6K2 C terminus (141.8.5 and
141.5.23) were identified, and milligram amounts were produced by using a
Miniperm culture system (Heraeus). Clones were screened for binding to the
full-length S6K2 protein fused to GST.
2D PAGE, immunoprecipitation, immunoblotting, kinase assays, and nuclear
fractionation. Total 80S ribosomal proteins were isolated from either MEFs or
mouse liver, and the level of in vivo S6 phosphorylation was examined by
two-dimensional (2D) polyacrylamide gel electrophoresis (PAGE) as previously
described (36, 41). For the preparation of total protein extracts, MEFs and
hepatocytes were washed twice with cold PBS, scraped from the culture dish into
egg lysis buffer, and homogenized with 10 strokes in a Teflon-glass homogenizer.
To remove cell debris, homogenates were spun at 8,000  g for 10 min. For the
preparation of nuclear and cytosolic extracts, cells were scraped into hypotonic
buffer (10 mM morpholinepropanesulfonic acid [MOPS] [pH 7.4], 10 mM KCl,
2 mM MgCl2, 0.1 mM EDTA, 5 mM dithiothreitol [DTT]), homogenized with 10
strokes in a glass-glass homogenizer, and spun at 8,000  g for 3 min. The
supernatants represented the cytosolic extracts. To purify nuclear proteins, pel-
lets were resuspended in buffer I (0.32 mM sucrose, 3 mM CaCl2, 2 mM Mg
acetate, 0.1 mM EDTA, 0.1% Triton X-100, 1 mM DTT, 10 mM Tris [pH 8]),
layered onto a sucrose cushion (2 M sucrose, 5 mM Mg acetate, 0.1 mM EDTA,
1 mM DTT, 10 mM Tris [pH 8]), and spun at 30,000  g for 45 min. Protein
concentrations were measured by using a Bio-Rad D/C protein assay.
For immunoblot analysis, protein extracts were resolved by sodium dodecyl
sulfate-PAGE before transfer to Immobilon membranes and incubation with the
following primary antibodies: mouse anti-N-terminal or anti-C-terminal S6K2,
rabbit anti-ribosomal protein L7a (62), rabbit anti-phosphorylated ribosomal
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protein S6 (Ser235 and Ser236 [Ser235/236] and Ser240 and Ser244 [Ser240/
244]), and anti-phosphorylated ERK1/ERK2 (Cell Signaling Technology). The
specificity of the anti-phoshorylated S6 antibodies was demonstrated by compe-
tition with differentially phosphorylated S6 peptides (V. L. Goss and R. Polak-
iewicz, unpublished data). For immunoprecipitation, 300 g of protein extract
was incubated with 4 g of MAb precoupled to protein G-Sepharose beads. S6K
activity was measured by using an immune complex assay with 40S ribosomal
subunits as a substrate as previously described (45).
Immunofluorescence analysis. Primary hepatocytes were plated at 12  104
cells/cm2 on coverslips coated with collagen I and incubated overnight in M-199
medium containing 1 mg of BSA/ml. Hepatocytes were stimulated with 1 M
insulin, 25 ng of epidermal growth factor (EGF)/ml, and 10% FCS for 1 h in the
presence or absence of 20 nM rapamycin. Cells were washed twice with Tris-
buffered saline (TBS) (50 mM Tris [pH 7.4], 150 mM NaCl), fixed with 4%
paraformaldehyde for 10 min at room temperature, and washed once again with
TBS. Cells were permeabilized with methanol for 5 min at 20°C and washed
three times for 5 min each time with TBS. Incubation in fresh 0.1% sodium
borohydride in TBS for 5 min quenched the activity of the cells. Cells were rinsed
once in TBS, blocked for 1 h at room temperature with PBS containing 10% goat
serum, 1% BSA, and 0.02% sodium azide, and washed for 5 min with TBS. Prior
to use, anti-phosphorylated ribosomal protein S6 (Ser235/236) primary antibod-
ies or anti-60S ribosomal protein L7a primary antibodies were centrifuged at
13,000  g for 5 min at 4°C, diluted 1:200 in TBS containing 0.1% BSA, and
applied to the cells during overnight incubation at 4°C. After three washes for 5
min each time with TBS, the cells were incubated with a secondary fluorescent
antibody (anti-rabbit Alexa 488; Molecular Probes) diluted 1:200 in TBS con-
taining 0.1% BSA for 45 min at room temperature. After the cells were washed
three times for 5 min each time with TBS in the dark, coverslips were mounted
with a ProLong antifade kit (Molecular Probes) and observed under a confocal
microscope.
Histological analysis. Newborn mice were left for several minutes on ice
before being anaesthetized and sacrificed. Tissues were fixed by injecting at
several points under the skin 10% formalin in 0.1 M phosphate buffer (pH 7.4)
(Baker) and incubating overnight at 4°C. Bodies were cut into three parts: the
head, the thorax, and the abdomen. Samples were embedded in paraffin, and five
consecutive transverse sections 5 m thick were obtained at different levels (100
m apart) of each mouse pup with a Leica RM2135 microtome. Sections were
mounted, and one out of five consecutive slides was stained with hematoxylin and
eosin for histological examination.
RESULTS
Deletion of the S6K2 gene in mice. The coding sequence of
the murine S6K2 gene spans a 7-kb region of genomic DNA
containing 15 exons (Fig. 1A). The overall structure of the
S6K2 gene was similar to that of the homologous S6K1 gene, as
FIG. 1. Generation of an S6K2-null allele. (A) Murine S6K2 gene map and targeting vector. Rectangles represent the coding exons of the S6K2
gene as well as the neomycin resistance (Neo) and thymidine kinase (TK) genes. The exons containing the T loop and APE sequences and the
initiation and stop codons are indicated. The four exons deleted following the homologous recombination event are shown in grey. Restriction sites:
B, BamHI; Sp, SpeI; E, EcoRI; P, PstI; Sm, SmaI. (B) Genotypes of littermates from S6K2/ crosses. Tail DNA was digested with BamHI,
analyzed by Southern blotting, and hybridized with the probe depicted in panel A. The corresponding BamHI fragments of genomic DNA are 9.8
kb in the wild-type allele and 8.2 kb in the targeted allele. (C and D) Loss of S6K2 protein and kinase activity in S6K2 homozygous mutant cells.
(C) Western blot (WB) analysis of fibroblast cell extracts from wild-type or S6K2/ embryos with a MAb against the N-terminal (N-term) region
of S6K2. The apparent molecular mass of S6K2 is 68 kDa. (D) MEFs from wild-type or S6K2/ embryos were starved overnight and either
stimulated with 10% FCS for 30 min or left untreated. Equal amounts of protein extracts were immunoprecipitated (IP) with the anti-S6K2
antibody, and S6K activity was measured with an immune complex assay (see Materials and Methods).
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most of the intron-exon boundaries were conserved between
the two genes (data not shown). To generate a targeted dele-
tion of the S6K2 gene by homologous recombination in ES
cells (6), we used a vector in which a neomycin resistance
cassette replaced four exons of the catalytic domain, including
the activation loop and the conserved APE motif (Fig. 1A).
Heterozygous mice carrying the targeted allele were identified
by Southern blot analysis and mated to obtain homozygous
mutant offspring (Fig. 1B). The resulting S6K2/ homozygous
mice were viable and showed no obvious phenotypic abnor-
malities. That the S6K2 gene had been correctly targeted was
demonstrated by the absence of S6K2 protein on Western blots
of extracts from S6K2/ MEFs compared to MEFs from
wild-type mice with monoclonal antibodies directed against
either the N terminus or the C terminus of the protein (Fig. 1C
and data not shown). Moreover, with either of the two anti-
bodies, S6K2 activity was undetectable by immunoprecipita-
tion in extracts derived from either quiescent or serum-stimu-
lated MEFs of S6K2/ mice compared to those of wild-type
mice (Fig. 1D and data not shown). These results indicated
that the gene had been correctly deleted without causing any
obvious phenotype.
Phenotypes of S6K1//S6K2/ mice. As the S6K1 and
S6K2 genes share a high degree of homology and as S6K2
mRNA is upregulated in S6K1/ mice (51), the two genes
might compensate functionally for one another in vivo. To fully
evaluate the impact of the S6K pathway on mouse develop-
ment, we set out to generate mice lacking both protein kinases.
We intercrossed mice null for the S6K1 and S6K2 genes to
obtain mice with combined heterozygous mutations in both
alleles. The S6K1//S6K2/ mice were bred, and the geno-
types of the progeny were identified by Southern blot analysis.
As shown in Table 1, all possible genotypic combinations
were represented, although S6K1//S6K2/ and S6K1//
S6K2/ mice were born at lower frequencies than expected,
65 and 30%, respectively (Table 1). Indeed, only 10 S6K1//
S6K2/ mice were viable from among 526 offspring. However,
analysis of embryos at 18.5 days of gestation indicated a normal
Mendelian distribution of genotypes (data not shown). These
data suggested that the reduced viability of S6K1//S6K2/
and S6K1//S6K2/ mice was due to wastage between de-
livery and the time of weaning. Close observation of the litters
revealed that approximately one-third of the S6K1//
S6K2/ mice were born dead. The corpses were found in a
fetal position, still lying in the yolk sac and attached to the
placenta (Fig. 2A). Among the S6K1//S6K2/ mice that
were born alive and emerged from the yolk sac, the majority
developed signs of cyanosis, and approximately half of them
died shortly after birth. The mice surviving the first day after
delivery usually reached adulthood and were fertile. However,
the litters from the viable S6K1//S6K2/ parents were
small and showed a high incidence of perinatal lethality (data
not shown). Caesarean delivery appeared to rescue neonatal
viability, although the S6K1//S6K2/ mice were more likely
to develop transient signs of hypoxia, as indicated by a bluish
discoloration of the skin (Fig. 2B).
To analyze the rates of growth of S6K1/, S6K2/, and
S6K1//S6K2/ mice during development, mice homozy-
gous for each genotype were inbred, and the weights of their
offspring were compared to those of wild-type mice during
embryonic development and early postnatal life (Fig. 2C and
D). As previously reported, at birth, S6K1/ mice were about
15% smaller than wild-type mice (51). This growth defect was
more evident in embryos at midgestation, when the difference
in body weight was approximately 30% at embryonic day 12.5
(Fig. 2C). During postnatal growth, the S6K1/ mice failed to
attain the same body size as wild-type mice and remained
about 20% smaller at 2 months of age (Fig. 2D). Conversely,
the S6K2/ mice tended to be larger at later stages of em-
bryonic development and during the postnatal period; how-
ever, their weights did not differ significantly from those of
wild-type mice throughout the entire period of observation
(Fig. 2C and D). Moreover, the growth defect of the S6K1/
mice was not reduced further in an S6K2/ background, as
S6K1/ mice and the surviving S6K1//S6K2/ mice had
similar growth rates (Fig. 2C and D). Growth rates and new-
born viability were initially assessed with mice in a hybrid
C57BL/6-129Ola genetic background and were confirmed fol-
lowing backcrossing for 10 generations in a C57BL/6 genetic
background (data not shown). Thus, the impairment of body
growth appears to be caused selectively by deletion of the S6K1
gene, whereas perinatal lethality is revealed only when the
S6K1 and S6K2 gene products are both absent.
To assess the possible causes of reduced viability of the
S6K1//S6K2/ mice, histopathological analyses of mice
born dead, viable mice with signs of cyanosis, and viable mice
with no signs of cyanosis were compared to those of wild-type
mice at postnatal day 0. Such analyses failed to reveal any gross
anatomical defects in S6K1//S6K2/ neonates. Moreover,
in all viable neonates, the lungs were inflated and properly
developed. However, in the nonviable neonates and in the
cyanotic neonates, the internal organs were hyperemic and the
heart chambers tended to be more dilated. In addition, the
nonviable neonates showed several hemorrhagic sites, as re-
vealed by diapedesis of red blood cells throughout the entire
myocardium (Fig. 2E).
S6 phosphorylation in S6K-deficient mice. Upon growth
factor stimulation, ribosomal protein S6 is multiply phosphor-
ylated at the carboxy terminus on five serine residues in an
ordered fashion beginning with Ser236, followed sequentially
by Ser235, Ser240, Ser244, and Ser247 (27, 36). This response
is readily measured by the decreased electrophoretic mobility
of S6 following the separation of its differentially phosphory-
lated derivatives by 2D PAGE. To determine whether the
deletion of the S6K2 gene affected the mitogen-induced phos-
TABLE 1. Genotype analysis of littermates from crosses of S6K1/
and S6K2/ mice at postnatal day 21
Genotype
% of mice
Expected Obtained
S6K1//S6K2/ 6.25 10.0
S6K1//S6K2/ 12.5 18.1
S6K1//S6K2/ 12.5 12.4
S6K1//S6K2/ 25 24.7
S6K1//S6K2/ 6.25 6.4
S6K1//S6K2/ 6.25 5.9
S6K1//S6K2/ 12.5 12.6
S6K1//S6K2/ 12.5 8.1
S6K1//S6K2/ 6.25 1.9
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FIG. 2. Phenotypes of S6K1//S6K2/ mice. (A) Littermates from an S6K1//S6K2/ cross a few minutes after natural delivery. The
genotypes of the mice are indicated. The S6K1//S6K2/ mouse was born dead and left in the yolk sac. (B) Littermates from an S6K1//
S6K2/ cross at embryonic day 19.5 a few minutes after caesarean delivery. The genotypes of the mice are indicated. S6K1//S6K2/ mice were
more prone to develop transient signs of cyanosis. (C and D) Fetal (C) and postnatal (D) growth curves for mice from homozygous crosses. Values
for mice with the same genotype did not differ from those for mice derived from heterozygous crosses. Data represent the average and standard
deviation for at least 10 mice per genotype. wt, wild type. (E) Heart histologic findings for wild-type and S6K1//S6K2/ mice a few minutes after
delivery. The S6K1//S6K2/ mouse was born dead. Note hemorrhages in the myocardium.
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phorylation of ribosomal protein S6, total ribosomal proteins
from serum-stimulated MEFs were analyzed by 2D PAGE. As
shown in Fig. 3A, in serum-stimulated wild-type MEFs, the
majority of S6 migrated in highly phosphorylated derivatives d
and e, corresponding to proteins phosphorylated on four and
five serine residues, respectively (36, 41). Under similar exper-
imental conditions, Shima et al. previously demonstrated that
the extent of S6 phosphorylation in S6K1/ cells was largely
comparable to that in wild-type MEFs (51). In S6K2/ MEFs,
S6 was still highly phosphorylated in response to serum, al-
though to a lesser extent than in wild-type and S6K1/ MEFs;
a considerable amount of S6 was present in phosphorylated
derivatives a, b, and c, representing phosphorylation on one,
two, and three serine residues, respectively (Fig. 3A). Pretreat-
ment with rapamycin drastically decreased S6 phosphorylation
in all three genotypes, resulting in the presence of the unphos-
phorylated, monophosphorylated, or biphosphorylated forms
of S6 (Fig. 3A) (51). These data suggest that in S6K2/ cells,
S6 phosphorylation was catalyzed by a second rapamycin-sen-
sitive kinase, most likely S6K1, although somewhat less effi-
ciently. To test this hypothesis, we assessed S6 phosphorylation
in MEFs from S6K1//S6K2/ mice. As shown in Fig. 3B,
the combined deletion of the S6K1 and S6K2 genes severely
suppressed S6 phosphorylation compared to that in wild-type
cells. Moreover, rapamycin treatment attenuated S6 phosphor-
ylation in wild-type MEFs, bringing it to the same level as that
in serum-stimulated S6K1//S6K2/ MEFs, where rapamy-
cin had no effect on S6 phosphorylation (Fig. 3B). S6 phos-
phorylation was also attenuated in the liver of S6K1//
S6K2/ mice following refeeding of starved animals (data not
shown). These data suggested that S6K1 and S6K2 are the sole
kinases responsible for mediating rapamycin-sensitive phos-
phorylation.
Intracellular localization of S6K activity. The majority of S6
is found in the cytoplasm as an integral component of the 40S
ribosomal subunit. However, S6 is also present in nucleoli, the
site of ribosome biogenesis, and in perinucleolar structures
called coiled bodies (or Cajall bodies). Given the large relative
abundance of S6 in the cytoplasm compared to the nucleus, the
quantitation of S6 phosphorylation by 2D PAGE would largely
reflect the status of S6 phosphorylation in the cytoplasm. How-
ever, as the p85S6K isoform of S6K1 is targeted to the nucleus
(46) and S6K2 also contains a nuclear targeting sequence (17,
47, 51), it is possible that one of the two kinases is responsible
for mediating selective phosphorylation of S6 in the nucleolus.
Consistent with this idea, previous studies demonstrated that
S6K1 and S6K2 are differentially targeted within the cell (26,
46, 57). In wild-type hepatocytes, growth factors predominantly
stimulated S6 Ser235/236 phosphorylation in the cytosol and
nucleoli (Fig. 4A). This staining matched the localization of the
ribosomal subunits, as shown by immunostaining with antibod-
ies against 60S ribosomal protein L7a (Fig. 4A) (62). In agree-
ment with the 2D PAGE analysis (Fig. 3A), the deletion of
S6K2 caused a sharper reduction of S6 phosphorylation in the
cytosol than did the deletion of S6K1 (Fig. 4A). Interestingly,
this also appeared to be the case in nucleoli (Fig. 4A). The
overall intensity of S6 phosphorylation was further reduced by
combining the deletion of S6K1 with the deletion of S6K2. In
addition to the immunofluorescence analysis, nuclear fraction-
ation of hepatocytes was performed following growth factor
stimulation (Fig. 4B). The purity of the fractions was assessed
with specific nuclear and cytosolic protein markers, CREB and
-tubulin, respectively (Fig. 4B). Consistent with the results of
the immunofluorescence experiments, the deletion of S6K2
significantly affected S6 phosphorylation in both cell compart-
ments, and the combination of the two gene deletions further
reduced the levels of the phosphorylated protein. Moreover, in
FIG. 3. Regulation of S6 phosphorylation. (A) In S6K2/ cells, S6
phosphorylation was reduced yet regulated by mitogens and inhibited
by rapamycin (Rapa). 2D PAGE was carried out with 80S ribosomal
proteins from wild-type and S6K2/ MEFs. Cells were stimulated
with 10% FCS for 1 h, with or without pretreatment with 20 nM
rapamycin. (B) S6 phosphorylation in S6K1//S6K2/ cells was re-
duced to the same extent as in rapamycin-treated cells. 2D PAGE was
carried out with 80S ribosomal proteins from wild-type and S6K1//
S6K2/ MEFs. Cells were treated as described for panel A. See the
text for an explanation of a to e on the panels.
VOL. 24, 2004 S6K1//S6K2/ MICE 3117
FIG. 4. Intracellular localization of S6K activity. (A) Immunostaining of wild-type, S6K1/, S6K2/, and S6K1//S6K2/ hepatocytes with
anti-phosphorylated S6 (Ser235/236) and anti-L7a antibodies (left panels). The right panels represent phase-contrast images of the same fields.
Cells were growth factor deprived for 1 day and stimulated with 4 nM EGF (25 ng/ml) and 1 M insulin for 1 h (GF), with or without pretreatment
with 20 nM rapamycin (R). Arrowheads indicate nucleoli. (B) Immunoblot analysis of nuclear and cytosolic extracts from wild-type, S6K1/,
S6K2/, and S6K1//S6K2/ hepatocytes with anti-phosphorylated S6 (Ser235/236), anti--tubulin, and anti-CREB antibodies. The latter two
were used as cytosolic and nuclear markers, respectively.
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contrast to the results obtained with the other genotypes, the
residual S6 phosphorylation staining observed with the anti-
phosphorlyated S6 (Ser235/236) antibody in the cytosol and
the nuclei of S6K1//S6K2/ hepatocytes was not inhibited
by rapamycin treatment (Fig. 4A) (also see below).
5TOP mRNA translation and cell cycle progression of
S6K1//S6K2/ cells. It was previously demonstrated that
rapamycin inhibits the selective upregulation of 5TOP
mRNAs following mitogen stimulation (20, 55) and that this
effect requires intact 5TOP (19, 49) and may be mediated by
S6K1 (19, 49). However, recently it was claimed that neither
the S6Ks nor rapamycin appears to be involved in this response
(53). As 5TOP mRNAs code for ribosomal proteins, their
increased expression is essential to sustaining translation dur-
ing the phases of cell growth (56). To examine the roles of
S6K1, S6K2, and rapamycin in this response, we used cells
derived from S6K1//S6K2/ mice. Initially, we examined
the distribution of 5TOP elongation factor 1 (EF1) mRNA
on polysomes in MEFs derived from wild-type and S6K1//
S6K2/ mice. As shown in Fig. 5A, serum induced the re-
cruitment of EF1 mRNA into polysomes in both cell types to
almost the same extent, and this effect was largely abolished by
rapamycin in both S6K1//S6K2/ and wild-type cells. Fur-
thermore, the combined deletion of S6K1 and S6K2 did not
alter the cell doubling times or the saturation densities com-
pared to that of wild-type MEFs (data not shown). Rapamycin
inhibited the S-phase entry of cells from both genotypes with
similar potencies and 50% inhibitory concentrations (Fig. 5B).
The analysis of 5TOP mRNA translation was extended to
ES cells, as Kawasome et al. (24) previously reported that
5TOP mRNAs are constitutively upregulated in S6K1/ ES
cells and resistant to the effects of rapamycin, although these
findings were not consistent with those of a later study with the
same ES cells (53). To examine this possibility, we analyzed the
distribution of EF1 mRNA on polysomes in ES cells derived
from embryos of S6K1//S6K2/, S6K1/, and wild-type
mice. Similar to what was observed for MEFs, the deletion of
S6K1 alone or the deletion of both S6K1 and S6K2 in ES cells
did not alter the upregulation of 5TOP mRNA or sensitivity to
rapamycin (Fig. 5C). Thus, despite a pronounced effect on the
development and growth of the animal, in two distinct cell
types, neither the reduction of S6 phosphorylation nor the loss
of S6K1 and S6K2 function is sufficient to deregulate 5TOP
mRNA translation; these findings suggest that other rapamy-
cin-sensitive events are required.
Evidence for functional redundancy with the mitogen-acti-
vated protein kinase (MAPK) pathway. The findings described
above raised the possibility of either a compensatory or a
redundant S6K pathway. On closer analysis of S6 phosphory-
lation, a small amount of partially phosphorylated S6 was still
detected in MEFs from S6K1//S6K2/ mice as well as in
rapamycin-treated wild-type MEFs, as evidenced by the pres-
ence of derivatives a and b (Fig. 3B). The residual S6 phos-
phorylation in wild-type MEFs could have been due to the
relatively short treatment in the presence of rapamycin, as
longer times were reported for complete S6 dephosphorylation
(20). However, this finding was unexpected for S6K1//
S6K2/ MEFs, as the level of S6 phosphorylation was low in
these cells and was unaffected by rapamycin (Fig. 3B). To
examine this situation further, we monitored S6 phosphoryla-
tion in primary hepatocytes stimulated with EGF and insulin
by using phosphospecific antibodies directed against the first
and second phosphorylation sites, Ser236 and Ser235, or the
third and fourth phosphorylation sites, Ser240 and Ser244.
Following insulin stimulation, phosphorylation at both Ser235/
236 and Ser240/244 increased in wild-type, S6K1/, and
S6K2/ hepatocytes, whereas only Ser235/236 phosphoryla-
tion was detectable in S6K1//S6K2/ hepatocytes (Fig. 6A
and B); these results were consistent with the order and extent
of S6 phosphorylation (Fig. 3B) (3). In wild-type hepatocytes
as well as in S6K1/ and S6K2/ hepatocytes, the increase in
S6 phosphorylation was sensitive to rapamycin (Fig. 6A). How-
ever, in S6K1//S6K2/ hepatocytes, the increase in S6
phosphorylation was resistant to rapamycin (Fig. 6B), suggest-
ing that a rapamycin-resistant S6K was operating in the ab-
sence of S6K1 and S6K2.
It is known that Akt has a substrate recognition motif similar
to that of S6K1 and S6K2 (32) and phosphorylates S6 in vitro
(23). However, the phosphatidylinositide-3OH kinase inhibitor
wortmannin, which blocks Akt activation, had no effect on
insulin-induced S6 phosphorylation in S6K1//S6K2/ hepa-
tocytes, whereas it was as potent as rapamycin in blocking S6
phosphorylation in wild-type hepatocytes (Fig. 6B). As p90rsk
appears to be the rapamycin-resistant kinase responsible for
regulating S6 phosphorylation during progesterone-induced
meiotic maturation of Xenopus oocytes (9, 49), we next tested
the effect of the MEK inhibitor U0126 on S6 phosphorylation
in S6K1//S6K2/ hepatocytes. MEK mediates MAPK ac-
tivation, which in turn phosphorylates and activates p90rsk (13,
54). Such treatment had no measurable effect on S6 phosphor-
ylation in wild-type cells; however, it inhibited Ser235/236 and
MAPK phosphorylation in a dose-dependent manner in
S6K1//S6K2/ cells (Fig. 6C).
The MAPK-dependent phosphorylation of S6 could repre-
sent either the upregulation of a compensatory pathway or the
presence of a pathway that normally operates in wild-type cells
but whose activity is masked by S6Ks. It was difficult to distin-
guish between these possibilities, given the high level of basal
S6 phosphorylation displayed by wild-type hepatocytes. To cir-
cumvent this problem, hepatocytes were deprived of nutrients
as well as serum, a step which resulted in the complete de-
phosphorylation of S6 (Fig. 6D). Under these conditions, rapa-
mycin abolished the insulin-induced increase in Ser240/244
phosphorylation but only attenuated the phosphorylation of
Ser235/236 (Fig. 6D). In contrast, PD184352, an MKK1/
ERK1/ERK2 pathway inhibitor that is more specific than
U0126 (38), had little effect on S6 phosphorylation when used
alone but, when used together with rapamycin, totally abol-
ished the insulin-induced response. In contrast, in S6K1//
S6K2/ hepatocytes, rapamycin had no effect on Ser235/236
phosphorylation, whereas PD184352 abolished this response
(Fig. 6C). Thus, in the absence of S6K1 and S6K2 activity, an
MAPK pathway which cooperates in the regulation of S6 phos-
phorylation was unveiled.
DISCUSSION
Studies with gene deletions or RNA interference can be
instructive in revealing biological functions. For S6Ks, such
studies have been carried out by double-stranded RNA inter-
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ference with Caenorhabditis elegans (33) and by gene deletion
with Drosophila melanogaster (39) and mice (42). In C. elegans,
disruption of the gene encoding the S6K1/S6K2 orthologue,
Cep70, by double-stranded RNA interference led to only mi-
nor growth deficits (33). In contrast, deletion of the Drosophila
gene encoding the S6K1/S6K2 orthologue, the dS6K gene,
resulted in semilethality, with most flies dying during the late
third larval instar or early pupation (39). In addition, the sur-
viving flies were strikingly reduced in size and lived only a few
weeks, and the females were sterile (39). However, S6K1-
deficient mice are viable and fertile, although they are 15 to
20% smaller than wild-type mice at birth and are hypoinsu-
linemic (42, 51). Furthermore, these mice, unlike Drosophila,
have a second S6K, S6K2, which is upregulated in all tissues
examined in S6K1-deficient mice, suggesting a compensatory
response for the loss of S6K1. Consistent with this argument,
FIG. 5. Regulation of 5TOP mRNA translation and cell cycle progression is preserved in S6K1//S6K2/ MEFs. (A and C) 5TOP mRNA
translation is modulated by serum and rapamycin (Rapa), although S6 phosphorylation is resistant to rapamycin treatment. Cytoplasmic extracts
were prepared from wild-type (/), S6K1/, and S6K1//S6K2/ MEFs (A) or ES cells (C) that had been stimulated with 10% serum (FCS)
in the presence (empty circles) or absence (filled circles) of 20 nM rapamycin after serum deprivation for 48 h. Extracts were centrifuged on a
sucrose gradient prior to fractionation as previously described (22). RNA from the different fractions was analyzed by Northern blotting with a
probe specific for EF1 (EF-1a) mRNA. The relative amount of mRNA present in each fraction is expressed as a percentage. Fractions 1 to 7
contain polysomes, whereas fractions 8 to 14 are enriched in monosomes, ribosomal subunits, and mRNPs. nr., number. (B) Inhibitory effect of
rapamycin on the proliferation of S6K-null cells. Wild-type MEFs (filled circles) and S6K1//S6K2/ MEFs (empty circles) were seeded in a
24-well plate at a density of 2  104 cells per well. Cells then were treated with 0.5% serum for 48 h and stimulated for 20 h with 10% serum in
the absence or presence of rapamycin concentrations ranging from 0 to 100 nM. Cells were labeled with [3H]thymidine (1 Ci/ml) throughout the
entire stimulation period Radioactivity incorporated (incorp.) into the DNA was measured, and the average values for triplicate samples were
determined. Data are expressed as the percent inhibition of [3H]thymidine incorporation by rapamycin-treated cells compared to untreated cells.
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we show here that deletion of S6K1 and S6K2 in mice, as for
dS6K in flies, is also semilethal, with pups dying at the time of
delivery or shortly thereafter. A potential difference between
the findings for C. elegans or D. melanogaster and mice is that
small interfering RNAs reduce gene expression, whereas it is
abolished by gene deletion. It should also be noted that the
combined inactivation of two other elements of the phosphati-
dylinositide-3OH kinase pathway, Akt1 and Akt2, also leads to
perinatal lethality of unknown cause (43). The results of mac-
roscopic and histological analyses of newborns lacking S6K1
and S6K2 were compatible with the mutant mice experiencing
a period of hypoxic stress. This finding might have been partly
due to heart failure or a placentation defect, a possibility which
is presently being addressed.
One of the early intracellular responses to growth factor
stimulation in both invertebrates and vertebrates is multiple
phosphorylation of 40S ribosomal protein S6 (14, 58). Al-
though many kinases have been shown to mediate this re-
sponse in vitro, only two have been demonstrated to phosphor-
ylate S6 in the same specific order and extent as those observed
in vivo: S6K1 (10) and p90rsk from Xenopus (61). Although a
role for p90rsk in this response has been controversial, studies
of progesterone-induced meiotic maturation of Xenopus oo-
cytes support such a function (29, 49). That S6K1 is not in-
volved in this response is further supported by the fact that
rapamycin, which selectively inhibits S6K1 but not p90rsk ac-
tivation (28), abolished S6K1 activity, with little effect on pro-
gesterone-induced S6 phosphorylation (49). In contrast to the
findings in progesterone-treated Xenopus oocytes, rapamycin
eliminates serum-induced S6 phosphorylation in mammalian
cells (20), an inhibitory effect that is reversed by the use of an
S6K1 variant that is largely rapamycin resistant (19, 59). In
seeming agreement with the findings in mammalian cells,
S6K1/ ES cells were reported to be devoid of phosphory-
FIG. 6. Evidence for a rapamycin-insensitive S6K. Western blot analysis of protein extracts from wild-type, S6K1/, S6K2/, and S6K1//
S6K2/ hepatocytes was carried out with anti-phosphorylated S6 (Ser235/236 and Ser240/244), anti-phosphorylated ERK1/ERK2, anti-phospho-
rylated S6K (Thr389), anti-phosphorylated Rsk (Thr359 and Ser363), and anti-L7a antibodies, the latter being used as a loading control. Cells were
stimulated with 4 nM EGF (25 ng/ml) and 1 M insulin for 30 min (GF), with or without pretreatment with 20 nM rapamycin (R), 1 M
wortmannin (W), 10 or 30 M U0126 (U0 10 or U0 30, respectively), and 3 M PD184352 (PD). Extracts in panels A and C were derived from
cells deprived of GFs for 1 day, whereas those in panels B and D were derived from cells deprived of GFs for 2 days. In panel D, cells were also
deprived of nutrients (all of the amino acids and glucose) for 3 h.
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lated S6 (24, 53). However, in tissues derived from S6K1/
mice, S6 phosphorylation was shown to be intact but still rapa-
mycin sensitive (51), leading to the discovery of S6K2 (17, 47,
51). Although studies with ES cells have been difficult to ra-
tionalize, some investigators recently demonstrated that
growth factor stimulation of these same cells leads to S6K2
activation and increased S6 phosphorylation in a rapamycin-
sensitive manner (31, 60). These conflicting results may be
attributable to different stimulation conditions or detection
methods.
The studies presented here reveal two novel aspects of S6
phosphorylation in mammalian cells in vivo, i.e., the major role
of S6K2 in this response and the involvement of an MAPK
pathway, whose function is detectable when S6K1 and S6K2
are inactive. S6K2 appears to be the dominant S6K in embryo
fibroblasts as well as in adult hepatocytes and skeletal and
heart muscle, as S6K2/ mice showed a more dramatic re-
duction in the amount of phosphorylated S6 in these tissues
than did S6K1/ mice (Fig. 3 and 6 and data not shown). In
addition, the nucleolar phosphorylation of S6 was greatly af-
fected in S6K2/ hepatocytes (Fig. 4), implying that the nu-
cleus-targeted isoform of S6K1, p85S6K (46), may not effi-
ciently mediate phosphorylation in nucleoli. Ectopically
expressed S6K2 predominantly resides in the nucleus due to a
nuclear localization signal in the C-terminal region of the pro-
tein (26, 57). Upon mitogen stimulation, protein kinase C-
dependent phosphorylation of S6K2 in the C-terminal region
masks the nuclear localization signal, causing the retention of
the kinase in the cytosol (57). Our data are compatible with
this model and suggest the presence of active S6K2 in the
cytosol and nucleoli, where it can phosphorylate S6. However,
S6K1 clearly contributes to the overall amount of S6 phosphor-
ylation, as deletion of both kinases was required to reduce S6
phosphorylation to the same extent as rapamycin (Fig. 3).
Indeed, with our experimental model, we cannot conclusively
determine to what extent each kinase contributes to this re-
sponse under physiological conditions, as it was previously
reported that in S6K1/ mice, S6K2 mRNA transcripts are
upregulated in all tissues examined (51). Such upregulation of
S6K2 could explain its dominance as an S6K and the reliance
of complete S6 phosphorylation on S6K1. That S6K1 and S6K2
are the only genes coding for rapamycin-sensitive S6Ks is con-
sistent with two other S6K genes identified by the human
genome project representing pseudogenes (34). However, the
combined inactivation of S6K1 and S6K2 revealed the presence
of another S6K, most likely p90rsk, which is rapamycin resis-
tant and phosphorylates at least the first two Ser residues of S6
(Fig. 3 and 6). p90rsk appears to be the physiological S6K
during Xenopus (49) and mouse (15) meiotic maturation. The
murine p90rsk family includes several members which are di-
rectly phosphorylated and activated by ERK1 and ERK2 (12).
p90rsk family members have two kinase domains; the N-ter-
minal one shows approximately 60% sequence identity with
S6K1 and S6K2 and has a similar consensus substrate recog-
nition motif (32). The functional redundancy among the S6K
pathways indicates the importance of the phosphorylation of
S6 or another common substrate at one or more steps of
embryonic development.
The functional compensation between S6K1 and S6K2 was
initially proposed based on the upregulation of S6K2 in
S6K1/ mice and could represent a mechanism to ensure the
survival of the animal (51). This suggestion is supported by the
data presented here, showing semilethality in both S6K1//
S6K2/ and S6K1//S6K2/ mice. Interestingly, Wang et
al. (60) showed that S6 phosphorylation was reduced in the
S6K1/ ES cells described above (24) but found no difference
in the level of S6K2 protein. These ES cells were obtained by
selection in vitro with high doses of G418 (24), rather than
from crossing heterozygous founders. Therefore, they may not
have upregulated S6K2 compensatorily, as they have not un-
dergone the stress associated with embryonic development.
Following a similar reasoning, the MAPK-dependent S6K ac-
tivity described here could alleviate the phenotype of the dou-
ble-mutant mice. Surprisingly, the body size phenotype of the
single-mutant mice did not appear to correlate with the extent
of S6 phosphorylation. For S6K1/ mice, body size was clearly
reduced, with little effect on S6 phosphorylation, whereas
S6K2/ mice exhibited normal body size but had reduced
levels of S6 phosphorylation. Similarly, the defect in -cell
growth and insulin levels was associated mainly with the dele-
tion of S6K1, which has a minor effect on S6 phosphorylation
in  cells (data not shown). These data raise the interesting
possibility that S6K1 and S6K2 also exert specific functions
through distinct substrates. Consistent with such a model, the
two kinases have been reported to be differentially localized
and regulated (5, 31, 35). Despite these observations, it should
be noted that recent studies with phosphospecific site muta-
tions in Drosophila S6 suggested that Drosophila S6 is epistatic
to dS6K, the single S6K gene in Drosophila, arguing that it may
be required to elicit the dS6K growth response (T. Radimerski
and G. Thomas, unpublished data).
Initial studies showed that rapamycin selectively inhibited
the translation of 5TOP mRNAs (20, 55), with the extent of
inhibition varying between cell types (21). This finding led to
the conclusion that some cell types use both rapamycin-sensi-
tive and rapamycin-resistant pathways to control this response,
whereas other cell types are largely reliant on the rapamycin-
sensitive pathway (20). Such an explanation is consistent with
the ability of rapamycin to inhibit cell proliferation in certain
cell types, such as endothelial, smooth muscle, and naive T
cells, while having a less dramatic impact on other cell types.
Here we show, as previously demonstrated (51), that the in-
hibitory effect of rapamycin on 5TOP mRNA translation is
complete in MEFs derived from wild-type cells (Fig. 5). Earlier
it was also demonstrated that the effect of rapamycin requires
an intact polypyrimidine tract, that dominant interfering alleles
of S6K1 were as effective in blocking the upregulation of
5TOP mRNAs as rapamycin, and that the inhibitory effects of
rapamycin could be largely prevented by the use of a rapa-
mycin-resistant allele of S6K1 (19, 49). Unexpectedly, we
found here that rapamycin still inhibited the translation of
5TOP mRNAs despite the absence of S6K1 and S6K2 (Fig. 5).
The effect of the dominant-negative S6K1 allele can be ratio-
nalized by its ability to titrate mTOR, potentially through Rap-
tor (40), and block mTOR from phosphorylating other key
downstream targets (19, 59). However, in view of the findings
presented here, it is more difficult to understand the ability of
the rapamycin-resistant allele of S6K1 to protect 5TOP
mRNA translation from the inhibitory effects of rapamycin
(19, 49). One possibility is that S6K1 is not involved in this
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response but that ectopic expression of the rapamycin-resistant
allele can lead to the phosphorylation of a target protein that
is involved in 5TOP mRNA translation and whose phosphor-
ylation is not mediated by endogenous S6K1. It is also possible
that in the absence of S6K1 and S6K2, a rapamycin-sensitive,
compensatory pathway is activated during development.
Stolovich et al. (53) recently reported that S6 phosphorylation,
S6K1, and rapamycin had little impact on 5TOP mRNA trans-
lation. However, they used ES cells in which the S6K pathway
was not completely inhibited, as S6K2 was still expressed (31,
60). To resolve this issue and the discrepancies concerning the
inhibitory effect of rapamycin on 5TOP mRNA translation in
nerve growth factor-treated PC12 cells (42, 51), an understand-
ing of the molecular mechanisms which control 5TOP mRNA
translation is required.
In summary, these studies provide a first comparative anal-
ysis of the distinct phenotypes of S6K1- and S6K2-deficient
mice and should serve as a basis to search for other specific
cellular targets of these enzymes. They also reveal an alterna-
tive mechanism leading to S6 phosphorylation in the absence
of S6K1 and S6K2, i.e, an MAPK pathway; this function should
be taken into account when the impact of this pathway on
growth and development is evaluated.
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Elucidating the signalling mechanisms by which obesity leads to
impaired insulin action is critical in the development of thera-
peutic strategies for the treatment of diabetes1. Recently, mice
deficient for S6 Kinase 1 (S6K1), an effector of the mammalian
target of rapamycin (mTOR) that acts to integrate nutrient and
insulin signals2, were shown to be hypoinsulinaemic, glucose
intolerant and have reduced b-cell mass3. However, S6K1-
deficient mice maintain normal glucose levels during fasting,
suggesting hypersensitivity to insulin3, raising the question of
their metabolic fate as a function of age and diet. Here, we report
that S6K1-deficient mice are protected against obesity owing to
enhanced b-oxidation. However on a high fat diet, levels of
glucose and free fatty acids still rise in S6K1-deficient mice,
resulting in insulin receptor desensitization. Nevertheless,
S6K1-deficient mice remain sensitive to insulin owing to the
apparent loss of a negative feedback loop from S6K1 to insulin
receptor substrate 1 (IRS1), which blunts S307 and S636/S639
phosphorylation; sites involved in insulin resistance4,5. Moreover,
wild-type mice on a high fat diet as well as K/K Ay and ob/ob (also
known as Lep/Lep) mice—two genetic models of obesity—have
markedly elevated S6K1 activity and, unlike S6K1-deficient mice,
increased phosphorylation of IRS1 S307 and S636/S639. Thus
under conditions of nutrient satiation S6K1 negatively regulates
insulin signalling.
As animals reach adulthood their growth rate decreases and fatty
acids are largely converted into triglycerides and stored as an energy
reserve in adipose tissue. To investigate the effect of age on growth, a
matched set of S6K1-deficient (S6K12/2) and wild-type male mice
were placed on a normal chow diet (NCD) (4% total calories
derived from fat, 3,035 kcal kg21) and monitored over a period of
17 weeks from 10 weeks of age. The rate at which S6K12/2 mice
increased body weight on the NCD was significantly reduced
compared with wild-type mice: at 27 weeks of age the difference
in body weight was 25% (Fig. 1a). Dissection of S6K12/2 mice
revealed a marked reduction in epididymal white adipose tissue
(WAT) (Supplementary Fig. 1a). When normalized for body weight,
epididymal, inguinal and retroperitoneal fat pads (Fig. 1b), as well
as the brown fat pad (Supplementary Fig. 1b) were significantly
reduced. Furthermore, the decrease was specific for fat, as the weight
of other major organs such as liver was not affected after correction
for total body weight (Fig. 1b).
Analysis of adipocytes in epididymal fat pads by either scanning
electron microscopy or by haematoxylin and eosin staining showed
a sharp reduction in size, with some adipocytes exhibiting a multi-
locular-like phenotype (Fig. 1c and see below). Morphometric
analysis revealed that S6K12/2 adipocytes were consistently smaller
compared with adipocytes from wild-type mice (Fig. 1c), with an
average 71% decrease in size (Supplementary Fig. 1c). The decrease
in fat accumulation in S6K12/2 mice was not due to less food
intake, which was increased 17% when food consumption was
adjusted for body weight (Fig. 1d). Moreover, on the basis of
normal fasting and feeding glucose levels and no increase in ketone
body formation3 (Table 1), S6K12/2 mice did not seem to be
starving, nor was there an alteration in adaptive thermogenesis
(data not shown). This raised the possibility that triglycerides were
being broken down rather than stored in WAT. Consistent with this,
basal rates of lipolysis were fivefold higher in S6K12/2 versus wild-
type adipocytes, although norepinephrine-induced fatty acid and
glycerol release increased in both genotypes in a dose-dependent
manner to the same final extent (Fig. 1e; see also Supplementary
Fig. 1d). Moreover the metabolic rate was greatly enhanced in
S6K12/2 mice, as indicated by the 27% increase in oxygen con-
sumption versus wild-type mice (Fig. 1f). The respiratory exchange
ratio (RER) of 0.713 ^ 0.004 for wild-type mice and 0.709 ^ 0.003
for S6K12/2mice (P , 0.01) showed that both animals were largely
using fatty acids as an energy source. Thus the failure to accumulate
fat with age in S6K12/2mice seems to stem from a sharp increase in
lipolytic and metabolic rates.
These increased responses, combined with the finding that levels
of circulating triglycerides and free fatty acids (FFAs) were similar in
both genotypes (Table 1), suggested that in S6K12/2 mice tri-
glycerides were being rapidly oxidized in WAT and/or muscle. WAT
is not an energy-consuming tissue; however, electron micrographs
revealed multi-locular adipocytes, with mitochondria of increased
size and number—phenotypes that are absent in wild-type adipo-
cytes (Fig. 2a). Consistent with this, analysis of the messenger RNA
levels of genes involved in energy combustion and oxidative
phosphorylation were found to be strongly increased in S6K12/2
adipocytes compared with wild-type adipocytes, including uncou-
pling protein 1 (UCP1), UCP3, carnitine palmitoyltransferase 1
(CPT1) and PPAR-g co-activator 1-a (PGC1-a) (Fig. 2a; see also
Supplementary Fig. 2a). Mitochondrial content was also affected in
S6K12/2 skeletal muscle (Fig. 2b), consistent with increased
expression of peroxisome proliferator-activated receptor b/d
(PPAR-b/d), PGC1-a, UCP3 and CPT1 (Fig. 2b; see also Sup-
plementary Fig. 2b). As S6K12/2 mice have reduced WAT and
increased oxidative phosphorylation, this raised the possibility that
S6K12/2 mice are protected against diet-induced obesity, which is
linked to the oxidative phosphorylation pathway6–10. Indeed, when
S6K12/2 mice were challenged with a high fat diet (HFD) (60%
total calories derived from fat, 4,057 kcal kg21) weight accumu-
lation was significantly reduced compared with wild-type mice
during the 4-month feeding period (Figs 2c, d). Although food
intake in S6K12/2 mice is similar to that of wild-type mice, when
normalized to body weight they consume 44% more food (Sup-
plementary Fig. 2c). Metabolic rate measured by indirect calori-
metry increased for both genotypes on the HFD, with the effect
more pronounced for S6K12/2 mice (compare Figs 2e and 1f).
Table 1 One-hour post-prandial values after overnight fasting of wild-type and
S6K12/2mice
Wild type S6K12/2
Diet Normal High fat Normal High fat
.............................................................................................................................................................................
Insulin (mg l21) 0.57 ^ 0.09 2.22 ^ 0.87 0.38 ^ 0.08† 0.27 ^ 0.06†
Triglycerides (mmol l21) 0.61 ^ 0.09 1.08 ^ 0.15 0.55 ^ 0.06 0.95 ^ 0.14
FFAs (mmol l21) 0.26 ^ 0.05 0.27 ^ 0.02 0.19 ^ 0.04 0.56 ^ 0.10†
Leptin (ng ml21) 6.11 ^ 0.82 12.6 ^ 0.00 3.22 ^ 0.50 6.34 ^ 2.35†
b-Hydroxybutyrate (mg dl21)* 1.30 ^ 0.05 ND 1.40 ^ 0.16 ND
.............................................................................................................................................................................
Values are for 6-month-old male mice of the indicated genotype fed a normal or high fat diet. Data
represent mean ^ s.e.m. ND, not determined.
*The level of b-hydroxybutyrate was measured in 6-h-fasted mice.
†P , 0.05 compared with wild type (n ¼ 6–18).
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Moreover RER remained unchanged in S6K12/2 mice on a HFD
(0.708 ^ 0.002), whereas in wild-type mice it increased from
0.713 ^ 0.004 to 0.729 ^ 0.002 (n ¼ 6, P , 0.01), indicating an
increase in carbohydrate relative to fatty acid oxidation. To deter-
mine the weight gain corresponding to fat, mice were subjected to
magnetic resonance imaging (MRI) analysis at 2-month intervals
while on the HFD. A transverse section through the abdomen
showed a marked reduction in fat depots, depicted by the less
intense signal (Supplementary Fig. 2d). MRI assessment of total fat,
corrected for body weight, revealed that the body fat index for
S6K12/2 mice increased by 20% over this period, whereas it
doubled for wild-type mice (Fig. 2f). Thus, consistent with the
increase in oxidative phosphorylation, S6K12/2 mice are protected
against diet-induced obesity.
Although S6K12/2 mice have a high metabolic rate when on a
HFD, they exhibit a threefold increase in circulating FFAs (Table 1),
consistent with an increase in fat on their skin and hair (data not
shown). As increased circulating FFAs are implicated in insulin
resistance11–13 and S6K12/2 mice are hypoinsulinaemic3, it seemed
likely that they would become insulin resistant on the HFD. On a
NCD both S6K12/2 and wild-type mice exhibited similar fasting
levels of glucose (Fig. 3a), although S6K12/2 mice were more
insulin sensitive, as indicated by faster glucose clearance in the
insulin tolerance test (Fig. 3a). In contrast, both genotypes dis-
played increased hyperglycaemia on a HFD, although the effect was
more pronounced in wild-type mice (Fig. 3b). However, despite the
increases in glucose and in FFAs, S6K12/2 mice remain as insulin
sensitive on a HFD as on a NCD (Fig. 3b versus a). In the case of
wild-type mice, insulin resistance on a HFD (Fig. 3b) can be
explained by persistently elevated insulin levels (Table 1), inducing
insulin receptor desensitization, as measured by reduced receptor
auto-phosphorylation in response to insulin (Fig. 3c). In S6K12/2
mice insulin levels fail to rise on a HFD (Table 1), consistent with
higher insulin receptor auto-phosphorylation (Fig. 3c). However,
insulin receptors still desensitize in S6K12/2 mice on a HFD
(Fig. 3c), probably due to the large increase in FFA levels
(Table 1). That insulin receptors desensitize in S6K12/2 mice but
remain insulin sensitive suggests that absence of S6K1 facilitates
insulin signalling downstream of the insulin receptor. To test this we
monitored protein kinase B (PKB) phosphorylation, as insulin
sensitivity is tightly linked to the phosphatidylinositol-3-OH kinase
(PI(3)K)–PKB signalling pathway14. As with insulin receptor auto-
phosphorylation in wild-type mice on a HFD, insulin-induced PKB
phosphorylation was suppressed in fat, liver and muscle compared
with wild-type mice maintained on a NCD (Fig. 3d). However, there
was no significant effect on PKB phosphorylation in S6K12/2 mice,
Figure 1 Reduced adiposity in S6K1 2/2 mice. a, Growth curves of wild-type and
S6K1 2/2 mice on a NCD. Wild type, n ¼ 11; S6K1 2/2, n ¼ 13. b, Weights of
epididymal, inguinal and retroperitoneal adipose tissue (EWAT, IWAT and RWAT,
respectively) and liver normalized by body weight (n ¼ 6 each genotype). WT, wild type.
c, Scanning electron microscopic (top) and histological analysis of epididymal WAT
(bottom). Arrowheads indicate multi-locular adipocytes. Magnification for scanning
microscopy and for histology are £ 500 and £ 200, respectively. Mice were 6-month-
old males in b and c. d, Food intake per mouse measured over 15 days (n ¼ 12;
P ¼ 0.8) or normalized by body weight (n ¼ 12). e, Enhanced lipolysis in S6K1 2/2
adipocytes. f, Oxygen consumption (VO2) in wild-type and S6K1
2/2 mice fed a NCD
(n ¼ 6 each genotype). All values are given as mean ^ s.e.m. Asterisk, P , 0.01;
double asterisk, P , 0.001. Filled symbols/columns indicate wild type; open symbols/
columns, S6K1 2/2 mice.
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regardless of diet or tissue (Fig. 3d). This suggested that S6K1
elicited a selective inhibitory effect on PKB activation at a point
downstream of the insulin receptor, consistent with little effect on
mitogen activated protein kinase and S6K1 activation in wild-type
animals on a HFD (see below and data not shown).
Recently, we demonstrated in Drosophila that dS6K negatively
regulates dPKB activity in a cell-autonomous manner15. To test
whether this was the mechanism responsible for the observed
responses, S6K1 levels were reduced with small interfering RNAs.
The results show that lowering S6K1 levels potentiates insulin-
induced PKB phosphorylation, with no effect on insulin receptor
auto-phosphorylation (Fig. 3e), suggesting that the target of inhi-
bition resided downstream of the insulin receptor. Indeed,
reduction of S6K1 levels is paralleled by a decrease in phosphoryl-
ation of S307 and S636/S639 of insulin receptor substrate 1 (IRS1)
(Fig. 3e), sites shown to inhibit PI(3)K binding to IRS1 (ref. 4) and
Figure 2 Increased mitochondria and resistance to diet-induced obesity. a, The left
panels show transmission electron microscopic analysis of epididymal fat. Arrowheads
indicate mitochondria and lipid droplets (L) ( £ 5,000 magnification). The right panels
show UCP1 and mCPT1 mRNA (relative values) measured by quantitative RT–PCR (see
Methods). b, The left panels show transmission electron microscopic analysis of plantaris
muscle ( £ 10,000 magnification). m, mitochondria. The right panels show PPAR-d and
PGC1 mRNA levels (relative values) measured by quantitative RT–PCR. In a, b, n ¼ 4–7;
asterisk, P , 0.01; double asterisk, P , 0.001. c, Representative wild-type and
S6K1 2/2 mice after 6 months feeding on a HFD. d, Growth curves of wild-type and
S6K1 2/2 mice maintained on a HFD. WT, n ¼ 11; S6K1 2/2, n ¼ 15; P , 0.001.
e, Oxygen consumption (VO2) in wild-type and S6K1
2/2 mice maintained on a HFD for 6
months (n ¼ 6 each genotype). f, Body fat index determined by MRI analysis of wild-type
(n ¼ 10) and S6K1 2/2 mice (n ¼ 12) maintained on a HFD for 4 months. Filled
symbols/columns indicate wild type; open symbols/columns, S6K1 2/2 mice. Values are
mean ^ s.e.m. Asterisk, P , 0.01; double asterisk, P , 0.001 in d–f.
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to be involved in insulin resistance in skeletal muscle cells from
patients with type 2 diabetes5. Thus, removal of S6K1 can facilitate
insulin signalling in a cell-autonomous manner.
Hyperglycaemia, hyperaminoacidaemia and hyperlipidaemia are
associated with obesity and insulin resistance16; however, the role of
increased nutrients in insulin action is not well understood17–19. As
S6K1 is activated by nutrients20–22 and acts negatively on PI(3)K
signalling, this raised the possibility that on a HFD S6K1 is involved
in inducing insulin resistance. This hypothesis is supported by the
reversal of amino acid inhibition of insulin-induced PI(3)K signal-
ling by rapamycin, which inhibits mTOR23, an immediate upstream
S6K1 kinase2. Consistent with this hypothesis, phosphorylation of
S6K1 T389, S6 S240/S244, IRS1 S307 and IRS1 S636/S639 is highly
elevated in wild-type mice maintained on a HFD compared with
wild-type mice maintained on a NCD (Fig. 4a, b). Furthermore, the
increase in IRS1 S307 and S636/S639 phosphorylation is absent in
S6K12/2 mice on a HFD (Fig. 4b). Under these conditions there
were no apparent alterations in IRS1 levels (Fig. 4b). These findings
suggest that nutrient-induced S6K1 activation acts to suppress
insulin signalling through modulating IRS1 S307 and S636/S639
phosphorylation. To test this further, two genetic models of obesity
were examined: K/K Ay and ob/ob mice24,25. The results show that
the K/K Ay and ob/ob mice maintained on a NCD have elevated
S6K1 T389, S6 S240/S244, IRS1 S307 and IRS1 S636/S639 phos-
phorylation as compared with wild-type mice on a NCD (Fig. 4c).
Moreover, in contrast with PKB S473 phosphorylation in adipose
and muscle (Fig. 3d), insulin stimulates S6K1 T389 phosphoryl-
ation to even higher levels in wild-type animals on a HFD compared
with a NCD (Fig. 4d), potentially further suppressing PI(3)K
signalling. Thus, either nutritionally or genetically driven obesity
leads to the upregulation of S6K1, which may in turn act to suppress
PI(3)K signalling, contributing to insulin resistance.
The results presented here indicate that S6K12/2 mice are
protected against obesity and insulin resistance due to the upregu-
lation of the oxidative phosphorylation pathway and increased
insulin sensitivity. Enhanced oxidative metabolism is consistent
with the increase in mitochondria number, as well as the induction
of genes that control the oxidative phosphorylation pathway. That
S6K12/2 mice remain insulin sensitive despite high circulating
FFAs may be explained by the strong protection against metabolic
syndrome by overexpression or activation of PPAR-d6–8. Despite the
increase in the oxidative phosphorylation pathway and reduced
insulin levels, circulating glucose and FFA levels still rise in S6K12/2
mice; however, these animals remain sensitive to insulin, and PI(3)K
Figure 3 Enhanced insulin sensitivity and insulin signalling in the absence of S6K1.
a, b, Insulin tolerance test in 3-h-fasted mice on a NCD (a) or HFD (b) at 6 months of age.
Asterisk, P , 0.05; double asterisk, P , 0.01. Values are mean ^ s.e.m. c, Insulin
receptor tyrosine phosphorylation in liver of wild-type and S6K1 2/2 mice before (2) or
after (þ) insulin stimulation on a NCD or HFD. d, Level of phosphorylation of PKB Ser 473
in fat, liver and muscle (n ¼ 3–8 for each genotype in c, d). e, Lowering S6K1 expression
by siRNA potentiates insulin-induced PKB phosphorylation in HeLa cells.
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signalling is unaffected. This observation may be explained by the
loss of S6K1, whose activation by either nutrients or insulin leads to
increased IRS1 serine phosphorylation (Fig. 4e). In the case of
insulin, this is mediated by a negative feedback loop triggered by
PKB phosphorylation of the TSC1/2 tumour suppressor complex,
leading to Rheb activation and stimulation of S6K1 (ref. 26). Thus,
in a homeostatic setting, as nutrients and amino acids are con-
sumed, mTOR/S6K1 activity would decrease, restoring PI(3)K
signalling, whereas the incessant supply of nutrients associated
with the obese state would lead to constitutive activation of
mTOR/S6K1 and desensitization of insulin signalling (Fig. 4e).
Taken together the results suggest that S6K1 may have a central
function along with other signalling components in development of
obesity and insulin resistance, and may be an important drug target
in the treatment of patients suffering from these pathological
disorders. A
Methods
Mice
S6K12/2 mice were generated as previously described3. Male C57BL/6J, K/K Ay and ob/ob
(C57BL/6J background) mice were obtained from E. Janvier, CLEA Japan Inc., and The
Jackson Laboratory, respectively.
Metabolic studies
At 10 weeks of age male mice were placed on either a NCD (diet number 3807,
KLIBA-NAFAG) or HFD ad libitum (diet D12492, Researchdiets) and monitored for
24 weeks. Body weight was recorded weekly and food intake was measured every second
day for 15 consecutive days. Insulin tolerance tests, oxygen consumption, RER
measurements and quantification of blood metabolites were performed as previously
described27.
Histology and morphometric analysis of tissues
Adipose tissue was analysed by haematoxylin and eosin staining as previously described27.
Morphometric analysis of epididymal WAT from 500 or more cells from three different
animals per genotype was performed with ImageJ software (NIH). Adipose and plantaris
muscle tissue were prepared as described for scanning and transmission electron
microscopy27.
Magnetic resonance imaging analysis
MRI experiments were carried out on a Biospec 47/30 spectrometer (Bruker Medical) at
4.7 T equipped with a self-shielded 12-cm bore gradient system28. Animals were
anaesthetized with 1.5% isoflurane (Abbott). Adipose tissue was measured with an
optimized turbo-RARE2 imaging sequence. Acquisition parameters were: repetition delay
(TR) ¼ 250 ms; echo delay (TE) ¼ 8.6 ms; RARE factor ¼ 32 (effective echo time
73.1 ms); number of averages ¼ 8; slice orientation transverse, image matrix ¼ 128 £ 128
pixels; field-of-view ¼ 3.5 £ 3.5 cm; slice thickness ¼ 1.2 mm (contiguous). Fat pad
volumes were assessed with an in-house software algorithm based on IDL software
package (Research Systems Inc.). Body fat indices were calculated by dividing adipose
tissue weight by body weight.
Lipolysis in isolated adipocytes
Primary adipocytes were prepared from epididymal fat pads as described previously29.
Cells were incubated for 30 min at 37 8C with or without norepinephrine (Sigma-Aldrich
SARL) at the indicated concentrations.
Real-time quantitative RT–PCR
Total RNA was extracted from frozen tissue samples or cells using the RNeasy kit (Qiagen).
Complementary DNA was synthesized from total RNA with the SuperScript First-Strand
Synthesis System (Invitrogen) and random hexamer primers. The real-time polymerase
chain reaction (PCR) measurement of individual cDNAs was performed using SYBR
green dye to measure duplex DNA formation with the Roche Lightcycler system and
normalized to the expression of either b-actin or 18S ribosomal RNA. The primers and
probes used in the real time RT–PCR were the following: UCP1 sense 5
0
-GGCCCTTGT
AAACAACAAAATAC-3
0
, antisense 5
0
-GGCAACAAGAGCTGACAGTAAAT-3
0
; UCP3
sense 5 0 -ACTCCAGCGTCGCCATCAGGATTCT-3 0 , antisense 5 0 -TAAACAGGTGAG
ACTCCAGCAACTT-3
0
; mCPT1 sense 5
0
-TTGCCCTACAGCTCTGGCATTTCC-3
0
,
antisense 5 0 -GCACCCAGATGATTGGGATACTGT-3 0 ; mPPAR-d sense 5 0 -CTCTTCATC
GCGGCCATCATTCT-3 0 , antisense 5 0 -TCTGCCATCTTCTGCAGCAGCTT-3 0 ; PGC-1
sense 5
0
-AAGTGTGGAACTCTCTGGAACTG-3
0
, antisense 5
0
-GGGTTATCTTGGTTGG
CTTTATG-3 0 .
Figure 4 S6K1 activation in obesity. a, S6K1 Thr 389 and S6 Ser 240/244
phosphorylation in fat of wild-type mice maintained on a NCD (2) or HFD (þ) for 4
months. b, IRS1 Ser 307 and Ser 636/639 phosphorylation in fat of wild-type or
S6K1 2/2mice maintained on a NCD (2) or HFD (þ). c, S6K1 Thr 389, S6 Ser 240/244,
IRS1 Ser 307 and IRS1 Ser 636/639 phosphorylation in fat of wild-type, K/K A y or ob/ob
mice maintained on a NCD. d, S6K1 Thr 389 phosphorylation in fat or muscle of wild-type
mice maintained on a NCD or HFD for 4 months before (2) or after (þ) injection of
insulin (0.75 U kg21 of body weight). All mice of each genotype (n ¼ 3–8) in a–d were
fasted for 6 h and were 6 months old. e, Model of inhibition of IRS1 signalling through
activation of S6K1.
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Measurement of insulin receptor and IRS1 phosphorylation in vivo
After a 6-h fast mice were injected intravenously with 0.75 U kg21 insulin (Eli Lilly) or
equal volume of vehicle. All indicted tissues were collected in liquid nitrogen 5 min after
injection. Protein extracts from tissue samples were analysed as described30. Antibodies
were from Santa Cruz (anti-insulin receptor b and anti-S6K1 antibodies), Upstate
Biotechnology (anti-phosphotyrosine and anti-IRS1 antibodies) and Cell Signaling (anti-
PKB, anti-phospho-PKB Ser 473, anti-phospho-IRS1 Ser 636/639, anti-phospho-S6K Thr
389 and anti-phospho-S6 240/244 antibodies). Antibodies to S6 and phospho-IRS1 Ser
307 were from J. Mestan and Y. Le Marchand-Brustel, respectively.
RNA interference
RNA interference (RNAi) duplexes corresponding to human S6K1 (5
0
-
AAGGGGGCTATGGAAAGGTTT-3
0
) were purified, annealed and transfected into HeLa
cells using oligofectamine (Invitrogen). After 60 h cells were deprived of serum overnight
and either lysed directly or stimulated with 200 nM insulin for 30 min. The effect of RNAi
on S6K1 expression and PKB phosphorylation was measured by western blot analysis. Cell
lysates were incubated for 4 h with anti-IRS1 or anti-insulin receptor b antibody pre-
absorbed on protein A Sepharose at 4 8C, and analysed by western blot analyses after gel
electrophoresis.
Statistical analysis
Data are presented as mean ^ s.e.m. The main and interactive effects were analysed by
analysis of variance (ANOVA) factorial, repeated measurements or by one-way ANOVA
followed by Bonferroni t-test (MRI analysis). Differences between individual group means
were analysed by Fisher’s PLSD test. Analyses were performed using Statview Software
(Brainpower).
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Transforming growth factor b (TGF-b) is a pluripotent cytokine
that controls key tumour suppressive functions1–3, but cancer
cells are often unresponsive to it1,4. The promyelocytic leukaemia
(PML) tumour suppressor of acute promyelocytic leukaemia
(APL) accumulates in the PML nuclear body, but cytoplasmic
PML isoforms of unknown function have also been described5,6.
Here we show that cytoplasmic Pml is an essential modulator of
TGF-b signalling. Pml-null primary cells are resistant to TGF-b-
dependent growth arrest, induction of cellular senescence and
apoptosis. These cells also have impaired phosphorylation and
nuclear translocation of the TGF-b signalling proteins Smad2
and Smad3, as well as impaired induction of TGF-b target genes.
Expression of cytoplasmic Pml is induced by TGF-b. Further-
more, cytoplasmic PML physically interacts with Smad2/3 and
SARA (Smad anchor for receptor activation) and is required
for association of Smad2/3 with SARA and for the accumulation
of SARA and TGF-b receptor in the early endosome. The
PML–RARa oncoprotein of APL can antagonize cytoplasmic
PML function and APL cells have defects in TGF-b signalling
similar to those observed in Pml-null cells. Our findings identify
cytoplasmic PML as a critical TGF-b regulator, and further
implicate deregulated TGF-b signalling in cancer pathogenesis.
APL is almost invariably associated with chromosomal transloca-
tions involving the PML tumour suppressor and RARa genes,
resulting in the generation of a PML–RARa leukaemogenic fusion
protein that can function as a dominant-negative PML and RARa
mutant7–9. PML–RARa physically interacts with nuclear PML iso-
forms causing their delocalization from the PML nuclear body
(PML-NB) into aberrant microspeckled nuclear structures7,8. Until
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 paired adipogenesis in S6K1-/- mouse embryonic fibroblasts in vitro. 
l red O staining in wild type and S6K1-/- MEFs induced to differentiate into 
ipocytes by treatment with a differentiation cocktail (see Methods). aP2 mRNA 
els measured by quantitative RT-PCR (Right).  
pplementary Method: Induction of adipocyte differentiation 
use embryonic fibroblasts (MEFs) were prepared as previously described 
hima et al., 1998). To induce adipogenesis in MEFs, the medium was 
pplemented with 2 µM insulin, 1 µM dexamethasone, and 0.25 mM isobuthyl 
thyl xanthine for 2 days. The cells were then incubated with insulin and 10−7 M 
iglitazone for another 12 days, changing the medium every second day. Fat 
cumulation was scored by determination of mRNA and protein levels of 
ipocyte-specific genes and by staining of lipids with Oil Red O. 
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III. RESULTS 
 
Part:3:…………………………………………………………………………………...  
 
Regulation of pancreatic β-cell growth by S6K1 during development 
Um SH, Sticker M, Vintersten K, Gangloff YG, Adams R., Mueller M, Pyo S, Thomas G and 
Kozma S. 
Unpublished results and discussion. 
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Abstract 
 
The pancreatic β-cell mass is dynamically regulated in order to maintain 
nutrient homeostasis by changing β-cell number and size (Bernard et al., 
1999). S6K1 is a downstream effector of the mTOR-signalling pathway 
which integrates nutrient and mitogen signalling to regulate cell growth 
(Fingar et al., 2002). Consistent with this, S6K1-/- mice have previously been 
shown to be hypoinsulinemic and mildly glucose intolerant due to reduced 
β-cell size (Pende et al., 2000). However, the actual cause of diminished β-
cell size in adult S6K1-/- mice was not fully understood.  Here, we show that 
the loss of S6K1 leads to reduced β-cell size and number during 
development, retarded intrauterine growth, and impaired placental 
development. We used two complementary techniques, tetraploid 
aggregation (Tam and Rossant, 2003), and transgenic expression (Dandoy-
Dron et al., 1995) to dissect the role of S6K1 in body growth and β-cell-
specific growth during development. S6K1-deficient embryos supplied with 
a wild type normal placenta by tetraploid aggregation developed normally 
without any growth retardation. However, despite the normal growth of 
S6K1-deficient embryos when the placental defect was compensated for, β-
cells were still smaller than in the wild type, suggesting the defect in β-cell 
growth is independent of placental dysfunction. Furthermore, β-cell-
specific transgenic expression of S6K1 restores β-cell growth and 
development in S6K1-deficient embryos. These findings would suggest a 
novel function for S6K1 in extraembryonic cell lineages, that are required 
for embryonic growth, and indicate a cell autonomous role of S6K1 in β-cell 
size regulation during development.  
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Introduction 
 
β-cell mass in the pancreas plays an important role in determining the 
amounts of insulin that are secreted to maintain glucose homeostasis (Bonner-
Weir, 1994). Changes in β-cell mass are dynamic, and is regulated to meet 
metabolic demands in various metabolic conditions such as obesity, pregnancy, 
glucose infusion, partial pancretectomy, and islet transplantation (Bernard-Kargar 
and Ktorza, 2001). β-cell mass has a remarkable ability to adapt to different 
nutritional conditions by changing β-cell number and size (Chan et al., 1999). 
Increases in β-cell number are result of β-cell neogenesis, which is replication 
from existing β-cells or from pancreatic precursor stem cells, or by the 
proliferation of differentiated β-cells (Dor et al., 2004), (Bonner-Weir, 2000). 
Decreases in β-cell number are accomplished by β-cell apoptosis 
(Bernard et al., 1999). Recently, studies have shown that important components 
of the increases in β-cell mass after pancreatectomy are not only β-cell 
neogenesis and replication, but also increases in β-cell size (Jonas et al., 1999). 
Failure of the pancreatic β-cell mass to adapt to changes in metabolic demands 
can lead to type 2 diabetes (Kloppel et al., 1985). Understanding what regulates 
β-cell number and size, and how β-cell growth is coordinated with physiological 
demands, is important for developing therapeutic strategies for the treatment of 
any metabolic disease associated with pancreatic β-cell dysfunction.    
Previous studies in mammalian models have shown that the insulin 
signaling cascade regulates β-cell growth, signaling, and survival (Withers et al., 
1999). Despite a number of reports on the regulation of β-cell mass by β-cell 
number and survival, the regulation of β-cell size in mass and function is not fully 
understood. Overexpression of active PKBα in mouse β-cells results in increases 
of β-cell size and total islet mass, leading to resistance to streptozotocin-induced 
diabetes, suggesting that the genetic modulation of insulin signaling regulates β-
cell size although the mechanism is not fully understood (Tuttle et al., 2001). The 
growth of pancreatic β-cells is also regulated by growth factors and nutrients. 
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Feeding normal rats with a high fat diet for six weeks results in a modest 
increases in body weight and insulin resistance, but islet density and β-cell size 
significantly increase by 30-40% suggesting that β-cell growth adapts to changes 
in nutritional status (Buettner et al., 2000). β-cell mass is enhanced 50% in 
glucose-infused rats through inducing hyperplasia and hypertrophy (Bonner-Weir 
et al., 1989). In addition, nutrient signaling (especially that of amino acids) is 
found in β-cells and is known to promote insulin production, indicating that 
nutrients are important for β-cell function and mass (McDaniel et al., 2002).  
Previously, mice deficient in S6 Kinase 1 (S6K1), an effector of the 
mammalian Target Of Rapamycin (mTOR) which is activated in response to 
amino acids and insulin and mediates cell growth, were shown to be 
hypoinsulinemic and exhibited reduced β-cell size, suggesting β-cell growth can 
be regulated by S6K1 (Pende et al., 2000). Notably, that genetic factors and 
nutritional alterations during fetal and postnatal periods have been implicated in 
β-cell dysfunction and impaired β-cell growth in the adult (Blondeau et al., 2002), 
we questioned whether diminished β-cell size in adult S6K1-/- mice arose from 
altered nutritional environment during development in vivo or stemmed from 
impaired β-cell development due to the absence of the S6K1 gene.  
 
Results and discussion 
 
Given that fetal and neonatal life are known to be crucial periods for 
pancreatic β-cell growth and development, and most active for β-cell replication 
and neogenesis (Rahier et al., 1981), (Bonner-Weir, 2000), (Nielsen et al., 1999), 
(Finegood et al., 1995), (Kaung, 1994), we first questioned whether diminished β-
cell size in adult S6K1-/- mice originates from impaired pancreatic β-cell growth 
during embryonic development. We first analyzed haematoxylin- and eosin-
stained embryonic pancreas sections at E16.5. S6K1-deficient pancreatic 
sections appeared to have more dense nuclei per endocrine pancreas area, 
reflecting a reduction in cell size during pancreas development (Fig. 1a). To 
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further examine pancreatic development, embryonic pancreas sections were 
stained for insulin and glucagon. Consecutive sections were scored for the 
number of insulin- or glucagon-positive cells per pancreatic area (Fig. 1b). The 
morphometric analysis of the pancreas at E16.5 showed a decrease in β-cell 
number in the S6K1-/- embryo compared to the wild type (wt: 594±87, n=3; S6K1-
/-: 446±58, n=3, 18 sections each genotype, P<0.05) indicating delayed 
pancreatic β-cell development, but no significant difference in α cell number in 
S6K1-/- embryos, although there tended to be fewer α cells (Fig. 1d).  Reduced β-
cell number was not due to increased cell death, as judged by TUNEL staining 
(data not shown).  Morphometric analysis revealed that β-cells in S6K1-/- 
embryos were smaller than β-cells from wild type embryos (Fig. 1e), with an 
average of 27% decrease in size (wt: 95.60±2.69 µm2, n=3; S6K1-/-: 69.54±1.5 
µm2, n=3, P<0.01).  Notably, there were no significant differences in size and 
number of glucagon-positive cells between genotypes, suggesting that the 
impairment observed was limited to β-cells in adult S6K1-/- mice (Fig. 1d and Fig. 
1e). Diminished β-cell size in S6K1-/- embryos was more obvious in sections of 
the embryonic pancreas which were labeled with an antibody directed against the 
GLUT2 glucose transporter, residing in the plasma membrane of cells (Fig. 1c). 
In addition, the reduction in β-cell size was consistent with lower insulin levels in 
S6K1-/- compared to wild type mice (Fig. 1f). Because pancreatic weights of 
embryos could not be reliably ascertained due to the small size of embryos, and 
the total numbers of pancreatic sections were correlated with whole embryo 
weight, insulin content normalized with embryo body weight. Such 
measurements revealed that S6K1-/- pancreas had about 50% reduced insulin 
content at E16.5 (Fig. 1f) indicating the reduction in β-cell size was consistent 
with lower insulin levels in S6K1-/- mice. Reduced β-cell size and number were 
persistent at E19.5 (data not shown). In summary, reduced insulin levels in the 
S6K1-/- embryonic pancreas was due to a reduction in the number and size of 
insulin-positive β-cells in the S6K1-/- embryonic pancreas, suggesting that the β-
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cell phenotype in adult S6K1-/- mice may be arising from impaired pancreatic β-
cell growth and development during embryogenesis.  
Since the reduced β-cell number and size, and diminished insulin contents 
in the S6K1-/- embryonic pancreas might be due to a general developmental 
delay, we next questioned whether general fetal growth and developmental 
retardation would be the cause of impaired pancreatic β-cell growth in the S6K1-/- 
embryo. To examine this, the body weight of embryos was measured from E12.5 
to E18.5. The results showed that S6K1-/- mice displayed growth retardation 
during embryogenesis (Fig. 2a), which became apparent at E12.5. In general, the 
overall embryo weight was about 80% of that of wild type, while the growth curve 
of S6K1-/- and wild type embryos exhibited parallel slopes between stages E12.5 
and E18.5 (Fig. 2a). Interestingly, In utero growth retardation did not arise from 
maternal malnutrition during pregnancy, as S6K1-/- mice displayed normal 
glucose levels in both fasting and fed states in addition to normal food intake (Um 
et al., in press). Moreover, fetal growth retardation was observed in S6K1-/- 
embryos from heterozygous matings, indicating the maternal nutritional 
environment was not likely to be the main cause of fetal growth retardation 
(Shima et al., 1998). 
To examine whether fetal growth retardation was accompanied by 
developmental delay, we analyzed bone development at E16.5. Such an analysis 
confirmed a delay in the formation of an ossification centers, as illustrated by the 
alcian blue (stains cartilaginous regions) and alizarin red S (stains ossified 
regions) staining and the chondrocyte hypertrophy in cervical vertebrae (Fig. 2b). 
To determine whether developmental delay starts earlier than E12.5, we 
analyzed the developmental hallmarks of whole embryos using scanning electron 
microscopy. At day E9.5, S6K1-/- embryos exhibited a decrease in somite number, 
delayed formation of limb buds and an opened otic pit, indicating a 
developmental delay at this stage (Fig. 2c).  Thus, the absence of S6K1 has an 
effect on both fetal growth and developmental timing.  In addition, based on the 
knowledge that the appearance of growth retardation in S6K1-/- embryos starts 
around E9.5 while insulin plays an role in late stage of development (Duvillie et 
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al., 1997), (Fowden, 1989), low levels of insulin production accompanied by 
delayed pancreatic β-cell development may not likely be the primary cause of 
growth retardation.  Moreover, given the fact that mice lacking the insulin 
receptor are born with 10% growth retardation and die with severe diabetes 
(Kitamura et al., 2003), altered levels of insulin or impaired insulin receptor 
signaling are unlikely the  main cause of growth retardation in S6K1-/-  embryos.  
To address whether the developmental delay starts even at the 
preimplantation stage, and examine whether the growth retardation and 
developmental delay in S6K1-/- embryos are due to the defective  intrinsic ability 
to develop, we examined preimplantation development using one-cell eggs in 
vitro. Single-cell fertilized eggs from wild type or S6K1-/- mice were collected for 
their ability to develop tested in vitro for 5 days. Single-cell fertilized eggs from 
S6K1-/- mice developed normally in vitro, with 60% of blastocysts recovered at 
day 3.5, and the rate of development from the one cell to the blastocyst stage 
was same as wild type (Fig. 2d), suggesting that developmental delay starts after 
implantation. Moreover, S6K1-/- blastocysts didn't appear have different growth 
rates than wild type ones (data not shown). Despite general growth retardation 
and developmental delay, no difference in the in vitro development of fertilized 
eggs and in the proliferation rate of blastocysts suggests that developmental 
phenotypes may arise from extraembryonic tissues.  
Impaired placental function or placental insufficiency accounts for 70-80% 
of fetal growth retardation and newborns that are born small for their gestational 
age (Rossant and Cross, 2001), (Baschat and Hecher, 2004). Placenta is 
specifically mammalian organ which allows oxygen exchange between mother 
and fetus and regulates nutrient levels in fetal tissues (Rossant and Cross, 2001).  
The differentiation of the trophoblasts, the most important placental cell type of 
the placenta, starts at E4.5, the time of implantation. Mature placenta, 
established after stage E10, is composed of three principal layers derived from 
the fetus: the outer trophoblast giant cells; a middle spongiotrophoblast layer; 
and the innermost labyrinth (Rossant and Cross, 2001). The labyrinth contains 
cells of both trophoblast and mesodermal origin that together undergo branching 
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morphogenesis to produce a large surface area of the placenta for nutrient and 
gas exchange. (Cross et al 2000) (Rossant and Cross, 2001).  
Given defects in placental development or dietary protein restriction during 
gestation lead to fetal growth retardation (Rossant and Cross, 2001), (Parimi et 
al., 2004), we next questioned whether growth retardation and developmental 
delay arise from low nutrient availability due to impaired placental development. 
We first examined the morphology of the placenta at E13.5. At the equivalent 
gestational stage, S6K1-/- placentas from a homozygous or heterozygous 
matings were smaller than the placentas of wild type mice (Fig. 4d). Analysis of 
haematoxylin- and eosin-stained cross-sections revealed that the 
spongiotrophoblast layer in S6K1-/- placentas was thinner than in wild type 
placentas (Fig. 3a, b). The spongiotrophoblast layer was further analyzed by in 
situ hybridization using the spongiotrophoblast-specific gene Tpbp. The results 
confirmed a significantly reduced layer of Tpbp-expressing cells (Fig. 3b). 
However, a typical feature was observed for the giant cells that form the multiple 
cell layers between maternal decidual tissue and the embryonic labyrinth (data 
not shown). As an intact spongiotrophoblast layer is required for the normal 
development of the labyrinthine trophoblast layer, and secretes the vascular 
endothelial growth factor needed for blood vessel function (Rossant and Cross, 
2001), we examined the labyrinthine layer. Closer examination of the labyrinthine 
layer using haemotoxylin and eosin staining revealed reduced intermingling of 
embryonic and maternal blood vessels (Fig. 3c). Embryonic blood vessels in the 
S6K1-/- labyrinthine layer appeared to be dilated and filled with more blood cells 
than vessels in wild type mice. (Fig. 3c, d). Morphometric analysis and 
immunohistochemical detection of PECAM-1, a fetal endothelial cell marker, 
revealed that the number of fetal blood vessels in the labyrinthine layer of S6K1-/- 
was reduced and that fetal blood vessels were irregular in diameter (Fig. 3d). 
Taken together, these observations indicate a decreased vascular capacity in 
S6K1-/- placentas and a role of S6K1 in the normal vascularization of the 
labyrinthine layer. Decreases in intermingling between maternal and fetal blood 
vessels may indicate restricted nutrient or oxygen exchange between the mother 
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and developing embryos. In addition, the S6K1-/- placentas had improperly 
positioned Tpbp-expressing cells in the labyrinthine region at E19.5. (Fig. 3e, f). 
Therefore, it appeared likely that the defect in spongiotrophoblast and the 
labyrinthine layer could be one of the causes for fetal growth retardation in S6K1-
/- mice. In addition, our results indicate that S6K1 is required for placental 
morphogenesis and vascularization. 
Considering the impaired placental development in S6K1-/- mice and the 
fact pancreatic β-cell development is exclusively sensitive to the level of nutrients 
provided by placenta (Godfrey, 2002), we questioned whether a faulty S6K1-/-  
placenta might be the primary cause of the embryonic growth retardation 
resulting in impaired pancreatic β-cell growth. To explore this possibility, we 
supplied S6K1-/- embryos with normal placenta by the tetraploid aggregation 
technique (Tanaka et al., 2001). To this end, we produced mouse fetuses by 
aggregating homozygous S6K1-/- embryonic stem (ES) cells with wild type 
tetraploid embryos. In the resulting chimeras, the embryos are ES-cell derived. 
The wild type tetraploid cells contribute exclusively to the placental trophoblast 
cells and the endoderm of the yolk sac, but owing to increased ploidity, they are 
rigorously excluded from the embryo proper. Conversely, diploid ES cells cannot 
make trophoblast tissues in vivo, but make up the entire embryo proper (Tam and 
Rossant, 2003). The absence of S6K1 in ES cell- derived embryos after 
tetraploid aggregation was confirmed by Southern blotting (Fig. 4a). Analysis of 
tetraploid wild type placenta at E13.5 using haematoxylin and eosin staining 
demonstrated extensive intermingling of blood vessels between mother and fetus 
and a well-organized placenta structure, indicating the tetraploid aggregation 
technique provided histologically normal wild type placenta for S6K1-/- embryos 
(Fig. 4c).  When tetraploid wild type morulae and diploid S6K1-/- ES cells were 
aggregated, the S6K1-/- ES-cell derived fetuses associated with wild type 
reconstituted placentas (indicated as S6K1-/-TR) appeared normal without 
developmental delay or growth retardation (Fig. 4b, d), indicating that growth 
retardation in S6K1-/- embryos was secondary to impaired placental development.      
No growth retardation in S6K1-/-TR  embryos was visible throughout the 
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embryonic stages from E13.5 to E19.5 (Fig. 4d and data not shown).  Thus, the 
absence of S6K1 in the trophoblasts leads to impaired placental development 
associated with fetal growth retardation, suggesting a new role of S6K1 in extra-
embryonic cell lineage.  
 As maturation of pancreatic β-cell growth and function takes place during 
early development, the pancreatic β-cells are particularly susceptible to the 
effects of poor nutrition and impaired placental development (Blondeau et al., 
2002).  We next questioned whether impaired β-cell growth in S6K1-/- embryos 
during development was also a secondary phenotype due to low levels of 
nutrient availability, potentially due to placental dysfunction driven by the loss of 
S6K1. To explore this possibility, we analysed pancreatic β-cell size, number, 
and insulin content in S6K1-/- embryos at E16.5 with a tetraploid wild type 
placentas. Consistent with a full resumption of body growth in the presence of 
tetraploid wild type placentas, there was also an increase in β-cell numbers in 
S6K1-/-TR embryos to the same level as wild type (indicated as S6K1-/-TR, Fig. 
4h). Surprisingly, β-cell density was higher in S6K1-/-TR embryos (Fig. 4e) 
although pancreatic β-cells in S6K1-/-TR embryos were still 27% smaller than 
those of wild type embryos (Fig. 4g and Fig. 4i), suggesting that the reduced 
number of β-cells, but not diminished β-cell size, could be rescued by providing 
wild type placentas.  Despite a nutrient-rich environment provided by the 
tetraploid placenta, loss of S6K1 function in β-cells results in smaller cells 
indicating the requirement of S6K1 for maintaining normal β-cell size during 
development.  Consistent with reduced β-cell size, there was a more striking 
reduction in insulin levels, when normalized with the body weight of the embryo, 
probably due to further increases in body weight in tetraploid embryo rescue 
experiments (Fig. 4j). Despite completely rescue of body size and development 
in the presence of a tetraploid wild type placentas, S6K1-/-TR embryos still had 
diminished β-cells (Fig. 4g. i), indicating that defects in placental development or 
nutritional environment during gestation in vivo may not be the primary cause for 
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reduced β-cell size in S6K1-/- embryos, but rather a specific effect of the genetic 
lesion.  
To further investigate the actual genetic cause of smaller β-cells in adult 
S6K1-/- mice, we generated transgenic mice in which a wild type form of S6K1 
was expressed in pancreatic β-cells. For this purpose, we used the rat insulin II 
promoter to drive expression of S6K1 in pancreatic β-cells (Dandoy-Dron et al., 
1995). We confirmed transgene expression by PCR and western blot analysis of 
pancreatic islet β-cell lysates using antibodies against S6K1 and the myc tag 
present on the N terminus of the expressed transgene.  Transgenic S6K1 
(indicated as ripS6K1) was detected in both WTripS6K1 and S6K1-/-ripS6K1 islet 
extracts, but was undetectable in WT and S6K1-/- islets (Fig. 5a). By breeding 
S6K1+/-ripS6K1 mice with S6K1+/- mice, we were able to generate S6K1-deficient 
embryos expressing S6K1 only in pancreatic β-cell (indicated as S6K1-/-ripS6K1). 
S6K1-/-ripS6K1 mice are viable and fertile but smaller than wild type mice. 
Morphometric analysis revealed that β-cell density (Fig. 5b), number (Fig. 5e), 
and size (Fig. 5f) in S6K1-/-ripS6K1 embryos were restored to wild type levels.  
Consistent with complete rescue of β-cell size and number in S6K1-/-ripS6K1, 
measurements of insulin levels also revealed no differences in insulin contents 
between WTripS6K1 and S6K1-/-ripS6K1 (Fig. 5g). Notably, smaller β-cell size and 
reduced cell number in the S6K1-/- embryos during development were completely 
restored by transgene expression in β-cells (Fig. 5e, f), but diminished β-cell size 
was not restored by providing tetraploid wild type placentas (Fig. 4e, i), indicating 
that extrinsic nutrients provided by the placenta cannot restore β-cell size in the 
absence of S6K1. Furthermore, morphometric analysis in 3-month-old adult mice 
revealed that higher β-cell density due to smaller cell size in S6K1-/- mice was 
also restored in adult transgenic S6K1-/-ripS6K1 mice with an average 19% 
decrease in β-cell density (wild type: 86.59±1.78 (n=32 islets); S6K1-/-: 
100.54±1.24 (n=31 islets), S6K1-/-ripS6K1: 81.53±2.39 (n=28 islets), wt vs. S6K1-/-
ripS6K1 P=0.09, wt vs. S6K1-/- P<0.001, S6K1-/- vs. S6K1-/-ripS6K1 P<0.001, four 
female mice of each genotype).  This indicates that the restoration of β-cell size 
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by transgene expression during embryonic development persists throughout 
adult life. Thus, transgenic expression of S6K1 in S6K1-deficient β-cells restores 
β-cell size and thereby restores β-cell development. (Fig. 5e, f). Consistent with 
this, we observed recently that overexpression of wild type mammalian S6K1 in 
dS6K-deficient Drosophila could rescue cell size defects as well as 
developmental delay by restoring cell cycle time (J. Montagne, unpublished data). 
Thus, these results suggest that the loss of S6K1 function in β-cells during 
development may lead to delayed β-cell development at a smaller size, but that 
the loss of S6K1 in the trophoblasts, results in impaired placental development, 
potentially leading to a general growth retardation and reduced β-cell number as 
demonstrated in tetraploid aggregation experiments. (Fig. 4e, 5b).    
Despite increases in β-cell size and number in S6K1-/-ripS6K1 embryos 
compared to S6K1-/- embryos, the expression of S6K1 in a wild type background 
fails to increase β-cell size further, and even resulting in a slightly decreased β-
cell size compared to wild type (Fig. 5f).  Although the levels of S6K1 expression 
in a S6K1-deficient background were higher than in a wild type mice (Fig. 5a), it 
did not increase β-cell size further than the wild type and exhibited no differences 
in insulin levels compared to wild type or wild type transgenic mice (Fig. 5f, g). 
These results suggest that there may be a critical cell size threshold operated by 
S6K1. Slightly reduced β-cell size in WTripS6K1 compared with wild type mice (Fig. 
5f) could be explained by the fact that overexpression of S6K1 in a wild type 
background is a dominant negative to itself as well as other downstream targets 
(Jefferies et al., 1997), (Von Manteuffel et al., 1996). This may be due to titrating 
out the mTOR/Raptor/LST8-signaling complex by the overexpression of 
transgenic S6K1 and the requirement for multi-site phosphorylation for S6K1 
activation (Von Manteuffel et al., 1996), (Kim et al., 2002). In contrast to β-cell-
enlargement phenotypes seen following increased PKB activity in mice (Tuttle et 
al., 2001), the failure of S6K1 overexpression to increase β-cell size over that of 
wild type (Fig. 5f) suggests that S6K1 does not function downstream of the PKB 
pathway, as demonstrated in the Drosophila system (Radimerski et al., 2002). 
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Given the difference in the β-cell size phenotype in wild type background versus 
transgenic mice expressing active PKB or S6K1 in β-cells, it would be interesting 
to investigate how the PKB and S6K1 pathways regulate β-cell size differently 
when there is a demand to increase β-cell mass in order to compensate insulin 
resistance in peripheral tissues. Nevertheless, transgenic expression of S6K1 
could revert the diminished β-cell size phenotype in S6K1-/- mice in a cell 
autonomous manner (Fig. 5f), indicating that S6K1 is clearly required for 
maintaining normal β-cell size. Furthermore, the results show the conservation of 
β-cell size (Fig. 5b, d, f) and prevention of hyperinsulinemia in S6K1-/-ripS6K1 
embryo under normal nutrient homeostasis suggesting that transgenic expression 
of S6K1 may be helpful for selectively restoring the function of β-cells under 
pathological conditions associated with reduced β-cell size and mass.  It will be 
interesting to determine whether a loss of S6K1 in pancreatic β-cells using 
conditional knockout strategies is sufficient to induce reduced β-cell size or a 
growth retardation phenotype in embryos and adult mice.  
Previous studies were unable to establish a cell autonomous vs. non-
autonomous role of S6K1 during development.  Here we find that the histological 
structure of the spongiotrophoblast layer is altered, and that vascularization in the 
labyrinth is reduced, in the S6K1-/- placenta resulting in growth retardation and 
developmental delay. Analysis using tetraploid aggregation indicates that a 
defect in S6K1-/- placental trophoblast cells leads to growth retardation and 
developmental delay phenotypes of S6K1-/- embryos because embryos, when 
supplied with a functionally normal placenta, grew to a normal size without delay 
in development and only diminished β-cell size (Fig. 4d, e, g, i). Our studies 
would suggest non-cell-autonomous role for S6K1 in fetal growth during 
development and a new role for S6K1 in trophoblast development. The molecular 
mechanism underlying the defect in S6K1-/- trophoblasts remains to be 
investigated. Importantly, restoration of S6K1 function in pancreatic β-cells by 
transgenic expression is sufficient to rescue the pancreatic β-cell size defect of 
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S6K1-/- embryonic and adult mice (Fig. 5d and Fig. 5f), indicating a cell 
autonomous role for S6K1 specifically in β-cell size determination.  
It has been shown that protein malnutrition during the fetal stages of 
pancreatic development leads to a reduction in pancreatic insulin content and β-
cell mass in the adult age, underscoring the importance of nutritional stimuli on β-
cell growth during fetal development (Swenne et al., 1992). Alterations in this 
stimulation may result in impaired β-cell growth and β-cell dysfunction in later life 
(Swenne et al., 1992), (Swenne et al., 1987). Our results suggest that S6K1 
signaling may be one key signaling molecule mediating β-cell growth for 
maintainance of the competence of β-cells to grow in response to nutrients and 
growth factors during development. Despite impaired β-cell growth, mild glucose 
intolerance, and hypoinsulinemia, S6K1-/- mice were not diabetic and maintained 
normal feeding and fasting glucose levels (Um et al., in press), (Pende et al., 
2000). The absence of diabetes in these mice can be explained by the presence 
of high insulin sensitivity in peripheral tissues through a negative feedback loop 
from S6K1 to IRS1 serine phosphorylation (Um et al., in press).  Similarly, low 
protein diets during late gestation leads to reduced β-cell size and 
hypoinsulinemia as in S6K1-/- mice but the effect of hypoinsulinemia was 
attenuated by high insulin sensitivity (Grace et al., 1990) through decreases of 
IRS1 serine phosphorylation in human and rats (Toyoshima et al., 2004).  Thus, 
the absence of S6K1 results in a phenotype strongly reminiscent of a human on 
a limited protein diet during gestation (Rigalleau et al., 1998). Taken together, 
these studies suggest that S6K1 acts as an important mediator in nutrient-
induced β-cell growth and placental development, and that loss of S6K1 may 
lead to the failure to integrate of nutrient and mitogen signaling required for β-cell 
growth under normal nutrient conditions.  This observation may help to develop 
therapeutic interventions for the treatment of pathological conditions associated 
with reduced β-cell growth, such as malnutrition-induced diabetes.   
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Figure legends 
 
Figure 1: Diminished β cell size in S6K1-/- embryonic pancreas.  a. Histology of 
pancreas from wild type (left) and S6K1-/- embryo (right) at E16.5. Tissue sections 
were stained by haematoxilin and eosin. b, Immunofluorescence staining of 
embryonic pancreas for insulin (red) and glucagon (green). c, Fluorescent staining    
for the GLUT2 glucose transporter. d, Reduced β cell number in S6K1-/- embryonic 
pancreas. e, Diminished β cell size in S6K1-/- embryonic pancreas. f, Reduced 
insulin contents normalized by body weight in S6K1-/- embryonic pancreas. (see 
Methods).  *, P < 0.05,  **, P < 0.01  
 
Figure 2: Growth retardation and developmental delay in S6K1-/- embryos. 
a, Fetal weights of wild type (WT) and S6K1-/- embryos at the indicated gestational 
ages. *, P < 0.05. b, Delayed bone development in S6K1-/-  embryo. Lateral view of 
skeleton at E16.5 analyzed for ossification using alcian blue and alizarine red (Top). 
Arrows indicate that ossification is present in frontal bone on the cranium and fibula 
and tibia bone on hind limb of WT, whereas cartilaginous regions are still present in 
the same regions of  S6K1-/- embryo. Presence of hypertrophic chondrocytes in WT 
but not in S6K1-/- at E14.5. (Bottom). c, Side views of embryos at E9.5 by scanning 
electron microscopic analysis (left) and somite numbers in embryos at E9.5 (right). 
Asterisk indicates somite. Note opened otic pit (open arrow) and the absence of limb 
bud (filled arrow) in  S6K1-/-  embryo. d, Normal preimplantation development in 
S6K1-/-  *, P < 0.05, WT, wild type. 
 
Figure 3: Abnormal placental development in S6K1-/- mice.  
a and c, Hematoxylin/eosin-stained cross sections of placenta from wild type (left) 
and S6K1-/- embryo (right) at E13.5. Labyrinthine trophoblast (Lb) and 
spongiotrophoblast layers (Sp) are indicated.   b, RNA in situ hybridization analysis 
of the spongiotrophoblast-specific marker Tpbp in E13.5 placenta. Note that 
spongiotrophoblast layer is thinner in S6K1-/- placenta. c, Reduced intermingling of 
maternal (containing enucleated erythrocytes, open arrow) and embryonic blood 
vessels (identified by nucleated erythrocytes, filled arrow) in labyrinthine layer of 
S6K1-/-  placenta. Size bar 100 µm. d, Anti-PECAM staining (brown color) shows 
dilated fetal blood vessels with irregular in diameter in S6K1-/- placenta. e, 
Hematoxylin/eosin-stained cross-sections of placenta from wild type and S6K1-/- 
embryo at E19.5. Size bar 1mm. f. RNA in situ hybridization analysis of the 
spongiotrophoblast-specific marker Tpbp in E19.5 placenta. Arrows indicate the 
improperly positioned Tpbp -expressing cells in the labyrinthine region of S6K1-/-  
placenta.   
 
Figure 4: Tetraploid wild type placenta rescues growth retardation but not β 
cell size in S6K1-/- embryos.  a, Southern blot of genomic DNA from tetraploid 
placenta and ES cell derived embryo. b, Fetal weights of wild type, S6K1-/- ,  S6K1-/-  
after tetraploid aggregation (S6K1-/- TR) at E13.5. c, Placenta after  tetraploid 
aggregation (S6K1-/-TR) as visualized in hematoxylin/eosin-stained sections. Note 
that well-developed intermingling of maternal (open arrow) and embryonic blood 
vessels (filled arrow) in labyrinthine layer of placenta after tetraploid aggregation. d, 
Appearance of wild type, S6K1-/-, S6K1-/- embryos after tetraploid aggregation 
(S6K1-/-TR). e, Histology of pancreas from wild type, and S6K1-/-TR  embryo (right) 
after tetraploid aggregation at E16.5. f, Immunofluorescence staining of embryonic 
pancreas for insulin (green) and glucagon (red). g, Fluorescent staining for the 
GLUT2 glucose transporter. h, β cell number in WT and S6K1-/-TR.  i, Diminished β 
cell size in S6K1-/- embryonic pancreas supplied with a normal placenta by tetraploid 
aggregation. j, Reduced insulin contents in S6K1-/-TR. **, P < 0.01 
 
Figure 5: Pancreatic β cell specific expression of S6K1 rescues diminished β 
cell size in S6K1-/-  mice.  a, Confirmation of transgene expression by western blot 
and PCR. Islet lysates of transgenic and nontransgenic mice were immunoblotted 
with antibodies against myc or S6K1 or PCR of genomic DNA to detect rat insulin 
promotor (rip). b, Histology of pancreas from WTripS6K1(left), S6K1-/- (middle), 
transgenic embryo (S6K1-/-ripS6K1, right) at E16.5. Tissue sections were stained by 
haematoxilin and eosin. c, Immunofluorescence staining of pancreas for insulin 
(green) and glucagon (red). d, Fluorescent staining for the GLUT2 glucose 
transporter. e, β cell number in transgenic pancreas. f, Rescued  β cell size in 
transgenic pancreas. g, Rescued insulin contents in transgenic pancreas. *, P < 0.05, 
**, P < 0.01 
 
IV. DISSCUSSION 
 
Why are S6K deficient mice resistant to age-and diet-induced obesity? 
  
Negative feed back from S6K1 activation to IRS1 serine phosphorylation  
S6K1 deficient mice were shown to be mild glucose intolerance and 
hypoinsulinemic due to selective reduction in pancreatic β-cell size (Pende et al., 
2000). However, such mice have normal fasting and feeding glucose levels 
despite their hypoinsulinemia (Pende et al., 2000; Um et al., in press). This 
suggests that they may have hypersensitivity to insulin in the peripheral tissues. 
Indeed, the present study revealed that S6K1 deficient mice exhibit slightly 
higher insulin sensitivity on a normal chow diet and that this phenotype was more 
pronounced when they were on a high fat diet (Um et al., in press).  Why is 
insulin sensitivity increased in the absence of S6K1? Is S6K1 one of the signaling 
molecules responsible for dampening insulin signaling?  
Previously, hyperglycemia, hyperaminocidemia, and hyperlipidemia, have 
been shown to be associated with obesity and insulin resistance (Kahn and Flier, 
2000; Pijl et al., 1994), suggesting insulin resistance may be caused by excess 
nutrient supply. Consistent with this, hyperglycemia, high protein diet, and high 
fat diet induce insulin resistance by inhibiting the early steps of the insulin 
signaling pathway, such as IRS tyrosine phosphorylation and PI3K activation 
(Hresko et al., 1998; Patti, 1999; Rossetti et al., 1989; Shulman, 2000).  Given 
that the mTOR/S6K1-signaling pathway is activated by nutrients (Hara et al., 
1998; Patti et al., 1998) and insulin (Dennis et al., 2001), S6K1 could be involved 
in inducing insulin resistance by inhibiting an early events in insulin signaling.  
The involvement of S6K1 in this process is supported by the observation that 
amino acids inhibit insulin-induced PI3K signaling, an inhibitory response which 
is reversed by the inhibition of mTOR/S6K1 signaling by rapamycin(Tremblay 
and Marette, 2001).   
One of the inhibitory signals for insulin action is the phosphorylation of 
IRS1 on serine residues such as S307, S632, and S612 of mouse IRS1, or 
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alternatively S312 and S636 of human IRS1. Ser307 phosphorylation induces a 
conformational change of the phosphotyrosine-binding domain that reduces its 
affinity for the IR (Aguirre et al., 2002), while Ser612 and Ser632 phosphorylation 
of IRS1 inhibits the binding of PI 3-kinase to IRS1 (Mothe and Van Obberghen, 
1996).  
How does nutrient-induced S6K1 activation dampen insulin signaling and 
which signaling molecules are involved in this process?  The present study has 
shown that the insulin receptor is still desensitized in response to insulin injection 
in S6K1 deficient mice on a high fat diet.  Furthermore, there are no changes at 
the level of insulin receptor tyrosine autophosphorylation, despite increases in 
insulin-induced PKB phosphorylation in S6K1 siRNA treated cells. This would 
suggest that S6K1 may elicit a selective inhibitory effect on PKB activation at a 
point downstream of the insulin receptor. Further analysis of IRS1 serine 
phosphorylation in S6K1 siRNA treated cells and S6K1 deficient mice on a high 
fat diet revealed that phosphorylation of S307 and S632 in IRS1 was abrogated 
both in vitro and in vivo, suggesting S6K1 may have a selective positive effect on 
serine phosphorylation of IRS1 leading to inhibition of PKB signaling and to 
insulin resistance. 
Given that phosphorylation of S307 and S632 in IRS1 is known to be 
elevated in animal models of obesity and in muscle from type 2 diabetes patients 
(Bouzakri et al., 2003) and phosphorylation of those sites are abrogated in S6K1 
deficient mice and siRNA treated cells, how then does S6K1 influence serine 
phosphorylation of IRS1 to inhibit insulin signaling?  
 
Is S6K1 able to phosphorylate directly serine sites of IRS1?  
Interestingly, Harmann et al have shown that insulin-activated S6K1 
phosphorylates IRS1 between residues 511 and 772 in vitro suggesting the S6K1 
may directly regulate of IRS serine phosphorylation. However, no serine sites 
were identified to be phosphorylated by S6K1. Given the fact that S6K1 
recognizes the RXRXXS/T motif in ribosomal protein S6 (Flotow and Thomas, 
1992), S307 and  S632 in IRS may not  be good candidates as S6K1 substrates.  
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(Gual et al., 2003b; Ozes et al., 2001).  An intriguing the findings by Harrington et 
al revealed that Ser302 proximal to the IRS1 PTB domain is phosphorylated by 
S6K in vitro (Harrington et al., 2004) and that this site contains an S6K1 
recognition  motif.  Moreover, they have shown that phosphorylation of this site 
disrupts the ability of the PTB domain to interact with activated insulin receptors.  
Their finding supports the model that S6K1 directly mediate IRS1 serine 
phosphorylation leading to dampening of insulin signaling.  Consistent with this 
study, a recent study showed that the level of phosphorylation of serine 302 in 
IRS1 is indeed increased along with S307 in animal models of obesity and insulin 
resistance, including genetically obese ob/ob mice, diet-induced obesity, and 
upon induction of hyperinsulinemia although the relevance of S6K1 in these 
models has not been tested (Werner et al., 2004). Interestingly, phosphorylation 
on both S307 and S302 sites is necessary for IR/IRS1 disruption but not 
sufficient for disruption (Werner et al., 2004), suggesting  an additional site or 
sites are required for  disruption of the IR/IRS1 interaction and insulin resistance.  
It will be interesting to determine whether the loss of S6K1 in cells and/or mice 
abrogates phosphorylation of S302 in IRS1 along with other sites such as S307 
and S632. In addition, further experiments are required to determine if S302 
phosphorylation alone is involved in predisposition of insulin resistance in vivo 
and in vitro.  Measurement of biological functional outcomes such as glucose 
uptake in cells or mice expressing an IRS1 S302 substitution mutant could be 
informative to evaluate this.  To test the physiological significance of this site in 
vivo, a more precise approach would involve generate knock-in mice expressing 
an IRS1 S302 mutant instead of wild type IRS1, and test their ability to maintain 
glucose homeostasis and insulin sensitivity following either high fat diet feeding 
or a genetic cross with ob/ob or K/K Ay mice. Crossing these mice with S6K1 
deficient mice can also be useful to determine the direct versus indirect roles of 
S6K1 on IRS1 serine phosphorylation in the context of insulin sensitivity.  
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-Does S6K1 interact with molecules, which mediate serine phosphorylation 
of IRS1 to regulate IRS1 indirectly?  
The mTOR (mammalian target of rapamycin) signalling pathway has been 
shown to be involved in insulin-induced phosphorylation of Ser307 in adipocytes, 
and muscles (Gual et al., 2003b), (Carlson et al., 2004). In addition, 
hyperosmotic stress, which also induces insulin resistance, increases the 
phosphorylation of IRS1 on S307 by an mTOR-dependent pathway (Carlson et 
al., 2004) indicating the relevance of mTOR on  phosphorylation of IRS1 on S307 
in insulin resistance. Moreover, mTOR can catalyse the phosphorylation of set of 
Ser/Thr-Pro sites which may make an IRS1 S307 and  S632 as mTOR 
substrates (McMahon et al., 2002). Recent studies have also supported this by 
showing the physical association between IRS1 and mTOR (Gual et al., 2003b; 
Ozes et al., 2001). Surprisingly, the association between IRS1 and mTOR was 
not changed by insulin treatment (Gual et al., 2003b; Ozes et al., 2001) 
suggesting that there may be  other regulators besides insulin  which control the 
association of these two signalling components leading to further change of 
mTOR activity. Given the fact that amino acids activate mTOR signalling, it would 
be interesting to determine whether the association between IRS1 and mTOR is 
regulated by exogenous nutrients such as amino acids or free fatty acids. Those 
studies would aid in understanding the mechanism of insulin resistance arising 
not only from hyperinsulinemia but also from incessant nutrient supply.  Given 
that mTOR binds S6K1 and 4E-BP1 via raptor (Hara et al., 2002; Kim et al., 
2002; Nojima et al., 2003), one interesting question arises; Does S6K1 regulate 
the association between IRS1 and mTOR?  Further experiments will be required 
to address whether lowering S6K1 level or loss of S6K1 influences the 
association between IRS1 and mTOR to modulate mTOR activity.  
 As raptor enhances the mTOR-catalyzed phosphorylation of S6K1 in vitro 
via TOR signaling (TOS) motif (Schalm et al., 2003) and the TOS motif is found 
in mTOR substrates and responsible for association with mTOR through 
interaction with raptor,  we examined whether IRS1 also has a TOS motif by 
sequence analysis. Surprisingly, IRS1 does not have a TOS motif, even though 
 85
mTOR is known to mediate phosphorylation of serine 307 in IRS1 in response to 
insulin and TNF-α (Carlson et al., 2004). This would indicate that the interaction 
between mTOR and IRS1 may not require a TOS motif. Nevertheless, it would 
be interesting to investigate whether raptor is required for the ability of mTOR to 
phosphorylate IRS1, thereby assessing the relevance of this molecule in insulin 
sensitivity. These studies will be helpful to understand how nutrient sensitive 
signaling components integrate with insulin signaling through the interaction 
between mTOR or S6K1 and IRS1.  
 On the other hand, Harrington et al showed that reduced IRS1 mRNA 
levels in TSC2 deficient cells where mTOR/S6K signaling is hyperactivated, were 
restored by rapamycin treatment but reversed by actinomycin D (Harrington et al., 
2004), suggesting mTOR/S6K signaling reduces mRNA abundance at the level 
of transcription. Furthermore, they have shown that suppression of S6K1 mimics 
the effect of rapamycin treatment and restores IRS1 mRNA.  In contrast to this, 
the level of IRS1 protein in S6K1 deficient mice and S6K1 siRNA treated cells 
was not obviously different from wild type mice either on a normal chow diet or a 
high fat diet in our study.  Because measurement of IRS mRNA expression levels 
has not been done in our study, it is difficult to compare these conflicting results. 
However, it will be valuable to test whether IRS1 gene transcription is enhanced 
in S6K1 deficient mice given that the level of IRS1 gene expression is important 
for maintaining insulin sensitivity on the long term.   
 
Upregulation of the OXPHOS pathway in S6K1 deficient mice. 
Another mechanism of protection against obesity and insulin resistance in 
S6K1 deficient mice is the upregulation of the oxidative phosphorylation 
(OXPHOS) pathway. Our study showed an increased metabolic rate, enhanced 
oxidative metabolism, consistent with the increase in mitochondria number, as 
well as the induction of genes that control the OXPHOS pathway. That S6K1 
deficient mice remain insulin sensitive, despite high circulating FFAs, may be 
explained by overexpression or activation of PPARδ. More specifically, an 
interesting finding of this work was that the deletion of S6K1 results in an 
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increase of PGC1, UCP1, mCPT, and PPARδ expression in vivo. These genes 
induce expression of mitochondrial respiratory genes and enhance fatty acid β-
oxidation (Lowell and Spiegelman, 2000; Puigserver et al., 1998). How then does 
the loss of S6K1 increase OXPHOS pathway?  Interestingly, Serkova et al have 
shown that SDZ-RAD, a rapamycin analogue, antagonizes the effects of 
cyclosporine by stimulating oxidative phosphorylation in isolated rat brain slices 
(Serkova et al., 2000). It would be informative to assess whether the S6 kinases 
might be involved in the transcriptional activation of PGC1, UCP1, mCPT, and 
PPARδ by using rapamycin or RNA interference against S6K1 or S6K2 gene 
expression. Given that S6K2 gene expression is upregulated in all tissues 
examined of S6K1 deficient mice and that S6K2 is localized in the nucleus 
(Shima et al., 1998) (Savinska et al., 2004), it remains to be addressed whether 
upregulation of the OXPHOS pathway is due to direct genetic deletion of S6K1 or 
to compensatory S6K2 gene upregulation.   
 Infusion of glucosamine under hyperinsulinemic conditions leads to down-
regulation of OXPHOS gene expression and lower oxygen consumption (Obici et 
al., 2002). Similar changes in OXPHOS gene expression occur with overfeeding 
(Obici et al., 2002). Conversely, caloric restriction and exercise are associated 
with lower glucosamine production and high insulin sensitivity (Koubova and 
Guarente, 2003).  Previous and present findings in S6K1 deficient mice are 
closely parallel by some of the effects of a low protein diet or low calorie diet 
feeding, despite the fact that these mice are not starved (Pende et al., 2000; Um 
et al., in press):  small body size during gestation, reduced pancreatic β-cell size, 
hypoinsulinemia, high insulin sensitivity in peripheral tissues, and enhanced 
OXPHOS gene expression. Thus, these results indicate that S6K1 may be one of 
signaling molecules mediating the effect of overnutrition to induce insulin 
resistance by downregulation of OXPHOS pathway, although the mechanism is 
not fully understood.  
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How is an enhanced OXPHOS pathway coordinated with insulin sensitivity 
by loss of S6K1?   
The activation of increased energy expenditure and PGC1 expression in 
S6K1 deficient muscle ultimately requires an increased uptake and metabolism 
of fuels. Therefore, is increased expression of PGC1 able to induce glucose 
uptake leading to hypersensitivity to insulin?  Indeed, adenovirus-mediated 
PGC1 expression induces gene expression of the insulin-sensitive glucose 
transporter (Glut-4) in muscle in vivo and increases glucose uptake, although this 
process occurs even in the absence of insulin (Michael et al., 2001). Thus, it 
would be interesting to investigate whether S6K signaling is involved in PGC1 
induced Glut-4 expression. Signaling responsible for the effects of PGC1 on 
glucose uptake and metabolism is of particular interest in type 2 diabetes 
because there are numerous studies indicating that the rates of mitochondrial 
oxidation can affect glucose uptake, where PGC1α gene expression is altered in 
type 2 diabetic patients with insulin resistance (Mootha et al., 2003). Interestingly, 
the phenotype of increased mitochondrial number and size and UCP1 gene 
expression in S6K1 deficient adipose tissue could be attributed to PGC1 
expression, based on previous findings showing that PGC1 induces endogenous 
UCP1 gene expression and mitochondrial biogenesis when PGC1 is introduced 
into white fat cells (Puigserver et al., 1998). 
  
What is the relationship between an enhanced OXPHOS pathway and 
reduced adiposity in S6K1 deficient mice? 
 Why do S6K1 deficient mice have reduced adipose tissue mass? 
Is an enhanced OXPHOS pathway responsible for reduced adipocyte cell 
number and size? We showed that deletion of S6K1 results in increased PGC1, 
UCP1, mCPT, and PPAR-δ expression.  Expression of PGC1 in white fat cells 
turned on UCP1 gene expression but fails to activate the adipocyte specific aP2 
gene (Puigserver et al., 1998), the first gene actually identified as a target of 
PPAR- γ2(Tontonoz et al., 1994). This indicates that increased PGC1 expression 
 88
in adipose tissue may not be involved in reduced adiposity although it may 
enhance insulin sensitivity (Michael et al., 2001).    
 Increased PPAR-δ expression could be related to reduced adiposity in 
such mice. Tanaka et al have shown that the PPAR-δ agonist, GW501516, 
stimulates fatty acid β-oxidation and energy expenditure in skeletal muscle, 
leading to reduced lipid content in both skeletal muscle and liver (Tanaka et al., 
2003). Moreover, accumulation of excess lipid in skeletal muscle or liver disturbs 
insulin signaling. In skeletal muscle, this disturbance has been linked to impaired 
activity of the insulin receptor substrate (IRS)-1-associated phosphatidyl inositol 
3-kinase (PI3-kinase) (Dresner et al., 1999; Shulman, 2000; Yu et al., 2002).  
    
Is reduced adiposity arising from a defect in adipogenesis?  
 Adipose tissue expands as existing adipocytes enlarge and as new 
adipocytes mature from fibroblast-like preadipocytes (MacDougald and Mandrup, 
2002). Tontonoz et al have shown that expression of PPAR-γ2 and RXR α 
activates the adipocyte specific aP2 enhancer in cultured fibroblasts, and this 
activation is potentiated by peroxisome proliferators, fatty acids, and 9-cis retinoic 
acid (Tontonoz et al., 1994).  They therefore suggested a mechanism whereby 
fatty acids, peroxisome proliferators, 9-cis retinoic acid, and other lipids may 
regulate adipocyte gene expression and differentiation (Tontonoz et al., 1994). 
Despite the disappearance of the smaller adipocyte size phenotype in S6K1 
deficient mice fed on a high fat diet compared to a normal chow diet  (Um SH, 
Thomas G, unpublished results), such mice exhibited dramatically reduced 
adipose tissue mass, indicating the defect may reside in adipogenesis stimulated 
by high fat diet. Thus, reduced adipogenesis in S6K1 deficient mouse embryonic 
fibroblasts in vitro (Frigerio F, Um SH, Kozma S, Thomas G, unpublished results) 
may arise from impaired signalling from adipogenic stimuli such as fatty acids or 
PPAR- gamma agonist due to the loss of S6K1.  Consistent with this, rapamycin 
inhibits adipogenesis partially in 3T3 L1 cells in vitro (El-Chaar et al., 2004; Yeh 
et al., 1995a) although the molecular mechanisms by which rapamycin inhibits 
adipogenesis remains unclear. Furthermore, Bell et al have demonstrated that 
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rapamycin can interrupt adipogenesis independently from its antiproliferative 
effect. These experiments were performed in primary human adipocytes which 
undergo differentiation in the absence of clonal expansion (Bell et al., 2000). 
Therefore, this study would imply that the mTOR/S6K pathway may be involved 
in adipogenesis at the differentiation stage following clonal expansion. It would 
be interesting to determine whether PPAR-γ2 (Peroxisome proliferator-activated 
receptor-γ2) and C/EBPα (CCAAT/enhancer-binding protein), two key 
transcription factors for adipocyte differentiation (Wu et al., 1999b), are regulated 
by the S6K pathway. Given that rapamycin inhibits many mTOR targets besides 
S6K1, including S6K2, the 4EBPs, eIF4B, and eEF2 kinase (Gingras et al., 2001; 
Hay and Sonenberg, 2004), it will be informative to determine whether lowering 
S6K1 levels or other mTOR target levels  using lentiviral vector expressing short 
hairpin RNA inhibit adipogenesis  in vivo and in vitro (Katayama et al., 2004). By 
analyzing what kind of factors are involved in this process, this approach will 
serve to clarify the role of S6K1 pathway in adipocyte differentiation and to 
identify potential targets of mTOR/S6K pathway during adipogenesis.   
Furthermore, because of the role of S6K1 in many important metabolic 
processes in adipose tissue and muscle, it is worth asking whether and how the 
activities of S6K1 might be modulated in a tissue specific manner. Conditional 
knockout approaches could be useful to understand the tissue specific 
physiological action of S6K1 in metabolism.  
 
Human obesity and S6K1 
Human body fat mass is to a large extent genetically determined, but little 
is known about the susceptibility genes for common obesity (Barsh et al., 2000; 
Snyder et al., 2004). So far, single gene mutations have only been identified as 
the cause of morbid obesity in about 5% of young individuals (Barsh et al., 2000; 
Vaisse et al., 2000). One of the most successful routes for identification of body 
fat regulative mechanisms as well as genetic causes of obesity in humans has 
been systematic investigation of genes shown to affect energy metabolism in 
gene knockout mice (Butler and Cone, 2001; Snyder et al., 2004). Based on 
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resistance to age- and diet- induced obesity and insulin resistance in S6K1 
knockout mice, it would be particularly informative to analyze single-nucleotide 
polymorphisms (SNPs) and repeat polymorphisms in the human S6K1 gene 
region which may drive constitutive activation of this pathway, thereby finding a 
relationship between S6K1 and   susceptibility for insulin resistance and obesity.  
The present study indicates the impact of S6KI signaling in age- and diet- 
induced obesity and insulin resistance, and gives insight into the interaction 
between insulin induced IRS-PI3K pathway and nutrient induced mTOR-S6K 
pathway in metabolism and nutrient homeostasis.  Furthermore, S6K1’s function 
in insulin sensitivity and regulation of the oxidative phosphorylation pathway, as 
shown in this study, all suggest that S6K1 could be an attractive target for 
antiobesity or diabetes drugs. 
In analyzing the role of S6K1 in obesity and diabetes, one must also 
consider S6K2. S6K1-deficient mice are smaller, have reduced pancreatic β cell 
size, and are resistant to age- and diet-induced obesity. In contrast, S6K2-
deficient mice are not reduced in body size nor do they exhibit reduced 
pancreatic β cell size, despite reduced S6 phosphorylation. These findings 
indicate that each kinase may have distinct targets independent of S6. 
Interestingly, Richardson et al have shown that SKAR, a RNA binding protein is a 
specific target for S6K1 but not S6K2 (Richardson et al., 2004), suggesting 
differential substrate specificity for each kinase. Interestingly, Zhu et al have 
shown that main mutational locus for Bardet Biedl syndrome, which presents 
hypogonadism with predisposition to diabetes, hypertension, obesity and mental 
retardation, maps within or nearby the S6K2 gene (Zhu and Gerhard, 1998) 
suggesting that potential relevance of S6K2 gene mutation in predisposition of 
metabolic disorders. Analyzing the phenotype of S6K2 deficient mice and 
comparing it with that of S6K1 deficient mice in the context of insulin sensitivity 
and OXPHOS pathway may improve our understanding of the role of each 
kinase in metabolism and potential mechanism by which substrate specificity is 
driven.  
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